Board of Directors

President
Jon Kobashigawa, MD, Los Angeles, CA

President-Elect
Alec Patterson, MD, St. Louis, MO

Past President
Stephan Schueler, MD, Newcastle, United Kingdom

Secretary/Treasurer
Robert C. Bourge, MD, Birmingham, AL

Directors
Paul A. Corris, MB, FRCP, Newcastle, United Kingdom
F. Jay Fricker, MD, Gainesville, FL
Katherine Hoercher, RN, Cleveland, OH
Luigi Martinelli, MD, Genova, Italy
Keith McNeil, MD, FRACP, Brisbane, Australia
Mandeep R. Mehra, MD, New Orleans, LA
Soon J. Park, MD, San Francisco, CA
Hermann Reichenspurner, MD, PhD, Hamburg, Germany
Bruce Rosengard, MD, FRCS, FACS, Cambridge, United Kingdom
Heather J. Ross, MD, Toronto, Canada
Adriana Zeevi, PhD, Pittsburgh, PA

JHLT Editor
James K. Kirklin, MD, Birmingham, AL

Heart and Lung Transplant Registry Medical Director
Marshall I. Hertz, MD, Minneapolis, MN

Mechanical Circulatory Support Device Database Medical Director
Mario C. Deng, MD, New York, NY

Staff
Amanda W. Rowe
Executive Director
Phyllis Glenn
Assistant Executive Director
Director of Membership Services

Lisa Edwards
Director of Meetings
LeeAnn Mills
Director of Operations

14673 Midway Road, Suite 200
Addison, TX  75001
Phone: 972-490-9495
Fax: 972-490-9499
www.ishlt.org
ishlt@ishlt.org
### PAST PRESIDENTS

<table>
<thead>
<tr>
<th>Year</th>
<th>President</th>
</tr>
</thead>
<tbody>
<tr>
<td>1981-1982</td>
<td>Michael Hess, MD</td>
</tr>
<tr>
<td>1982-1984</td>
<td>Jack Copeland, MD</td>
</tr>
<tr>
<td>1984-1986</td>
<td>Terence English, FRCS</td>
</tr>
<tr>
<td>1986-1988</td>
<td>Stuart Jamieson, MD</td>
</tr>
<tr>
<td>1988-1990</td>
<td>Bruno Reichart, MD</td>
</tr>
<tr>
<td>1990-1991</td>
<td>Margaret Billingham, MD</td>
</tr>
<tr>
<td>1991-1992</td>
<td>Christian Cabrol, MD</td>
</tr>
<tr>
<td>1992-1993</td>
<td>John O’Connell, MD</td>
</tr>
<tr>
<td>1993-1994</td>
<td>Eric Rose, MD</td>
</tr>
<tr>
<td>1994-1995</td>
<td>John Wallwork, FRCS</td>
</tr>
<tr>
<td>1995-1996</td>
<td>Sharon Hunt, MD</td>
</tr>
<tr>
<td>1996-1997</td>
<td>William Baumgartner, MD</td>
</tr>
<tr>
<td>1997-1998</td>
<td>Leslie Miller, MD</td>
</tr>
<tr>
<td>1998-1999</td>
<td>Alan Menkis, MD, FRCS(C)</td>
</tr>
<tr>
<td>1999-2000</td>
<td>Robert L. Kormos, MD</td>
</tr>
<tr>
<td>2000-2001</td>
<td>Anne Keogh, MBBS, MD</td>
</tr>
<tr>
<td>2001-2002</td>
<td>James B. Young, MD</td>
</tr>
<tr>
<td>2002-2003</td>
<td>Stephan Schuler, MD</td>
</tr>
</tbody>
</table>
AWARD RECIPIENTS

LIFETIME SERVICE AWARD
1996  Michael Kaye
1997  Jacques Losman

LIFETIME ACHIEVEMENT AWARD
2004  Sir Magdi Yacoub, MD
1999  Keith Reemtsma, MD
1996  Norman Shumway, MD

ISHLT/ROCHE TRANSPLANT CAREER DEVELOPMENT AWARD
2002  Anthony Azakie, MD
2000  Gordon D. Wu, MD

ISHLT/ROCHE TRANSPLANT RESEARCH FELLOWSHIP GRANT
2003  Felix Fernandez, MD
2002  Ruediger Hoebelt, MD
2001  Matteo Vatta, PhD
2001  Arnar Geirsson, MD
2000  Christopher H. Wigfield, FRCS
1999  Donald Wong, PhD
      Sivasai Krovvidi, PhD
1998  Kelly S.A. Blair, MD
      A.M. El Gamel, MD
1997  Jonathen Chen, MD
      Anne K. Raisanen-Sokolowski, MD
1996  Tuija S. Ikonen, MD

ISHLT/NOVARTIS TRANSPLANT RESEARCH FELLOWSHIP GRANT
2000  Richard S. Lee, MD
1999  George Juang, MD
      Satoshi Saito, MD
1998  Margaret L. Schwarze, MD

ISHLT TRANSPLANT RESEARCH FELLOWSHIP GRANT
1998  Scott D. Ross, MD

ISHLT/WYETH-AYERST TRANSPLANT RESEARCH FELLOWSHIP GRANT
1998  Christine L. Lau, MD

ISHLT/ORTHO BIOTECH TRANSPLANT RESEARCH FELLOWSHIP GRANT
1997  Owen T. Lawrence, MD
1996  Andrew F. Pierre, MD
1995  Frances L. Johnson, MD

ISHLT/FUJISAWA TRANSPLANT RESEARCH FELLOWSHIP GRANT
2003    Ewout J. van den Bos, MD
1997    Alyssa M. Krasinskas, MD

**ISHLT NURSING RESEARCH GRANT**

2003   Diane H. Leloudis, RN, MSN
2003   Janet E. Madill, PhD
2002   Annette J. De Vito Dabbs, RN, MN, PhD
2001   Lynn Doering, RN, DNSc
2000   Nancy M. Albert, MSN, RN
1999   Jeannine Salyer, PhD
1998   Katherine St. Clair, RN, MSN
1997   Eileen Collins, RN, PhD

**CAVES AWARD**

2003   Sigrid Sandner, MD
2002   Peter Blaha, MD
2001   Alexander S. Krupnick, MD
2000   Michael P. Fischbein, MD
1999   Joerg Koglin, MD
1998   Carla C. Baan, MD
1997   Simon D. Eiref, MD
1996   Moninder S. Bhabra, MD
1995   Elizabeth A. Davis, MD
1994   Joost Winter, MD
1994   Alain Chapelier, MD
1993   David Marshman, MD
1992   David P. Kapelanski, MD
1991   A. Jiminez, MD
1990   Andres J. Duncan, MD
1989   A.M. Wood, MD
1988   Charles D. Fraser, Jr., MD
1987   Wim Van Der Bij, MD
1986   Stuart J. Knechtle, MD
1985   Michael A. Breda, MD
1984   Hermann Reichenspurner, MD
1983   Robbin G. Cohen, MD
SCIENTIFIC PROGRAM COMMITTEE

Program Committee

Mandeep R. Mehra, MD, New Orleans, LA, Chair
Jon Kobashigawa, MD, Los Angeles, CA, President
Abbas Ardehali, MD, Los Angeles, CA
Mark L. Barr, MD, Los Angeles, CA
Robert C. Bourge, MD, Birmingham AL
Maryanne R. Chrisant, MD, Philadelphia, PA
Paul A. Corris, MB FRCP, Newcastle Upon Tyne, United Kingdom
Sandra A. Cupples, DNSc, Potomac, MD
Debi H. Dumas-Hicks, RN, Metairie, LA
Michael C. Fishbein, MD, Los Angeles CA
Kate Gould, MB, BS, Newcastle Upon Tyne, United Kingdom
Eduardo G. Gronda, MD, Milan, Italy
Jeffrey D. Hosenpud, MD, Milwaukee, WI
Manfred Hummel, MD, PhD, Berlin, Germany
Sharon Hunt, MD, Palo Alto, CA
Valluvan Jeevanandam, MD, Chicago, IL
Shaf Keshavjee, MD, FRCSC, Toronto, ON, Canada
James K. Kirklin, MD, Birmingham, AL
Keith McNeil, FRACP, Brisbane, Australia
Robert E. Michler, MD, Columbus, OH
Paul Josef Mohacsi, MD, Berne, Switzerland
Francesco Parisi, MD, Rome, Italy
Alec Patterson, MD, St. Louis MO
Bransilav Radovancevic, MD, Houston, TX
Bruce R. Rosengard, MD, Cambridge, United Kingdom
Susan Stewart, FRCPath, Cambridge, United Kingdom
Patricia A. Uber, Pharm.D, New Orleans, LA
Clifford Van Meter, Jr., MD, New Orleans, LA
George M. Wieselthaler, MD, Vienna, Austria
James B. Young, MD, Cleveland, OH

Reviewers

William T. Abraham, MD, FACP, FACC, Columbus, OH
Michael A. Acker, MD, Philadelphia, PA
Maria C. Albanese, MD, Udine, Italy
Annalisa Angelini, MD, Padova, Italy
Carl Atkinson, MD, Cambridge, United Kingdom
Nicholas R. Banner, FRCP, Harefield, Middlesex, United Kingdom
William A. Baumgartner, MD, Baltimore, MD
Raymond L. Benza, MD, Birmingham, AL
Claes-Hakan Bergh, MD, PhD, Vastra Frolunda, Sweden
Geetha Bhat, MD, Louisville, KY
Annette Boehler, MD, Zurich, Switzerland
Heidi Boettcher, MD, Berlin, Germany
Caron Burch, RN, MSN, FNP, Manhattan Beach, CA
Carlo Campana, MD, Pavia, Italy
Cecilia Chaparro, MD, Toronto, ON, Canada
John V. Conte, MD, Baltimore, MD
Maria Rosa Costanzo, MD, Naperville, IL
Maria G. Crespo-Leiro, MD, La Coruna, Spain
Teresa DeMarco, MD, FACC, San Francisco, CA 94143
CONTINUING MEDICAL EDUCATION INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education. The International Society for Heart and Lung Transplantation is accredited by the ACCME to provide continuing medical education for physicians. ISHLT designates this activity for a maximum of 29 hours in Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Educational Objectives

The International Society for Heart and Lung Transplantation is a leading organization providing education for medical professionals involved in heart and lung transplantation. Because of the rapid advances in medicine in general and transplantation medicine specifically, transplant professionals are in need of regular opportunities to update and maintain their knowledge of advances and changes in transplant medicine. This meeting is designed to address their need.

Goals

To enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease; and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.

Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end stage heart or lung disease.

Learning Objectives

At the conclusion of this meeting, participants should be able to:
* identify, prevent, and treat post-transplant complications of immunosuppression including infection, renal dysfunction, and post-transplant malignancy
* compare and evaluate the relative advantages and disadvantages of various pharmacologic, non-pharmacologic, and biologic immunosuppression techniques
* understand current and developing organ preservation/reperfusion techniques and the impact of these on the transplanted organ, and use that knowledge to optimize donor selection and extend the donor pool
* compare and evaluate the advantages and disadvantages of various mechanical circulatory support systems and their associated patient selection criteria
* describe the state of the art in clinical heart and lung failure treatment and the criteria for the selection of patients for transplant therapy
* understand current animal models of basic science immunology and their application to the transplant setting
* evaluate issues of controversy, such as age, prior transplantation, and systemic diseases, in the selection of candidates for heart and lung transplantation
* understand the pathology of acute and chronic rejection and its application in the formulation of a definitive diagnosis of rejection
* identify the issues unique to pediatric transplantation, and apply to pediatric transplantation the relevant practices and therapies of adult transplantation
* evaluate the current and developing alternatives to orthotopic transplantation, including mechanical
circulatory support, xenotransplantation, and a variety of surgical alternatives; assess the future of these therapies; and compare the value of these therapies as alternatives and/or bridges to transplantation
* evaluate and implement the use of alternative methods of monitoring and treating rejection
* identify, prevent, and treat donor-transmitted diseases
Disclosure

Current guidelines state that participants in CME activities should be made aware of any affiliation or financial interest that may affect a speaker’s presentation. Each speaker has been requested to complete a disclosure statement. The names of the speakers declaring such affiliations are shown below.

Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

<table>
<thead>
<tr>
<th>FACULTY/PRESENTATION</th>
<th>COMPANY AFFILIATION</th>
<th>RELATIONSHIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicholas Banner, MD</td>
<td>Roche, Novartis</td>
<td>Clinical Investigator, Advisor</td>
</tr>
<tr>
<td>Sangeeta M. Bhorade, MD</td>
<td>Fujisawa, Wyeth</td>
<td>Research Support</td>
</tr>
<tr>
<td>Margaret E. Billingham, MD</td>
<td>XDX, Inc.</td>
<td>Consultant</td>
</tr>
<tr>
<td>Edimar A. Bocchi, MD</td>
<td>Abbott</td>
<td>Research Support</td>
</tr>
<tr>
<td>Aaron S. Blom, MD</td>
<td>Acorn Cardiovascular</td>
<td>Research Support</td>
</tr>
<tr>
<td>Ashley Byno, MD</td>
<td>Fujisawa Healthcare</td>
<td>Research Support</td>
</tr>
<tr>
<td>Marcelo Cantrovich, MD</td>
<td>Novartis</td>
<td>Consultant</td>
</tr>
<tr>
<td>Jason D. Christie, MD, MS</td>
<td>Novartis Pharma UK</td>
<td>Consultant</td>
</tr>
<tr>
<td>Jacqueline Cornelissen, BSc</td>
<td>Novartis, Thoratec</td>
<td>Educational Grant</td>
</tr>
<tr>
<td>Howard J. Eisen, MD</td>
<td>Novartis, Thoratec</td>
<td>Consultant</td>
</tr>
<tr>
<td>Donald S. Esmore, MD</td>
<td>Ventracor, Ltd.</td>
<td>Consultant</td>
</tr>
<tr>
<td>David J. Farrar, MD</td>
<td>Thoratec</td>
<td>Employee</td>
</tr>
<tr>
<td>Jay A. Fishman, MD</td>
<td>Roche, Fujisawa, Novartis, Pfizer</td>
<td>Grants, Speaker’s Bureau, Consultant</td>
</tr>
<tr>
<td>Torin P. Fitton, MD</td>
<td>Argon Recovery Systems</td>
<td>Research Funding</td>
</tr>
<tr>
<td>Reda E. Girgis, MB, BCh</td>
<td>Actelion</td>
<td>Speaker/Lecturer</td>
</tr>
<tr>
<td>Roland Hetzer, MD, PhD</td>
<td>Berlin Heart</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Aldo T. Iacono, MD</td>
<td>Chiron</td>
<td>Commercialization of Product</td>
</tr>
<tr>
<td>Anne Keogh, MD</td>
<td>Actelion, Wyeth</td>
<td>Advisory Board</td>
</tr>
<tr>
<td>Walter Klepetko, MD</td>
<td>Fujisawa, Roche, Novartis</td>
<td>Consultant</td>
</tr>
<tr>
<td>Jon Kobashigawa, MD</td>
<td>Novartis, Roche, Fujisawa</td>
<td>Consultant</td>
</tr>
<tr>
<td>Robert L. Kormos, MD</td>
<td>Thoratec</td>
<td>Medical Advisory Board</td>
</tr>
<tr>
<td>Bronwyn Levvey, MD</td>
<td>Novartis</td>
<td>Research Support</td>
</tr>
<tr>
<td>Natalia Lobach, MD</td>
<td>Wyeth-Ayerst</td>
<td>Supporting Grant</td>
</tr>
<tr>
<td>Charles C. Marboe, MD</td>
<td>XDX, Inc.</td>
<td>Consultant</td>
</tr>
<tr>
<td>Mandeep R. Mehra, MD</td>
<td>Pfizer, XDX, Biosite, Novartis</td>
<td>Consultant, Research Grant</td>
</tr>
<tr>
<td>Bruno Meiser, MD</td>
<td>Fujisawa, Wyeth Ayerst, Roche</td>
<td>Consultant</td>
</tr>
<tr>
<td>Keith McNeil, MD</td>
<td>Actelion, Roche</td>
<td>Clinical Investigator</td>
</tr>
<tr>
<td>Tofy Muccicand, MD</td>
<td>World Heart Corp.</td>
<td>Scientific Advisor</td>
</tr>
<tr>
<td>Walter E. Pae, Jr., MD</td>
<td>Arrow International</td>
<td>Research Support</td>
</tr>
<tr>
<td>Jignesh Patel, MD, PhD</td>
<td>Fujisawa, Novartis, Roche, Scios, XDX</td>
<td>Research Grants</td>
</tr>
<tr>
<td>Myung Park, MD</td>
<td>Biosite, United Therapeutics</td>
<td>Consultant, Research Grant</td>
</tr>
<tr>
<td></td>
<td>Actelion,</td>
<td></td>
</tr>
<tr>
<td>Ulrich Pirro, MD</td>
<td>Novartis Pharma AG</td>
<td>Employee</td>
</tr>
<tr>
<td>Stacey Pollock-BarZiv, PhD</td>
<td>Novartis Canada, Fujisawa</td>
<td>Research Support</td>
</tr>
<tr>
<td>Raymund R. Razonable, MD</td>
<td>Roche, Eli Lilly and Co, Pfizer</td>
<td>Honorarium/Advisory Board, Visiting</td>
</tr>
<tr>
<td>Filip R. Rega, MD</td>
<td>Zambon</td>
<td>Consultant</td>
</tr>
<tr>
<td>Eric A. Rose, MD</td>
<td>Thoratec, Micromed, Arrow</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Mitchell T. Saltzberg, MD</td>
<td>Scios, Inc.</td>
<td>Consultant</td>
</tr>
<tr>
<td>Heinrich Schima, MD</td>
<td>Micromed</td>
<td>Medical School Research Grant</td>
</tr>
<tr>
<td>Elizabeth Shane, MD</td>
<td>Merck</td>
<td>Clinical Trial Investigator</td>
</tr>
<tr>
<td>Gregory Snell, MD</td>
<td>Novartis Pharma</td>
<td>Research Support, Consultant</td>
</tr>
<tr>
<td>Randall C. Starling, MD</td>
<td>Novartis, Fujisawa, SangStat</td>
<td>Research Support</td>
</tr>
<tr>
<td>Guillermo Torre-Amione, MD</td>
<td>Argen</td>
<td>Scientist, Research Support</td>
</tr>
<tr>
<td>Patricia A. Uber, Pharm D</td>
<td>Fujisawa</td>
<td>Speaker’s Bureau</td>
</tr>
<tr>
<td>Name</td>
<td>Company and Activities</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Adrian B. Van Bakel, MD</td>
<td>Scios, Glaxo Smith Kline, Medtronic, Speaker’s Bureau</td>
<td></td>
</tr>
<tr>
<td>Cynthia K. Wallace, MD</td>
<td>Merck, Research Support</td>
<td></td>
</tr>
<tr>
<td>Steven A. Webber, MD</td>
<td>XDx, Inc., Fujisawa, Research Support</td>
<td></td>
</tr>
<tr>
<td>Clyde W. Yancy, MD</td>
<td>Glaxo Smith Kine, Scios, Novartis, Sanofi-Synthelabo,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Meyers-Squibb, Medtronic, Nitromed, CardioDynamics</td>
<td></td>
</tr>
<tr>
<td>Martin Zamora, MD</td>
<td>Medimmune, ICN, Roche, Research Support, Consultant</td>
<td></td>
</tr>
</tbody>
</table>
The International Society for Heart and Lung Transplantation is most grateful for the educational grants and the support of

Platinum Partner
NOVARTIS

Gold Partner
FUJISAWA

Silver Partner
ROCHE

Bronze Partner
ACTELION
CHIRON
XDX, INC.

Corporate Partner
WYETH

Friend of the Society
GENZYME TRANSPLANT

toward this

TWENTY FOURTH ANNUAL MEETING AND SCIENTIFIC SESSIONS
THIS PAGE IS FOR HILTON MAP(S)
GROUND LEVEL

PLAZA A/B ROOM
Satellite Symposia
Concurrent Sessions

BALLROOM LEVEL

YOSEMITE
Exhibits
ISHLT Registration
Internet Cafe
Moderated Posters

FRANCISCAN
General Posters

GRAND BALLROOM LEVEL

GRAND BALLROOM A
Exhibits

GRAND BALLROOM B
Satellite Symposia
Concurrent Sessions
Plenary Sessions
Luncheon Symposia
SCIENTIFIC PROGRAM

Note: All meetings and activities will take place at the Hilton San Francisco unless otherwise specified. All papers will be presented in English. Speakers and Moderators have been invited but not confirmed as of the date of the printing of this program.

WEDNESDAY, APRIL 21, 2004

7:00 AM-6:30 PM
Speaker Ready Room (Green Room)

7:00 AM-12:30 PM
ISHLT Board of Directors Meeting (Executive Boardroom)

8:00 AM-10:00 AM
Exhibitor Set Up (Yosemite)

8:00 AM-5:00 PM
Exhibitor Set Up (Grand Ballroom A)

10:00 AM-6:30 PM
Registration Desk Open (Yosemite)

10:00 AM-6:30 PM
Exhibits Open (Yosemite)

NOON-6:00 PM
General Poster Display Session 1 Set-Up (Franciscan)

12:30 PM - 1:30 PM
SATELLITE SYMPOSIUM 1
Early Events and Late Outcomes in Heart Transplantation
(Grand Ballroom B)
Supported by an educational grant from Roche
Moderators: Axel Rahmel, MD and Stuart D. Russell, MD

12:30 PM Acute Cellular Rejection and Humoral Rejection Influence Long Term Survival Following Cardiac Transplantation

Evidence For: James K. Kirklin, MD, University of Alabama, Birmingham, AL
Evidence Against: Jeffrey D. Hosenpud, MD, St. Luke’s Medical Center, Milwaukee, WI

12:45 PM (1) Further Analysis of the Intravascular Ultrasound Data from the Randomized Mycophenolate Mofetil (MMF) Trial in Heart Transplant Recipients, J.A. Kobashigawa,1 J. Tobis,1 R.M. Mentzer,2 H.A. Valantine,2 R.C. Bourge,2 F.W. Smart,3 L.W. Miller,2 R.D. Gordon,2 M. Mehra,2

1University of California at Los Angeles, Los Angeles, CA; 2University of Kentucky, Lexington, KY; 3Stanford University, Stanford, CA

1:15 PM Panel Discussion

12:30 PM – 3:00 PM
SATELLITE SYMPOSIUM 2
Nursing and Social Sciences: Completing the Circle of Care in Thoracic Transplantation (Plaza A)
12:30 PM Welcome

12:35 PM Psychosocial Outcomes in Cardiothoracic Transplantation: Progress Towards Intervention Development, Dorothy Lanuza, PhD, RN, FAAN, FAHA, University of Wisconsin, Madison, WI

12:55 PM LVADs as Life Time Therapy: Psychosocial Issues, Mary Amanda Dew, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA

1:10 PM Post Transplant Education: Does It Ever End? Christiane Kugler, RB, MSN, Hannover Medical School, Hannover, Germany

1:25 PM Post Transplant Palliative Care and End of Life Issues, Linda Wright, MHSc, MSW, RSW, Toronto General Hospital, Toronto, ON, Canada

1:45 PM HIPAA: Is It Hurting or Helping? Caron Burch, RN, MSN, FNP, University of California at Los Angeles, Los Angeles, CA

2:00 PM Transplant Coordinator/Transplant Nurse Practitioner: Blending the Roles, Connie White-Williams, RN, MSN, University of Alabama, Birmingham, AL, and Sharon Augustine, RN, MS, University of Maryland, Baltimore, MD

2:40 PM Questions and Answer Session

12:30 PM – 3:00 PM

SATELLITE SYMPOSIUM 3

Current Trends in Mechanical Assistance: Role of Destination Therapy (Imperial B)

Moderators: Eric A. Rose, MD and Mariell Jessup, MD

12:30 PM Chairs’ Introduction

12:35 PM Limits of Medical Therapy: When Should we Refer for Destination Therapy? Lynne Warner Stevenson, MD, Brigham and Women’s Hospital, Boston, MA

1:00 PM Why do People Die with LVAD’s, James W. Long, MD, LDS Hospital, Salt Lake City, UT

1:25 PM Emerging Devices for Destination Therapy, Roland Hetzer, MD, German Heart Institute, Berlin, Germany

1:50 PM Real World Challenges to Implementation of Destination Therapy, Robert L. Kormos, MD, University of Pittsburgh, Pittsburgh, PA

2:15 PM Panel Discussion

1:45 PM – 3:00 PM

SATELLITE SYMPOSIUM 4

Enhancing Organ Donation in Thoracic Transplantation: Are We Doing All We Can to Maximize Donors in Heart Transplantation? (Grand Ballroom B)

Moderators: Bruce R. Rosengard, MD and James F. Burdick, MD

1:45 PM A Perspective From UNOS, Frank W. Smart, MD, FACC, FACP, Texas Heart Institute, Houston, TX

2:05 PM A Perspective From Eurotransplant, Jacqueline M. Smits, MD, PhD, Eurotransplant International Foundation, Leiden, The Netherlands

2:25 PM A Perspective From Spain, Blanca Miranda, National Transplant Organization, Madrid, Spain

2:45 PM Panel Discussion

3:00 PM - 3:30 PM

Coffee Break (Yosemite)

3:30 PM – 6:00 PM

SATELLITE SYMPOSIUM 5

Achieving Equilibrium in Risk and Outcome in Thoracic Transplantation (Grand Ballroom B)
Supported by an educational grant from Novartis
Moderators: Leslie W. Miller, MD and Howard J. Eisen, MD

3:30 PM Chairman’s Introduction: Co-Morbidities in Thoracic Transplantation: Causes and Management Strategies, Leslie W. Miller, MD, University of Minnesota, Minneapolis, MN

3:50 PM New Onset Diabetes in Transplantation, Jaime Davidson, MD, Endocrine & Diabetes Associates of Texas, Dallas, Texas

4:10 PM New Perspectives on Calcineurin Inhibitors: Friend or Foe? Anne Keogh, MD, St. Vincent’s Hospital, Sydney, Australia

4:30 PM Metabolic Factors in the Genesis of Cardiac Allograft Vasculopathy, Hannah Valantine, MD, Stanford University School of Medicine, Palo Alto, CA

4:50 PM BOS: Immune Versus Non-immune Strategies, Paul Corris, FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

5:10 PM Panel Discussion

3:30 PM – 6:00 PM SATELLITE SYMPOSIUM 6
ISHLT/AST Joint Symposium: Infectious Complications in Thoracic Transplantation (Imperial A)
Moderators: Kate Gould, MB BS (ISHLT) and Jay A. Fishman, MD (AST)

3:30 PM Introduction and Welcome

3:35 PM Fungal Infection in Thoracic Transplantation, Jose G. Montoya, MD, Stanford University School of Medicine, Stanford, CA

3:55 PM Infections of LVADS and Other Devices, Stephen M. Gordon MD, Cleveland Clinic Foundation, Cleveland, OH

4:15 PM Experiences with SARS and West Nile Virus, Atul Humar, MD, University of Toronto, Toronto, ON, Canada

4:35 PM Hepatitis Viruses and Transplantation, D.E. Jones, University of Newcastle, Newcastle upon Tyne, United Kingdom

4:55 PM HIV in Transplantation, Jay A. Fishman, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA

5:10 PM Panel Discussion

3:30 PM – 6:00 PM SATELLITE SYMPOSIUM 7
Primary Lung Graft Failure (Imperial B)
Moderators: Dirk Van Raemdonck, MD, PhD and Jason D. Christie, MD

3:30 PM Introduction, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD

3:35 PM Overview of the Problem, Dirk Van Raemdonck, MD, University Hospital Gasthuisberg, Leuven, Belgium

3:50 PM Definition and Grading of PGF, Jason D. Christie, MD, University of Pennsylvania, Philadelphia, PA

4:10 PM Risk Factors and Markers of PGF (Donor Factors), Marc de Perrot, MD, University of Toronto Hospital, Toronto, ON, Canada

4:30 PM Risk Factors and Markers of PGF (Recipient Factors), Mark L. Barr, MD, University of Southern California, Los Angeles, CA

4:50 PM Predictors of Outcome, Selim M. Arcasoy, MD, Columbia University, New York, NY

5:10 PM Treatment of PGF, Shaf Keshavjee, MD, Toronto General Hospital, Toronto, ON, Canada

5:30 PM Panel Discussion

5:45 PM Future Directions, Jonathan B. Orens, MD, Johns Hopkins Hospital, Baltimore, MD

6:00 PM-7:00 PM ISHLT Registry Executive Committee Meeting (Executive Board Room)
6:30 PM – 8:00 PM
Satellite Symposium 8
Expanding the Borders – What is Happening on the Other Side of the World?
(Imperial A/B)
Moderators: O. Howard Frazier, MD and Mark L. Barr, MD

6:30 PM Introduction, Branislav Radovancevic, MD, Texas Heart Institute, Houston, TX
6:35 PM Heart and Lung Transplant: The Future World Perspective, Sir Magdi Yacoub, MD, Magdi Yacoub Insitute, Heart Science Center, Harefield, Middlesex, United Kingdom
6:50 PM Heart Failure: Are There Regional Differences in Therapeutic Strategies? Jignesh Patel, MD, UCLA University Cardiovascular Medical Group, Los Angeles, CA
7:05 PM Living-related Lung Transplant: What if this is the Only Option? Hiroshi Date, MD, University School of Medicine, Okayama, Japan
7:20 PM Developing a Heart and Device Program in Countries Exceeding One Billion, Valluvan Jeevanandam, MD, University of Chicago, Chicago, IL
7:35 PM Devices as the Only Practical Choice, Hikaru Matsuda, MD, Osaka University Medical School, Osaka, Japan
7:50 PM Questions and Answer Session

8:30 PM-10:00 PM
Moderated Poster Session 1 Set-up (Yosemite)

THURSDAY, APRIL 22, 2004

7:00 AM-8:00 AM
Morning Coffee (Grand Ballroom A)

7:00 AM-10:00 AM
Moderated and General Poster Display Session 1 Set-Up (Franciscan/Yosemite)

7:00 AM-4:30 PM
Exhibits Open (Grand Ballroom A)

7:00 AM-6:30 PM
Speaker Ready Room (Green Room)

7:00 AM-6:30 PM
Registration Desk Open (Yosemite)

7:00 AM – 6:30 PM
Exhibits Open (Yosemite)

7:55 AM-10:00 AM
OPENING PLENARY SESSION
(Grand Ballroom B)
Moderators: Jon Kobashigawa, MD and Mandeep R. Mehra, MD

7:55 AM Welcome, Jon Kobashigawa, MD, ISHLT President, University of California at Los Angeles, Los Angeles, CA

8:00 AM Scientific Program Report, Mandeep R. Mehra, MD, ISHLT Scientific Program Chair, Ochsner Clinic Foundation, New Orleans, LA

8:05 AM Registry Reports, Marshall I. Hertz, MD, Registry Medical Director, University of Minnesota,
Minneapolis, MN, and Mario Deng, MD, MCSD Database Medical Director, Columbia University, New York, NY

8:30 AM President's Address, Jon Kobashigawa, MD, ISHLT President, University of California at Los Angeles, Los Angeles, CA

Featured Abstract


9:15 AM ISHLT Commentary: Is It Time for a Reappraisal of the Rejection Nomenclature: The ISHLT Initiative, Susan Stewart, FRCPath, Papworth Hospital, Cambridge, United Kingdom

9:30 AM Invited Lecture: The Pathology of Acute Rejection in Cardiac Allografts: View From the Past and a Journey Beyond, Margaret E. Billinghimation, MD, Palo Alto, CA

10:00 AM-10:30 AM Coffee Break (Grand Ballroom A)

10:30 AM-NOON CONCURRENT SESSION 1 Lung/Heart-Lung Transplantation 1: Risk Factors for BOS: Current Thinking (Grand Ballroom B) Moderators: Paul A. Corris, FRCP and Hiroshi Date, MD

10:30 AM (3) Bile Acids in Bronchoalveolar Lavage after Lung Transplantation as a Marker of Pulmonary Aspiration Associated with Alveolar Necrosis, F. D'Ovidio, M. Mura, T.K. Waddeell, A. Pierre, M. Hutcheson, D. Hadjilidas, L. Singer, L. Miller, G. Darling, M. de Perrot, Y. Shargall, S. Keshavjee, Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

10:45 AM (4) Non-Alloimmune Injury Mediated by Gastroesophageal Reflux Precipitates Alloimmune Injury in Lung Transplant Patients, M.G. Hartwig, E. Cantu, J.Z. Appel, H. Woretà, S.M. Palmer, R.D. Davis, Department of Surgery, Duke University Medical Center, Durham, NC; Lung Transplant Program, Duke University Medical Center, Durham, NC

11:00 AM (5) CMV Mismatch Is Not A Risk Factor for Survival or Severe Bronchiolitis Obliterans Syndrome after Lung Transplantation, A.R. Glanville, V.G. Valentine, C.L. Aboyoum, M.A. Malouf, The Lung Transplant Unit, St Vincent's Hospital, Sydney, NSW, Australia; Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

11:15 AM (6) Impact of Respiratory Syncytial Virus Pneumonia Following Lung Transplantation: A Case-Controlled Study, M.R. Zamora, T. Hodges, M.R. Nicolls, T.L. Astor, J. Marquesen, D. Weill, Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO; Pulmonary Medicine, University of Southern California, Los Angeles, CA

11:30 AM (7) De Novo HLA Antibodies and Lymphocytic Bronchiolitis Are Significantly Correlated with Bronchiolitis Obliterans Syndrome in Lung Transplantation, A.L. Gimita, A.T. Iacono, T.E. Corcoran, S.A. Yousem, R. Duquesnoy, B. Johnson, J.H. Dauber, K.J. Spichty, B.P. Griffith, K.R. Mccurry, Zeevi, Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA; Thoracic Surgery, University of Maryland School of Medicine, Baltimore, MD; Thoracic Surgery

11:45 AM (8) Role of Flow Cytometry To Exclude Unacceptable HLA Antigens in Lung Transplant Recipients with Anti-HLA Antibodies, J.Z. Appel, E. Cantu, M.G. Hartwig, N.L. Reinsmoen, S.M. Palmer, R.D. Davis, Surgery, Duke University Medical Center, Durham, NC
10:30 AM-NOON
CONCURRENT SESSION 2
Immunosuppression 1: State of the Art Immunosuppression: Sustained Benefits
(Imperial)
Moderators: David O. Taylor, MD and Patricia A. Uber, Pharm D

10:30 AM (9)  Six Month Data of a 12-Month, Single-Blind, Randomized, Parallel Group, Multicenter Study To Investigate the Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS, Myfortic®) Compared with Mycophenolate Mofetil (MMF) in De Novo Heart Transplant Recipients, J.A. Kobashigawa,1 S.F. Davis,2 D.G. Renlund,3 M. Hummel,4 G. Gerosa,5 R. Brambilla,6 1University of California at Los Angeles, Los Angeles, CA; 2Cardiac Transplant Program, Vanderbilt University, Nashville, TN; 3Heart Failure Treatment and Prevention, University of Utah, Salt Lake City, UT; 4Deutsches Herzzentrum, Berlin, Germany; 5Instituto Chirurgia Cardiovasculeare, Padova, Italy; 6Novartis Pharma AG, Basel, Switzerland

10:45 AM (10)  Two-Year Results of an International, Randomized, Double-Blind Study of Everolimus (RAD) vs Azathioprine To Inhibit the Decline of Pulmonary Function in Stable Lung Transplant Recipients, G.I. Snell,1 V.G. Valentine,2 R.B. Love,3 P. Vijulo,4 A.R. Glanville,5 U. Pirron,1 Lung Transplantation Service, Alfred Hospital, Melbourne, Australia; 2Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA; 3Lung Transplant Unit, University of Wisconsin, Madison, WI; 4Division of Pneumology, IRCCS Policlinico San Matteo, Pavia, Italy; 5The Lung Transplant Unit, St Vincent's Hospital, Sydney, Australia; 6Business Unit Transplantation, Novartis Pharma AG, Basel, Switzerland

11:00 AM (11)  24-Month Safety Results of a Randomized, Multicenter, Double-Blind Study of Everolimus vs Azathioprine in De Novo Heart Transplant Recipients, H. Eisen,1 J. Kobashigawa,2 R.C. Starling,3 N. Cretin,4 J.S. Jaffe,4 J. Murphy,5 1Temple University, Philadelphia, PA; 2UCLA, Los Angeles, CA; 3Cleveland Clinic Foundation, Cleveland, OH; 4Novartis Pharmaceuticals, E.Hanover, NJ

11:15 AM (12)  Risk/Benefit Evaluation of Tacrolimus (TAC) vs. Cyclosporine Microemulsion (CsA) after Cardiac Transplantation, M. Rinaldi,1 M. Grimm,2 N.A. Yonan,3 the European Tacrolimus Heart Study Group, 1Cardiac Surgery Division, Ospedale Policlinico San Matteo, Pavia, Italy; 2Department of Cardiothoracic Surgery, Allgemeines Krankenhaus Wien, Vienna, Austria; 3Cardiac Transplantation Unit, Wythenshawe Hospital, Manchester, United Kingdom

11:30 AM (13)  Sirolimus in Combination with Tacrolimus for Primary Immunosupression after Heart Transplantation, M. Mueller,1 B. Meiser,1 J. Groetzner,1 I. Kaczmarek, B. Reichart,1 1Department of Cardiac Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany

11:45 AM (14)  Five-Year Results of a Randomized Single Center Study of Tacrolimus (TAC) vs. Neoral Cyclosporine (CYA), J.A. Kobashigawa,1 J.D. Moriguchi,1 J. Patel,1 J. Shaw,1 B.T. Oeser,1 H. Laks,1 University of California at Los Angeles, Los Angeles, CA

10:30 AM-NOON
CONCURRENT SESSION 3
Basic Science 1: Alloimmune Responses
(Plaza A)
Moderators: Abbas Ardehali, MD and Richard N. Pierson, III, MD

10:30 AM (15)  Donor Specific Cytotoxic Non-Responsiveness Long after Clinical Heart Transplantation, C.C. Baan,1 A.H.M.M. Balk,2 B.J. van der Mast,3 S. van den Engel,4 A.P. Maat,2 W. Weimar,1 1Internal Medicine; 2Thorax Center, Erasmus Medical Center, Rotterdam, Netherlands

10:45 AM (16)  Chemokine MIG/CXCL9 Stimulates CD4 T Lymphocyte Proliferation and IFN-Expression, D. Whiting,1 G. Hsieh,1 A. Banerji,1 G.T. Schnickel,1 J. Yun,1 B. Bonavida,2 A. Ardehali,1 1Division of Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA

11:00 AM (17)  Indirect Allorecognition of MHC Class I Peptides Accelerates Lung Allograft Rejection in Miniature Swine, T. Shoji,1 D.R. Johnston,2 K. Hoerbelt,2 J.C. Wain,3 S.L. Houser,4 L.C., Benjamin,4 R.S. Lee,1 R.S. Hasse,1 L.G. Ledgerwood,1 D.A. Guenther,1 A. Muniappan,1 M.H. Sayegh,
J.C. Madsen, J.S. Allan, Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA; Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA; Laboratory of Immunogenetics and Transplantation, Brigham and Women’s Hospital, Boston, MA

11:15 AM (18) Human Endothelial T Cell Costimulation Is Inhibited by Interleukin 10 (IL-10) through Induction ofSuppressor of Cytokine Secretion-3 (SOCS-3) and ILT-3. C.A. Gleissner, A. Zatrow, R. Klingenberg, N. Xia, T.J. Dengler, Cardiology, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany

11:30 AM (19) Inhibition of T-Lymphocyte Stimulation by a Trophoblast Non-Coding RNA Suppressing MHC Class II Expression in Murine B-Cells. A. Geirsson, A.L.M. Bothwell, G.L. Hammond, Department of Surgery, Yale University School of Medicine, New Haven, CT; Section of Immunobiology, Yale University School of Medicine, New Haven, CT


10:30 AM-NOON
CONCURRENT SESSION 4
Donor Management, Preservation, and Organ Distribution 1: Plucking More From the Organ Orchard: Better Use of Existing Donors (Plaza B)
Moderators: Stephen R. Large, MD and Alfredo Trento, MD


11:00 AM (23) Pre-Implantation Multiple Cytokine MRNA Expression Analysis in Donor Lung Grafts Predicts Survival after Lung Transplantation in Humans. H. Kaneda, Ç. Gutierrez, M. de Perrot, M. Yamane, S. Quadri, T. Arenovich, T. Waddell, M. Liu, S. Keshavjee, Thoracic Surgery Research Laboratory, Toronto General Hospital Research Institute, Toronto, ON, Canada


11:30 AM (25) Use of Marginal Donor Hearts in Paediatric Heart Recipients. S. Neligan, P. Whitmore, M.J. Fenton, M. Elliott, M. Burch, Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children, London, United Kingdom


12:15 PM-1:30 PM
LUNCHEON SYMPOSIUM
IVUS and Cardiac Allograft Vasculopathy: Late Breaking Trials (Grand Ballroom B)
Supported by an Educational Grant from Novartis
Mandene R. Mehra, MD and Randall C. Starling, MD

12:15 PM (27) Multi-Center Intravascular Ultrasound Validation Study among Heart Transplant Recipients: Outcomes after 5 Years, J.K. Kobashigawa, J.M. Tobis, R.C. Starling, M.R. Mehra, A. Young, H. Valantine, A. Smith, H. Anzai, B.T. Oeser, K. Abyeywickrama, J. Murphy, N. Çetin, University of California at Los Angeles, Los Angeles, CA; Cleveland Clinic, Cleveland, OH; Ochsner Clinic, New Orleans, LA; Stanford University, Stanford, CA; Emory University, Atlanta, GA; Novartis Pharma, Basel, Switzerland

12:30 PM (28) Favorable Effect of Everolimus on Cardiac Allograft Vasculopathy Is Maintained through 24 Months, E.M. Tuzcu, J.A. Kobashigawa, H.J. Eisen, R.C. Starling, T. Crowe, K. Abyeywickrama, J.S. Jaffe, Cleveland Clinic Foundation, Cleveland, OH; University of California at Los Angeles, Los Angeles, CA; Temple University, Philadelphia, PA; Novartis Pharmaceuticals, E. Hanover, NJ; Cleveland Clinic Foundation; Novartis Pharmaceuticals; Novartis Pharmaceuticals


1:00 PM Chairs' Perspectives and Panel Discussion

2:00 PM-3:30 PM CONCURRENT SESSION 5
Mechanical Circulatory Support 1: Insights to Bridge to Recovery: Is It a Realistic Goal? (Grand Ballroom B)
Moderators: George M. Wieselthaler, MD and Asghar Khaghani, MD

2:00 PM (30) Low Rate of Cardiac Recovery Despite Cellular Recovery during LVAD Support: Results from the LVAD Working Group, S. Maybaum, O.H. Frazier, R. Starling, L. Miller, S. Murali, K. Aaronson, K. Margulies, S. Xydas, S. McKee, G. Torre, Columbia University, NY, NY; Texas Heart Inst, Houston, TX; The Cleveland Clinic, Cleveland, OH; University of Minnesota, Minneapolis, MN; University of Pittsburgh, Pittsburgh, PA; University of Michigan, Ann Arbor, MI; Temple University, Philadelphia, PA; Baylor College of Medicine, Houston, TX

2:15 PM (31) Mechanical Unloading Reverses Alterations in Cytoskeletal Proteins in the Failing Human Heart, L.A. Aquila-Pastir, N.G. Smedira, P.M. McCarthy, J.B. Young, C.S. Moravec, Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH; Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Cleveland, OH

2:30 PM (32) Sustained Reversal of Electrical Remodeling during and after Left Ventricular Assist Device (LVAD) Support, J. Hardy, C. Terracciano, P. Tansley, E. Barks, C. Bowles, A. Khaghani, N. Banner, M. Yacoub, Cardiothoracic Surgery, Harefield Hospital, Harefield, Middlesex, United Kingdom

2:45 PM (33) Mechanical Unloading Leads to Echocardiographic, Electrophysiological, Histological and Serological Recovery, S. Xydas, Y. Naka, D.M. Mancini, C.C. Marboe, J. Cohen, A. Magnano, A.D. Arnold, N.M. Joyce, M.C. Oz, S. Maybaum, Departments of Surgery, Medicine, and Pathology, Columbia University, New York, NY

3:00 PM (34) Selective Upregulation of the Beta1-Adrenergic Receptor, Dephosphorylation of Cardiac Troponin I and Influence of Beta-Blocker Therapy in Patients Suffering from Terminal Heart Failure and Supported by Ventricular Assist Devices, H. Milting, Ch. Scholz, M. Freitag, K. Jaquet, O.E. Brodde, B. Pieske, A. Kassner, L. Arusoglu, D. v. Lewiniski, R. Koerfer, A. El Banayosy, Research Laboratory, Ruhr-University, Heart- Diabetescenter NRW, Bad Oeynhausen, NRW, Germany; Research Laboratory Molecular Cardiology, Ruhr-University, St. Josef Hospital, Bochum, NRW, Germany; Department Pharmacology, University, Essen, NRW, Germany; Department Pneumology and Cardiology, Georg-August University, Goettingen, NDS, Germany

3:15 PM (35) Morphological and Molecular Effects of Clenbuterol on Cardiac Myocytes - Role of IGF-I, P.J.R. Barton, P.K. Bhavsar, L.E. Felkin, P.H. Sugden, M.H. Yacoub, Heart Science Centre, Harefield, Middlesex, United Kingdom; National Heart and Lung Institute, Imperial College, London, United Kingdom
2:00 PM-3:30 PM
CONCURRENT SESSION 6
Lung/Heart-Lung Transplantation 2: Pulmonary Vascular Disease
(Imperial)
Moderators: Keith McNeil, MD and Jean-Luc Vachiery, MD

2:00 PM (36) TRACLEER® (Bosentan), for the Treatment of Pulmonary Arterial Hypertension (PAH) – 6 Month Quality of Life Data, A. Keogh, P. Macdonald, T. Williams, K. McNeil, E. Gabbay, S. Proudman, P. Steele, J. Wlodarczyk, K. Trimble, St Vincent's Hospital, Sydney, NSW, Australia; Alfred Hospital, Melbourne, VIC, Australia; Prince Charles Hospital, Brisbane, QLD, Australia; Royal Perth Hospital, Perth, WA, Australia; Royal Adelaide Hospital, Adelaide, SA, Australia; JWCS, Sydney, NSW, Australia; Actelion Pharmaceuticals Pty Ltd, Sydney, NSW, Australia

2:15 PM (37) Soluble CD40 Ligand in Pulmonary Arterial Hypertension - Possible Pathogenic Role of Interaction between Platelets and Endothelial Cells, J.K. Damas,1 K. Otterdal,1 A. Yndestad,1 H. Aass,1 S.S. Froland,1 S. Simonsen,1 P. Aukrust,1,2 A.K. Andreassen,1 1Research Institute for Internal Medicine, University of Oslo, Oslo, Norway; 2Department of Cardiology, Rikshospitalet, Oslo, Norway; 3Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, Norway

2:30 PM (38) A Prospective Longitudinal Study of Airway Vasculature in the Pathogenesis of Bronchioitis Obliterans Syndrome (BOS), S.Y. Langenbach,1 L. Zheng,1 T. McWilliams,1 B. Levey,1 B. Orsida,1 M. Bailey,1 T.J. Williams,1,2 G.I. Snell,1,2 1Department of Allergy Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, VIC, Australia; 2Department of Medicine, Monash University, Melbourne, VIC, Australia

2:45 PM (39) Long Term Outcome of Bosentan Treatment in Primary Pulmonary Hypertension (PPH) and Pulmonary Arterial Hypertension Associated with the Scleroderma Spectrum of Diseases (PAH-SSD), R.E. Girgis,1 S.C. Mathai,1 J.A. Krishnan,1 F.M. Wigley,2 P.M. Hassoun,2 1Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, MD; 2Rheumatology, Johns Hopkins University, Baltimore, MD

3:00 PM (40) Alteration in B-Type Natriuretic Peptide Levels with Epoprostenol Therapy in Pulmonary Hypertension: An Important Marker of Clinical Outcome, M.H. Park, R.L. Scott, P.A. Uber, M.L. Franklin, H.O. Ventura, M.R. Mehra, Ochsner Clinic Foundation, New Orleans, LA

3:15 PM (41) Cardiac Transplantation for Congenital Heart Disease in Teenagers and Adults, R. Radley-Smith,1 N.R. Banner,1 A. Khaghani,1 J. Wray,1 M. Yacoub,1 Transplant Directorate, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

2:00 PM-3:30 PM
CONCURRENT SESSION 7
Clinical Heart Failure 1: New Concepts in Assessing Advanced Heart Failure Severity (Plaza A)
Moderators: Carlos Campana, MD and Nicholas R. Banner, MD

4:00 PM (42) Comparison between Gene Expression in Explanted Hearts with Endstage Coronary Artery Disease and in "Hibernating Myocardium", H. Hausmann,1 R. Pregla,1 R. Meyer,1 H. Sinilawski,1 M. Guterlet,1 H. Amthauer,1 R. Hetzer,1 Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; 2Nuclear Medicine and Radiology, Charite, Campus Virchow Clinic Berlin, Berlin, Germany

4:15 PM (43) Effects of Beta-Blockers and Resynchronization Therapy on the Performance of the Heart Failure Survival Score (HFSS), G.D. Distefano,1 M. Frigerio,1 F. Oliva,1 F.M. Turazza,2 A. Garascia,1 G. Foti,2 G. Mascoliaco,2 G. Cattafi,2 G. Magenta,2 M. Cipriani,2 1DeGasperis' Cardiac Department, Niguarda-Ca' Granda Hospital, Milan, Italy

4:30 PM (44) Utility of Iodine-123 Metaiodobenzylguanidine Scintigraphy on Candidate Selection for Heart Transplantation, Y. Yazaki, Y. Kamiyoshi, Y. Osamu, K. Osamu, M. Hongo, K. Kogashi, H. Kasai, K. Kubo, First Department of Internal Medicine, Shinshu University, Matsumoto, Nagano, Japan

4:45 PM (45) Sudden Death in Patients Evaluated for Heart Transplantation: HFSS Detects Possible Candidates for Prophylactic ICD Implantation, H. Naegele,1 M.A. Castel,1 G. Groth,1 F.M. Wagner,1 H.H. Reichenspunser,1 1Cardiac Surgery, University Clinic Eppendorf, Hamburg, Germany
5:00 PM (46)  B-Type Natriuretic Peptide, a Marker for Selection of Heart Transplant Candidates, M. Rothenburger,1 J. Stypmann,2 A. Hoffmeier,2 E. Berendes,2 C. Etz,2 A. Pioux,2 A. Rukosujew,2 A. Löher,2 H.B. Scheld,2 C. Schmid,3 Thoracic- and Cardiovascular Surgery, University Hospital, Muenster, Germany; 4Cardiology and Angiology, University Hospital, Muenster, Germany; 5Anesthesiology and Operative Intensive Care Medicine, University Hospital, Muenster, Germany; 6Institute of Clinical Chemistry and Laboratory Medicine, University Hospital, Muenster, Germany

5:15 PM (47)  Predictors of Survival in Heart Failure Patients in NYHA Class IV, D. Pini,1 L. Ardino,1 L. Genovese,2 P. Galimberti,2 B. Andreuzzi,1 A. Municino',1 M. Mangiavacchi,1 M. Gasparini,2 E. Gronda,1 Heart Failure Service, Istituto Clinico Humanitas, Rozzano, MI, Italy; 7Electrophysiology Service, Istituto Clinico Humanitas, Rozzano, MI, Italy

2:00 PM-3:30 PM  CONCURRENT SESSION 8  Pediatrics 1: Thoracic Transplantation for Congenital Disease  (Plaza B)  Moderators: Tom R. Karl, MD and Marilyn S. Woo, MD

2:00 PM (48)  The Impact of Pretransplant Diagnosis and Surgical Palliation on the Long-Term Outcome of Pediatric Cardiac Transplantation, J.M. Eckermann,1 A.J. Razzouk,1 L.L. Bailey,1 R.E. Chinnock,2 R.L. Larsen,2 J.K. Johnston,2 S.L. Robie,2 J.A. Fits,2 Surgery, Loma Linda University, Loma Linda, CA; 3Pediatrics, Loma Linda University, Loma Linda, CA

2:15 PM (49)  Heart Transplantation to a Physiologic Single Lung in Patients with Congenital Heart Disease, J.M. Lamour,1 D.T. Hsu,1 S. Pinney,1 S. Mital,1 J.M. Quaegebeur,2 R. Mosca,2 L.J. Addonizio,3 Pediatric Cardiology, Columbia University, New York, NY; 4Cardiology, Columbia University, New York, NY; 5Pediatric Cardiothoracic Surgery, Columbia University, New York, NY

2:30 PM (50)  Congenital Category Is Not a Risk Factor for Pediatric Heart Transplantation, K.R. Kanter,1 A.M. Berg,1 R.N. Vincent,1 W.T. Mahle,1 J.M. Forbess,1 P.M. Kirshbom,1 Division of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA; 6Division of Pediatric Cardiology, Emory University School of Medicine, Atlanta, GA

2:45 PM (51)  Airway Complications Following Pediatric Lung Transplantation: Incidence, Etiology, Management and Outcome, C.K. Choong,1 S.J. Sweet,1 E.N. Mendeloff,1 J. Bell,1 F.J. Haddad,1 J.S. Huang,1 P. Schuler,1 M. de la Morena,2 C.B. Huddleston,1 Cardiothoracic Surgery, Washington University Medical School, St. Louis, MO; 3Pediatric Pulmonology, Washington University Medical School, St. Louis, MO

3:00 PM (52)  10 and 20-Year Long-Term Survival after Pediatric Orthotopic Heart Transplantation, P. Kouretas,1 M. Ross,1 B. Reitz,3 R. Robbins,1 N. Shumway,1 S. Harbi,1 J. Miller,1 P. Gamberger,1 C. Chin,1 D. Bernstein,1 Pediatrics, Stanford University, Stanford, CA; 2Cardiothoracic Surgery, Stanford University, Stanford, CA

3:15 PM (53)  Role of Open Lung Biopsy for Diagnosis in Pediatric Lung Transplant Recipients: A Twelve-Year Experience, C.K. Choong,1 C.B. Huddleston,1 F.J. Haddad,1 E.N. Mendeloff,1 J. Bell,1 A. Froemming,1 P. Schuler,1 M. de la Morena,2 S.C. Sweet,2 Cardiothoracic Surgery, Washington University Medical School, St. Louis, MO; 3Pediatric Pulmonology, Washington University Medical School, St. Louis, MO

3:30 PM-4:00 PM  Coffee Break (Grand Ballroom A)

4:00 PM-5:30 PM  CONCURRENT SESSION 9  Clinical Heart Transplantation 1: Circulating Anti HLA Antibodies in Heart Transplantation  (Grand Ballroom B)  Moderators: Jeffrey D. Hosenpud, MD and Niloo M. Edwards, MD

4:00 PM (54)  HLA Class I and II Antibodies Post Heart Transplant Are Associated with Poor Allograft Outcome, A.R. Tambur,1 S. Pamboukian,1 P. Berikai,1 D. Delgado,1 L. Gu,1 N.D. Herrera,1 S. Dunlap,1 M.
4:15 PM (55) Significance of Persistent Post-Transplant Antibody after Cardiac Transplantation, S.K. Takemoto, J. Zhang, E. Chang, J. Sňaw, P.A. Ayele, B.T. Oeser, D.W. Gjertson, M.C. Fishbein, E.R. Reed, J.A. Kobashigawa, Immunogenetics Center; Cardiology; Surgical Pathology, UCLA David Geffen School of Medicine, Los Angeles, CA

4:30 PM (56) The Highly Sensitized Patient Awaiting Heart Transplantation: Success with Combination Therapy of Plasmapheresis and Intravenous Gamma Globulin, J.A. Kobashigawa, G. Cogert, J.K. Patel, H. Laks, Division of Cardiology, University of California, Los Angeles, Los Angeles, CA; Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

4:45 PM (57) Outcome after Pre-Transplant Plasmapheresis for Sensitized Recipients Awaiting Heart Transplantation, S.K. Takemoto, G. Cogert, B.T. Oeser, P.A. Ayele, D.W. Gjertson, M.C. Fishbein, E.R. Reed, J.A. Kobashigawa, Immunogenetics Center, University of California, Los Angeles, Los Angeles, CA; Cardiology, University of California, Los Angeles, Los Angeles, CA; Surgical Pathology, University of California, Los Angeles, Los Angeles, CA

5:00 PM (58) The Prospective Use of Plasmapheresis and IVIG in Sensitized Patients Prior to Heart Transplantation, M.W. Weston, M.M. Lopez-Cepero, L. DiChiara, LifeLink Transplant Institute, Tampa, FL; CardioTransplant, Tampa General Hospital, Tampa, FL

5:15 PM (59) The Relevance of HLA Antibody and a Donor Specific Flow Cytometry Crossmatch to Rejection and Graft Survival in Cardiac Allograft Recipients, P. Przybylowski, B. Radovanovic, O.H. Frazier, F. Smart, N. Acorda, P.V. Juarez, B.D. Kahan, R.H. Kerman, Surgery, Texas Heart Institute, Houston, TX; Surgery, University of Texas Medical School, Houston, TX

4:00 PM-5:30 PM

CONCURRENT SESSION 10
Cells, Animals, Machines: Are They the Future?
(Imperial)
Moderators: Paul Mohacsi, MD and Robert E. Michler, MD

4:00 PM (60) Combine Autologous Myoblast Intramyocardial Injection with Coronary Revascularization in Patients with Non-Acute Myocardial Infarction, F. Prosper, G. Rábago, A. Perez, J.J. Gavira, M.J. Garcia Velloso, J. Barba, P.L. Sanchez, C. Cañizo, J.M. Martí, M. Hernández, N. Lopez Holgado, J.M. Gonzalez, C. Martin Luengo, E. Alegria, J. Herrera, Cardiovascular, Clinica Universitaria, Pamplona; Hospital Clinico de Salamanca, Salamanca, Spain

4:15 PM (61) Surgical Treatment for Congestive Heart Failure Using Autologous Adult Stem Cell Transplantation: Early Results, A.N. Patel, L. Geffner, R.F. Vina, H.C. Urschel, Jr., R. Kormos, F. Benetti, Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; Cardiovascular Surgery, Benetti Foundation, Rosario, Argentina; Cardiothoracic Surgery, Baylor University Medical Center, Dallas, TX

4:30 PM (62) Gal (1,3)-Galactose on Xenogeneic Endothelium Is a Putative Ligand for Human Monocytes, M.D. Peterson, R. Jin, T.K. Waddell, Surgery, University of Toronto, Toronto, ON, Canada

4:45 PM (63) Lack of Porcine Endogenous Retrovirus (PERV) Infection in Pig-to-Baboon Heart Xenotransplantation with Persistent Depletion of Anti-Gal Antibodies Despite the Presence of Xenoquimerism, N. Domenech, M. Hermida, I. Moscoso, T. Diaz, R. Manez, Unidad de Investigacion, Chu Juan Canalejo, La Coruna, Spain

5:00 PM (64) Will Device Change-Out Be Inevitable in Destination Therapy?, S.J. Park, L.D. Joyce, K.K. Liao, A.J. Boyle, M.M. Colvin-Adams, S. Ormaza, J. Thompson, L.W. Miller, Cardiovascular Surgery, University of Minnesota, Minneapolis, MN; Cardiology, University of Minnesota, Minneapolis, MN

5:15 PM (65) Early Mechanical Restraint Improves Border Zone Function during Infarction Induced Ventricular Remodeling, J.J. Pilla, A.S. Blom, J. Aftuso, V.A. Ferran, J.H. Gorman III, R.C. Gorman, M.A. Acker, Radiology, University of Pennsylvania; Surgery, University of Pennsylvania; Medicine, University of Pennsylvania
4:00 PM-5:30 PM
CONCURRENT SESSION 11
Nursing and Social Sciences: Strategies for Optimizing Pre- and Post-Transplant Function
(Plaza A)
Moderators: Fabienne Doebbel, MsC, PhDc, and Katherine Hoercher, RN

4:00 PM (66) Impact of Adequacy of Transplant Specific Education on Clinical Outcomes after Heart Transplantation, A.J. Bordelon, P.A. Uber, M.R. Mehra, Ochsner Clinic Foundation, New Orleans, LA

4:15 PM (67) Relation between Quality of Life and Functional Variables in Lung Transplant Recipients, C. Sievers, C. Kugler, J. Niedermeyer, M. Struer, G. Warnecke, K. Pethig, A. Haverich, U. Tegtbur, Sportsmedicine, Hannover Medical School, Hannover, Germany; Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; Internal Medicine, University of Jena, Jena, Germany

4:30 PM (68) The Impact of Transplantation on the Cognitive Development and Behaviour of Children, J. Wray, R. Radley-Smith, Paediatrics, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

4:45 PM (69) Evaluation of a Fast-Track Cardiac Rehabilitation Program after Heart Transplantation, A.F. Kaan, C. Imai, A.G. Taylor, A.L. Zutz, S. Barr, Heart Transplant Program, St Paul's Hospital, Vancouver, BC, Canada

5:00 PM (70) Predictors of Physical Functional Disability at 5 - 6 Years after Heart Transplantation, K.L. Grady, D.C. Naftel, J.K. Kirklin, C. White-Williams, J. Kobashigawa, J. Chait, J.B. Young, D. Pelegrin, K. Patton-Schroeder, B. Rybarczyk, J. Daily, W. Piccione, A. Heroux, Cardiology, Rush University Medical Center, Chicago, IL; Cardiothoracic Surgery, University of Alabama, Birmingham, AL; Cardiology, University of California, Los Angeles, CA; Cardiology, Cleveland Clinic Foundation, Cleveland, OH

5:15 PM (71) Striving for Normalcy: Symptoms and the Threat of Rejection after Lung Transplant, A.J. DeVito Dabbs, L.A. Hoffman, V. Swigart, M.B. Happ, J.H. Dauber, A. Iacono, School of Nursing; Department of Pulmonary, Allergy & Critical Care, University of Pittsburgh, Pittsburgh, PA

4:00 PM-5:30 PM
CONCURRENT SESSION 12
Immunosuppression 2: Experimental Immunosuppression
(Plaza B)
Moderators: Karl B. Lemstrom, MD and Howard Eisen, MD

4:00 PM (72) CCR5 Blockade Modulates the Primate Immune Response after Cardiac Allotransplantation, C. Schroeder, R.N. Pierson III, G. Wu, L.B. Peterson, M.S. Springer, A.M. Azimzadeh, I.I. Singer, J.A. DeMartino, Division of Cardiac Surgery, University of Maryland, Baltimore, MD; Research Laboratories, Merck Inc, Rahway, NJ

4:15 PM (73) Peroxisome Proliferator-Activated Receptor- Activation Ameliorates Acute Rejection in Rat Cardiac Allografts, Y. Tanaka, K. Okada, T. Hasegawa, M. Okada, Y. Okita, Department of Cardiothoracic Surgery, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan

4:30 PM (74) Gene Transfer-Based Blockade of IL-1, IL-17, IL-18, RANTES or MCP-1 Cytokine Activatory Pathways Results in Prolonged Allograft Survival in a Rat Model of Heart Transplantation, J. Li-Zhong, S. Fleury, J. Dudler, L.K. von Segesser, G. Vassalli, 1,2,3 Cardiology, CHUV University Hospital, Lausanne, Switzerland; Organ Transplantation, CHUV University Hospital, Lausanne, Switzerland; Transplantation Research, Novartis Pharma, Basel, Switzerland; Rheumatology, CHUV University Hospital, Lausanne, Switzerland; Cardiovascular Surgery, CHUV University Hospital, Lausanne, Switzerland

4:45 PM (75) Tetrahydrobiopterin Prevents Cyclosporine Induced Vasomotor Dysfunction of the Rat Thoracic Aorta, D. Ramzy, L.C. Tumiati, S. Miriu, D. Delgado, H.J. Ross, V. Rao, Cardiac Surgery, Toronto General Hospital, Toronto, ON, Canada; Cardiology, Toronto General
5:00 PM (76) The Effect of CSA, FK506 and MMF on the Expression of Inducible Cell Adhesion Molecules (iCAMs), Transplant Vasculopathy and Leukocyte Infiltration, M.H.C. Richter, A. Rahmel, H. Bittner, J. Gummert, F.W. Mohr, University of Leipzig, Heart Center of Leipzig, Leipzig, Germany

5:15 PM (77) FK 778 Directly Inhibits Adhesion Molecule Expression after Cardiac Transplantation: In Vivo and In Vitro Studies, T. Deuse, S. Schrepfer, F. Koch-Nolte, H.J. Schäfer, Cardiovascular Surgery, University Hamburg, Hamburg, Germany; Immunology, University Hamburg, Hamburg, Germany; Pathology, University Hamburg, Hamburg, Germany; Pharmacology, University Hamburg, Hamburg, Germany

5:30 PM-6:30 PM MODERATED POSTER SESSION 1/Wine and Cheese Reception (Yosemite)

Immunosuppression
Moderator: Clyde W. Yancy, Jr., MD

(78) Chronic Renal Failure Following Lung Transplantation, K.D. Lake, A.O. Ojo, L.L. Christensen, R.T. Bustami, R.M. Merion, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; Scientific Registry of Transplant Recipients, Ann Arbor, MI; Department of Surgery, University of Michigan, Ann Arbor, MI

(79) Renal Recovery after Conversion to Mycophenolate Mofetil (MMF) and Sirolimus (Sir) as Calcineurininhibitor-Free Immunosuppression in Late Cardiac Transplant Recipients, J. Groetzner, I. Kaczmarek, P. Landwehr, M. Mueller, L. Buehse, M. Vogeser, P. Ueberfuhr, S. Daebritz, B. Meiser, B. Reichart, Cardiovascular Surgery, LMU University Hospital Grosshadern, Munich, Germany; Clinical Chemistry, LMU Grosshadern, Munich, Germany

(80) Early Experience with Sirolimus Based, Calcineurin Inhibitor Free, Immunosuppression for Lung Transplant Recipients, Y. Shargall, M. de Perrot, T.K. Waddell, L.S. Singer, D. Hadjiliadis, M. Hutcheon, S. Chernenko, A. Pierre, F. D'Ovidio, S. Kheshavjee, Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada

(81) RAD Alters the Immune Response in Bronchoalveolar Lavage(BAL) and Endobronchial Biopsy(EBB) Post Lung Transplantation(LTX), G. Snell, B. Levvey, L. Zheng, M. Bailey, B. Orsida, T. Kotsimbos, T. McWilliams, H. Whitford, E.H. Walters, T. Williams, Allergy, Immunology & Respiratory Medicine, The Alfred, Melbourne, Australia; Monash University, Melbourne, Australia

(82) Plasmapheresis for Humoral Rejection and Severe Graft Dysfunction after Heart Transplantation, K. Ramasubbu, D.H. Yawn, V. Thohan, M. Loebe, J.A. Lafuente, G.P. Noon, G. Torre-Amione, M.M. Koerner, Department of Medicine, Section of Cardiology, Baylor College of Medicine, Methodist DeBakey Heart Center, Houston, TX; Department of Surgery, Baylor College of Medicine, Methodist DeBakey Heart Center, Houston, TX; Department of Pathology, Baylor College of Medicine, Methodist DeBakey Heart Center, Houston, TX

(83) Successful Treatment of Vascular Rejection with Rituximab in Cardiac Transplants, H.E. Garrett, Jr., K. Groshart, D. Duvall-Seaman, C. Graves, R. Suggs, B. Helsley, Department of Surgery, University of Tennessee, Memphis, TN

Post Transplant Complications
Moderator: Roberta C. Bogeav, MD

Pamboukian,¹ D.C. McGiffin,² D.C. Naftel,² ¹Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL; ²Cardiovascular Surgery, University of Alabama at Birmingham, Birmingham, AL

(85) Has Newer Therapies Improved the Survival of Cardiac Death Due To Transplant Coronary Artery Disease?, S.-Z. Gao,¹ B. Cantin,¹ M. Perlroth,¹ S. Hunt,¹ J. Schroeder,¹ ¹Cardiology, Stanford University School of Medicine, Stanford, CA

(86) Routine Angiography Post Cardiac Transplantation: What Value?, M.A.J. Rockx,¹ P.W. Pflugfelder,¹ W.J. Kostuk,¹ ¹Cardiology, London Health Sciences Centre - University Campus, London, ON, Canada

(87) Epidemiology and Clinical Implications of Atypical Mycobacterial Infections in Cadaveric Lung Transplants: The Role of Surveillance Bronchoscopy and Bronchoalveolar Lavage Phenotype, C. Hoopes,¹ A.F. Luetkemeyer,¹ D. Jablons,¹ T. Hall,¹ T. Weaver,¹ J. Golden,¹ ¹Thoracic Surgery, University of California San Francisco, San Francisco, CA

(88) Retransplantation - Never Too Old for One?, J.K. Patel,¹ B.T. Oeser,¹ S. Go,¹ B.J. Rivera,¹ M.L. Plesa,¹ J.D. Moriguchi,¹ J.A. Kobashigawa,¹ ¹University of California at Los Angeles, Los Angeles, CA

(89) Intravascular Ultrasound Findings 10 Years after Heart Transplantation, J. Segovia,¹ L. Alonso-Pulpón,¹ J. Jiménez-Mazuecos,¹ B. Fuertes,¹ F. Alfonso,² R.A. Hernández-Antolín,² J. Escaned,² C. Bañuelos,² M. Sabaté,² C. Macaya,² ²Cardiac Transplant Unit, C. Puerta de Hierro, Madrid, Madrid, Spain; ²Interventional Cardiology Department, Hosp. Clínico, Madrid, Madrid, Spain

Outcomes in Lung and Heart-Lung Transplantation
Moderator: Vincent G. Valentine, MD

(90) Quantifying Health Status and Functional Outcomes Following Lung Transplant, J.M. L’Abbe,¹ M. Loadman Joyce,¹ M.J. Bentley,¹ D.C. Lien,¹ ¹Transplant Services, University of Alberta Hospital, Edmonton, AB, Canada

(91) Survival Following Lung Transplantation (LT) of Cystic Fibrosis (CF) Patients Infected with Burkholderia Cepacia Complex (Bcc), B.D. Alexander,¹ E.A. Wills,¹ L.B. Reller,¹ E.S. Yow,² S.M. Palmer,¹ R.D. Davis,¹ C.W. Woods,¹ J.J. LiPuma,¹ ¹Division of Infectious Diseases and International Health, Department of Medicine, Duke University Medical Center, Durham, NC; ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC; ³Division of Pulmonary and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, NC; ⁴Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, Durham, NC; ⁵Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, Ann Arbor, MI

(92) High Dose Rate Brachytherapy for In-Stent Restenosis of Lung Transplant Bronchi, S.M. Studer,¹ B.A. Johnson,¹ K.R. McCurry,² E. Cano,¹ A.T. Iacono,¹ ¹Division of Pulmonary & Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA; ²Division of Cardiothoracic Surgery, University of Pittsburgh

(93) Successful Transplantation of B. cepacia Complex Infected Cystic Fibrosis Patients; Transplanting B. cenocepacia (Genomovar III) Infected Patients, A. De Soyza,¹ A. McDowell,² J.R.W. Govan,³ K.F. Gould,⁴ P.A. Corris,¹ ¹Transplantation and Immunobiology, University of Newcastle, Newcastle, Tyne and Wear, United Kingdom; ²Biomolecular Sciences Group, School of Pharmacy, Queen's University, Belfast, Northern Ireland, United Kingdom; ³Medical Microbiology, University of Edinburgh, Edinburgh, Lothian, United Kingdom; ⁴Medical Microbiology, Freeman Hospital, Newcastle, Tyne and Wear, United Kingdom
(94) Lung Transplant with Concomitant Cardiac Surgery: Results and Long-Term Survival, K. Parekh,1 N. Moazami,1 B.F. Meyers,1 T.J. Guthrie,1 E.P. Trulock,2 J.D. Cooper,1 G.A. Patterson,1 1Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; 2Division of Pulmonary Medicine, Washington University School of Medicine, St. Louis, MO

(95) Heart-Lung Transplantation for Complex Pulmonary Atresia: A Single Centre Experience, R. Radley-Smith,1 N.R. Banner,1 A. Khaghani,1 J. Wray,1 M. Yacoub,1 1Transplant Directorate, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

Heart Transplant Follow-Up
Moderator: Hannah A. Valantine, MD

(96) Frequent Surveillance Biopsies Do Not Improve Survival Following Heart Transplant, C.K. Wallace,1 M. Koerner,2,3 V. Thohan,2,3 G. Torre-Amione,2,3 1Baylor College of Medicine, Houston, TX; 2Department of Medicine, Cardiology Section, Baylor College of Medicine, Houston, TX; 3The Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX

(97) Pre-Operative Diabetes Is Associated with Reduced Survival in the Early and Chronic Phase after Heart Transplantation, T.J. Dengler,1 R. Klingenberg,1 C.A. Gleissner,1 A. Koch,2 F.U. Sack,2 P.A. Schnabel,3 A. Remppis,1 1Cardiology, University of Heidelberg, Heidelberg, Germany; 2Cardiac Surgery, University of Heidelberg, Heidelberg, Germany; 3Pathology, University of Heidelberg, Heidelberg, Germany

(98) Endothelial Dysfunction in Cardiac Transplant Recipients Is Associated with a Vasoconstrictor Response to L-NMMA and Elevated Endothelin Levels, S.S. Kushwaha,1 S. Higano,1 R. Nelson,1 G. Pumper,1 A. Lerman,1 1Cardiovascular Diseases, Mayo Clinic, Rochester, MN

(99) Noninvasive Identification of Cardiac Allograft Vasculopathy with Real-Time Myocardial Contrast Echocardiography: Comparison with IVUS, Coronary Angiography and 99mTc Sestamibi Perfusion Imaging, H.-U. Stempfle,1 C. Übleis,1 H.-X. Hoyer,1 P. Überfuhr,2 V. Klauss,1 K. Theisen,1 1Cardiology, Med. Poliklinik-Innenstadt, LMU, Munich, Germany; 2Cardiac Surgery, Klinikum Grosshadern, LMU, Munich, Germany

(100) Ex Vivo 31P Magnetic Resonance Spectroscopy (MRS) of Heart Grafts Provides Metabolic Markers of Early Dysfunction in Operating Room, T.G. Caus,1 F. Kober,2 A. Mouly-Bandini,1 S. Confort-Gouny,1 Y. Le Fur,2 M. Izquierdo,2 J.P. Ranjeva,2 P. Viout,2 D. Metras,1 P.J. Cozzone,2 M. Bernard,2 1Adult's Cardiac Surgery, University Hospital Timone, Marseilles, France, Metropolitan; 2CRMBM, Faculty of Medicine Timone, Marseilles, France, Metropolitan

(101) Benefits of Three Years of Controlled Exercise Rehabilitation on Heart Transplant Recipients, U. Tegtbur,1 K. Pethig,2 M.W. Busse,3 K. Jung,1 A. Haverich,4 1Sportsmedicine, Hannover Medical School, Hannover, Germany; 2Internal Medicine, University of Jena, Jena, Germany; 3Sportsmedicine, University of Leipzig, Leipzig, Germany; 4Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany

5:30 PM-6:30 PM
GENERAL POSTER SESSION 1
(Franciscan Ballroom)

Pediatrics

(102) Influence of Pre and Post-Transplant ELISA-Detected Anti-HLA Antibodies on Pediatric Heart Transplant Outcome, S. Di Filippo,1 A. Girma,1 S. Tsao,7 G.J. Boyle,7 S.A. Miller,7 S.A. Webber,2 S.K. Gandhi,7 A. Zeevi,1 1Transplant Pathology, Biomedical Science Tower, W1550, Pittsburgh, PA; 2Pediatric Cardiology, Children's Hospital UPMC, Pittsburgh, PA; 3Pediatric Cardiothoracic Surgery, Children's
(103) Basiliximab in Pediatric Heart Transplantation - Initial Experience, K.M. Ward, S.E. Crawford, S.G. Pophal, S.R. Rodgers, C.L. Backer, C. Mavroudis, E. Pahl, Pediatric Cardiology, Northwestern Feinberg School of Medicine, Chicago, IL; Pathology, Northwestern Feinberg School of Medicine, Chicago, IL; Cardiovascular and Thoracic Surgery, Northwestern Feinberg School of Medicine, Chicago, IL

(104) Experience with Sirolimus in Pediatric Cardiac Transplant Recipients, T.M. Shankel, D.C. Cutler, J.K. Johnston, J.A. Fitts, R.E. Chinnock, Pediatric Heart Transplant Program, Loma Linda University Children's Hospital, Loma Linda, CA

(105) Non-Adherence to Therapy Is a Common Cause of Death in Adolescence Following Heart or Lung Transplantation, T. Lunnon-Wood, P. Aurora, P. Whitmore, M.J. Fenton, R. Radley-Smith, M. Elliott, Department of Cardiothoracic Transplant, Great Ormond Street Hospital for Children, London, London, United Kingdom

(106) Post-Operative Use of Aerosolized Aztreonam in Cystic Fibrosis Patients Colonized with Burkholderia Cepacia Prior to Lung Transplantation, M.S. Woo, E. Perez, M.V. Horn, V.A. Starnes, Cardiothoracic Transplant Team, Childrens Hospital Los Angeles, Los Angeles, CA

(107) A Randomized Clinical Trial of Tacrolimus [Prograf®] and Cyclosporine [Neoral®] Immunosuppression in Pediatric Heart Recipients, S.M. Pollock-BarZiv, A.I. Dipchand, B.W. McCrindle, L.J. West, Cardiology, The Hospital for Sick Children, Toronto, ON, Canada; University of Toronto, Toronto, ON, Canada


(109) Value of Early Creatinine Clearance To Predict Late Renal Function in Pediatric Heart Transplant Patients, S. Di Filippo, G.J. Boyle, S.A. Miller, S.K. Gandhi, R. English, S.A. Webber, Transplant Pathology, Basic Science Tower, W1551, UPMC, Pittsburgh, PA; Pediatric Cardiology, Children's Hospital UPMC, Pittsburgh, PA

(110) Ten Year Survival after Paediatric Heart Transplantation: A Single Centre Experience, R. Radley-Smith, J. Wray, A. Khaghani, M. Yacoub, Transplant Directorate, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(111) Late Acute Cardiac Rejections in Pediatric Heart Transplantation: Incidence and Impact on Long-Term Outcome, M. Dandel, D. Kemper, H. Lehmkuhl, M. Hummel, C. Knosalla, R. Hetzer, Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

(112) Results of Cardiac Transplantation in Grown-Up Patients with Congenital Heart Disease, J. Groetzner, B. Reichart, P. Ueberfuhr, I. Kaczmarek, M. Mueller, P. Landwehr, J. Sachweh, B. Meiser, M. Naebauer, H. Netz, S. Daebritz, Department of Cardiac Surgery, Ludwig Maximilians University Hospital Grosshadern, Munich, Germany; Department of Internal Medicine, Germany; Department of Pediatric Cardiology

New Genes and Proteins in Thoracic Transplantation

(113) The TGF- Signalling Pathway Is Activated in Coronary Artery Vasculopathy, C. Atkinson, M. Southwood, E. Moseley, J. Wallwork, M. Goddard, Pathology Department, Papworth Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom; Transplant Department, Papworth Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom
(114) Bone Morphogenetic Protein Signalling Is down Regulated in the Intima of Transplant Coronary Artery Vasculopathy Lesions, M. Southwood, M. Goddard, E. Moseley, C. Atkinson, Pathology Department, Papworth Hospital NHS Trust, Cambridge, Cambridgeshire, United Kingdom

(115) Bone Morphogenetic Protein (BMP) and SMAD Signalling Is Important in the Development of the Human Pulmonary Vasculature, M.R. Southwood, P.D. Upton, C. Atkinson, S. Stewart, N.W. Morrell, Department of Pathology, Papworth and Addenbrookes Hospitals NHS Trusts, Cambridge, United Kingdom; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom

(116) Gene Expression Profiling by Multiplex, Real Time PCR in Bronchoscopic Biopsies and Lavages of Allografts in Lung Transplant Recipients, X. Xu, J.A. Golden, G. Dolganov, T. Weaver, K.D. Jones, S. Donnelly, G.H. Caughey, Cardiovascular Research Institute; Department of Pathology, University of California at San Francisco, San Francisco, CA

Issues and Challenges in Heart Failure Management


(118) Inflammatory Parameters as Predictors of Clinical Course in Patients with End-Stage Heart Failure, E.V. Potapov, F.D. Wagner, F. Hennig, H.D. Volk, S. Ignatenko, H.B. Lehmkühl, R. Hetzer, Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; Immunology, Charité-Humboldt University Berlin, Berlin, Germany

(119) Should MADIT-II Criteria Apply to Patients Treated in a Heart Failure Specialty Clinic?, M.C. Montpetit, S.H. Dunlap, M. McLeod, L. Gu, A.L. Heroux, Heart Failure and Transplant Program, Rush University Medical Center, Chicago, IL

(120) The Significance of a Low Initial Hematocrit Value as a Prognostic Factor in Patients with Severe Heart Failure, J. Terrovitis, G. Alexopoulos, E. Tsolakis, E. Tsagalou, S. Drakos, P. Papazaglou, G. Karanastasis, P. Gounopoulos, S. Makri, J. Nanas, Department of Clinical Therapeutics, University of Athens, Athens, Greece


(122) Insurance with Medicare/Medicaid Is Associated with Non-Adherence in Heart Failure Patients, S.V. Pamboukian, I. Nisar, S. Patel, L. Gu, M. McLeod, S. Dunlap, M.R. Costanzo, L. Hayes, A. Heroux, Cardiology, University of Alabama at Birmingham, Birmingham, AL; Cardiology, Rush Presbyterian St. Luke's Medical Center, Chicago, IL; Cardiology, Edward Hospital, Naperville, IL

(123) Anemia in Advanced Chronic Heart Failure: The Importance of Iron Deficiency, D. Karageorgopoulou, C. Matsouka, E. Tsolakis, J. Terrovitis, A. Ntalianis, G. Alexopoulos, J. Kanakakis, M. Anastasiou-Nana, J. Nanas, Department of Clinical Therapeutics, University of Athens, Athens, Greece

(124) Upgrade from Standard Right Sided Pacing to Cardiac Resynchronization Therapy Shows Clinical Benefit as in De Novo Implantation, S.V. Pamboukian, I. Nisar, S. Patel, L. Gu, M. McLeod, R. Trohman, S. Dunlap, M.R. Costanzo, A. Heroux, Cardiology, University of Alabama at Birmingham, Birmingham, AL; Cardiology, Rush Presbyterian St. Luke's Medical Center, Chicago, IL;
3Cardiology, Edward Hospital, Naperville, IL

(126) Prognostication in Advanced Heart Failure with a Modified Heart Failure Survival Score That Takes into Account Beta-Blockers and Cardiac Resynchronization Therapy, G.D. Distefano, M. Frigerio, P. Oliva, F.M. Turazzia, G. Foti, A. Garascia, G. Masciocco, M. Lunati, G. Cattafi, "A De Gasperis" Cardiac Department, Niguarda-Ca' Granda Hospital, Milan, Italy

(127) Preoperative Screening Scale Predicts Prolonged ICU Stay after Implantation of Left Ventricular Assist Devices, J.A. Morgan, R. John, B.J. Lee, D.A. Jordan, M.C. Oz, Y. Naka,

1Surgery, Columbia University, New York, NY

New/Alternative Therapies to Transplantation

(128) VEGF-C Induces Collateral Formation in Ischaemic Porcine Heart Model, T.I. Pätilä, T.S. Ikonen, J. Rutanen, A. Ahonen, J. Lommi, K. Lappalainen, L. Ihlberg, T.A. Partanen, K. Virtanen, K. Alitalo, S. Ylä-Herttuala, A. Harjula, Department of Cardiothoracic Surgery, University of Helsinki Meilahti Hospital, Helsinki, Finland; Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Kuopio, Finland; Molecular/Cancer Biology Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland

(129) Autologous Bone-Marrow Stem Cell Transplantation for Ischaemic Cardiomyopathy. First Findings on Procedure Safety in Human, A. Angelini, I. Vendramin, C. Messina, P. De Coppi, M.V. Gazzola, R. Destro, L. Zanesco, C. Castellani, M. Della Barbera, M. Valente, G. Thiene, D. Casarotto, G. Gerosa, Institute of Pathological Anatomy, University of Padua, Padua, Italy; Department of Cardiovascular Surgery, University of Padua, Padua, Italy; Department of Pediatric Oncology-Haematology, University of Padua, Padua, Italy; Division of Pediatric Surgery, University of Padua, Padua, Italy

(130) High-Risk Coronary Interventions Involving Percutaneous Left Ventricular Support, B. Kar, A. Civitello, I.D. Gregoric, B. Radovancevic, C. Gemmato, T.J. Myers, R.M. Delgado, O.H. Frazier,

1Cardiopulmonary Transplantation and Cardiovascular Surgical Research, Texas Heart Institute, Houston, TX

(131) Ex-Vivo and In-Vivo Effects of Gas 914 on Pulmonary Xenograft Rejection, K. Wiebe, T. Schuerholz, M. Oezkur, M. Mengel, R. Schwinzer, M. Winkler, A. Haverich, Department of Surgery, Hannover Medical School, Hannover, Germany; Department of Anesthesiology, Hannover Medical School, Hannover, Germany; Department of Pathology, Hannover Medical School, Hannover, Germany


(133) CD20+ B-Cells Contribute to Natural Xenoreactive Antibody Production While Elicited Responses Are Partially Mediated by CD19-/CD20- B-Cells, G.V. Gonzalez-Stawinski, C.L. Lau, J.G. Gaca, R.D. Davis, Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH; Cardiothoracic Surgery, Barnes Jewish Hospital, St Louis, MO; Surgery, Duke University Medical Center, Durham, NC

(134) Withdrawn

Donor Management, Organ Preservation, Organ Distribution
Are out Hospital Non Heart Beating Donors (NHBD) Better Than Brain Death Lung Donors?, A. Varela, J.R. Nuñez, A.P. Gamez, F. Rio, M. Cordoba, J. Calatayud, P. Ussetti, M.C. Carreño, F. Alfageme, D. Gomez, Lung Transplantation, Hospital Universitario Clinica Puerta de Hierro, Madrid, Spain; Transplantation Unit, Hospital Clinico San Carlos, Madrid, Spain

How Long Does It Take To Optimise Donor Haemodynamics?, F. Ozalp, V. Pathi, U. Nkere, A. Kirk, A.J. Murday, Scottish Cardiopulmonary Transplant Unit, Glasgow Royal Infirmary, North Glasgow University Hospitals NHS Trust, Glasgow, United Kingdom

Systemic Neutrophil Activation and Lung Injury in the Brain-Dead Donor Is a Biphasic Phenomenon, V.S. Avlonitis, C.H. Wigfield, C.M. Gilfillan, J.A. Kirby, J.H. Dark, Department of Surgery, University of Newcastle, Newcastle upon Tyne, United Kingdom

Computer Simulation Predictions of the Impact of Broader Allocation within Zone A to Status 1A and 1B Heart Waitlist Patients, R.T. Bustami, S. Murray, K.P. McCullough, A.M. Rodgers, T.E. Hulbert-Shearon, R.A. Wolfe, W.S. Ring, R.M. Merion, SRTR/URREA, Ann Arbor, MI; SRTR/University of Michigan, Ann Arbor, MI; Southwestern Medical Center, University of Texas, Dallas, TX

Circulating Troponin I Is a Specific Marker of Donor Heart Dysfunction, B. Nyawo, S.M. Haj-Yahia, E.J. Birks, M. Kemp, N.R. Banner, A. Khaghani, M.H. Yacoub, Transplant Unit, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom; Heart Science Centre, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom; Biochemistry, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom


Increasing Frequency of Adenosine Monophosphate Deaminase 1 C34T T Allele in Cardiac Donors Is Associated with Reduced Pre Donation Inotrope Requirements, A.B. Taegtmeyer, J.B. Breen, J.D. Smith, N.R. Banner, M.H. Yacoub, P.J. Barton, Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; Tissue Typing Laboratory, Harefield Hospital, Harefield, Middlesex, United Kingdom; Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

Modified Reperfusion in Non-Standard Donor Lungs, G.T. Schnickel, D. Whiting, D. Ross, J. Belperio, M. Levine, R. Shpiner, H. Laks, R. Beygui, A. Argehali, Division of Cardiothoracic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA; Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA

Post Transplant Complications

The Use of Thiazolidinedione Agents in Post Cardiac Transplant Diabetic Patients, P. Srikanthan, W.A. Hsueh, J.A. Kobashigawa, Endocrinology, Diabetes and Hypertension, UCLA David Geffen School of Medicine, Los Angeles, CA; Endocrinology, Diabetes and Hypertension, UCLA David Geffen School of Medicine, Los Angeles, CA; Division of Cardiology, UCLA David Geffen School of Medicine, Los Angeles, CA

The Angiotensin Converting Enzyme Insertion Deletion Polymorphism Does Not Influence the Development or Progression of Post-Cardiac Transplant Hypertension, J.E. Fildes, A.H. Walker, C.G. Densem, A.K. Deiraniya, I.V. Hutchinson, C.T. Leonard, N. Yonan, The Transplant Centre, South Manchester University Hospital Trust, Manchester, Greater Manchester, United Kingdom; Cardiothoracic Surgery, Northern General Hospital, Sheffield, South Yorkshire, United Kingdom
(145) Diagnosis of Fungal Infections by Detection of Anti-Candida Manna Antibodies, Candida Mannan Antigen and Aspergillus Galactomannan Antigen in Patients Following Heart and Lung Transplantation, P. Heizmann, H.B. Lehmkul, W. Heizmann, O. Grauhan, R. Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany; Labor Professor Heizmann, Berlin, Germany

(146) Successful Treatment of Relapsed PTLD with Yt-90/Anti-CD20 Radioimmunotherapy, A.C. Patel, H.S. Lin, S.C. Sweet, Pediatric Allergy and Pulmonary Medicine, Washington University School of Medicine, St. Louis, MO; Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO

(147) Multiple Combination Bactericidal Testing for Patients with Cystic Fibrosis Infected with Burkholderia Cepacia before and after Lung Transplantation, A.R. Scott, J.M. Morton, C. Harbour, B. Rose, M. Robinson, M.L. Plit, A.R. Glanville, The Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia; The Infectious Disease Department, Sydney University, Sydney, Australia

(148) Safety and Efficacy of Rosuvastatin Therapy for the Prevention of Hyperlipidemia in Adult Cardiac Transplant Recipients, A.M. Samman, C. Imai, L. Straatman, J. Frohlich, A. Ignaszewski, Cardiology, St. Paul's Hospital, Vancouver, BC, Canada

(149) Increased Incidence of Hypertension after Orthotopic Cardiac Transplantation Compared with Heterotopic Cardiac Transplantation, A.B. Taegtmeyer, J.B. Breen, A.M. Crook, P.J. Barton, N.R. Banner, Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; Department of Public Health Research, Westminster Primary Care Trust, London, United Kingdom; Heart Science Centre, Harefield Hospital, Harefield, Middlesex, United Kingdom

(150) Post-Operative Atrial Dysrhythmias after Lung Transplantation, C.L. Lau, E.P. Trulock, T.J. Guthrie, A.A. Aloush, B.F. Meyers, R. Hachem, G.A. Patterson, M.M. Chakinala, Internal Medicine, Washington University School of Medicine, St. Louis, MO; Surgery, Washington University School of Medicine, St. Louis, MO

Clinical Lung/Heart-Lung Transplantation

(151) Predictive Value of the 6-Minute Walk Test in Lung Transplant Outcomes, J. L’Abbe, M. Loadman Joyce, S. Lau, M. Bentley, D. Lien, Transplant Services, University of Alberta Hospital, Edmonton, AB, Canada

(152) Single Centre Prognostic Modelling of Cystic Fibrosis Patients Referred for Lung Transplantation, A. De Soyza, J.H. Dark, P.A. Corris, Transplantation and Immunobiology Group, University of Newcastle, Newcastle, Tyne and Wear, United Kingdom; Cardiothoracic Surgery, Freeman Hospital, Newcastle, Tyne and Wear, United Kingdom

(153) Impact of Cystic Fibrosis-Related Diabetes (CFRD) on Lung Transplant Outcomes, M.R. Zamora, L.B. Edwards, D. Weill, T.L. Astor, M.R. Nicolls, Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO; The United Network for Organ Sharing, Richmond, VA

(154) Anaemia in Lung Transplant Recipients. Effect on Health Related Quality of Life, D. Swarbrick, P.A. Corris, Immunobiology and Transplantation Research Group, University of Newcastle, Newcastle upon Tyne, United Kingdom; Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom

(155) Cardiopulmonary Bypass, Controlled Reperfusion and C-1 Esterase Inhibitor Prevent Reperfusion Injury in Clinical Lung Transplantation, M. Kamler, U. Herold, A. Kravivski, I. Alekavic, R. Ragette, S. Hagl, H. Jakob, Thoracic and Cardiovascular Surgery, University of Essen, Essen,
(156) Long-Term Use of Inhaled Iloprost in Candidates Awaiting Heart-Heart-Lung- and Lung-Transplantation: Clinical Improvement and Reduced Pulmonary Pressure and Resistance, U. Schulz,1 G. Tenderich,1 S. Schulte-Eistrup,1 R. Koerfer,1 K. Minami,11 Thoracic and CardioVascular Surgery, Heart Center NRW, Bad Oeynhausen, NRW, Germany

(157) Long Term Outcome after Single and Bilateral Lung Transplantation for End-Stage Pulmonary Hypertension, M. de Perrot,1 Y. Shargall,1 T.K. Waddell1 J. Granton,1 K. McRae,1 A.F. Pierre,1 F. D'Ovidio,1 S. Chernenko,1 L.G. Singer,1 M. Hutcheon,1 S. Keshavjee,11 Toronto Lung Transplant Program, Toronto General Hospital, Toronto, ON, Canada

(158) Hypogammaglobulinemia after Lung Transplantation, L. Shah,1 S.M. Kawut,1 J.S. Wilt,1 M.K. O'Shea1 J.R. Sonett,2 S.M. Arcasoy,11 Lung Transplant Program, Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY; 2Lung Transplant Program, Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY

(159) Initial Experience with Oral Valgancyclovir for Pre-Emptive Cytomegalovirus Therapy after Lung Transplantation, C. Aigner,1 P. Jaksh,1 G. Winkler,1 C. Czebe,1 E. Devyatko,1 S. Taghavi,1 W. Wisser,1 W. Klepetko,11 Department of Cardiothoracic Surgery, Vienna University, Vienna, Austria

(160) A Controlled Trial of Exercise Rehabilitation after Lung Transplantation, U. Tegtbur,1 E. Guetzlaff,1 J. Niedermeyer,2 K. Pethig,3 G. Warnecke,4 C. Kugler,4 M. Strueber,4 M.W. Busse,4 A. Haverich,4 Sportsmedicine, Hannover Medical School, Hannover, Germany; 2Respiratory Medicine, Hannover Medical School, Hannover, Germany; 3Internal Medicine, University of Jena, Jena, Germany; 4Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Germany; 4Sportsmedicine, University of Leipzig, Leipzig, Germany

(161) A Donor History of Smoking Affects Early but Not Late Outcome from Lung Transplantation (LTx): A 7-Year Single Centre Experience, T. Oto,1 A. Griffiths,1 B. Levvey,1 D. Pilcher,1 H. Whitford,1 M. Rabinov,1 D. Esmore,1 T. Williams,1 G. Snell,11 Heart & Lung Transplant Unit, The Alfred Hospital, Monash University, Melbourne, VIC, Australia

(162) Function and Bulk of Respiratory and Limb Muscles after Lung Transplantation for Cystic Fibrosis, M. Estenne,1 C. Pinet,1 P. Scillia,2 M. Cassart,2 M. Lamotte,3 C. Knoop,3 C. Mélot,3 Chest Service, Erasme University Hospital, Brussels, Belgium; 2Department of Radiology, Erasme University Hospital, Brussels, Belgium; 3Department of Physiotherapy, Erasme University Hospital, Brussels, Belgium; 3Department of Intensive Care Medicine, Erasme University Hospital, Brussels, Belgium

Heart Transplantation

(163) Ventilatory Efficiency Is Improved in Cardiac Transplant Recipients Following 12 Weeks of Combined Aerobic and Strength Training, N.D. Eves,1 M.J. Haykowsky,1 L. Figgures,1 W.J. Tymchak,2 Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada; 2Faculty of Medicine, University of Alberta, Edmonton, AB, Canada

(164) Correlation between TGF- Genotypes and Acute and Chronic Rejection in Cardiac Transplant Recipients, R.L. Benza,1 J.P. Barchue,1 H.E. Grenett,1 C.S. Coffey,2 J.A. Tallaj,1 B.K. Rayburn,1 I.L. J. Pinderski,1 S.V. Pambokian,1 D.C. McGiffin,3 J.K. Kirklin,3 R.C. Bourge,11 Medicine, University of Alabama at Birmingham, Birmingham, AL; 2Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 3Surgery, University of Alabama at Birmingham, Birmingham, AL

(165) The Value of B-Type Natriuretic Peptide in Predicting Allograft Rejection in Cardiac

1 Cardiology- Heart Failure and Transplant, University of Utah School of Medicine, Salt Lake City, UT; 2Cardiology- Heart Failure and Transplant, LDS Hospital, Salt Lake City, UT

(166) N-Terminal Brain Natriuretic Peptide Can Help To Identify Patients with a Poorer Outcome Following Cardiac Transplantation, R.S. Gardner, F. Ozalp, C. Payne, A.J. Murday, T.A. McDonagh.

1Scottish Cardiopulmonary Transplant Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom; 2Department of Cardiology, University of Glasgow, Glasgow, United Kingdom


1Cardiology, University Hospital Heidelberg, Heidelberg, Germany; 2Cardiothoracic Surgery, University Hospital Heidelberg, Heidelberg, Germany; 3Pathology, University Hospital Heidelberg, Heidelberg, Germany


1Cardiology, Stanford University School of Medicine, Stanford, CA


1Medicine/Cardiology, UCLA School of Medicine, Los Angeles, CA


1Department of Cardiac Surgery, Ludwig-Maximilians-University, Munich, Bavaria, Germany

Basic Science and Immunobiology

(171) Localized Combinatorial IL-4 and IL-10 Gene Therapy Readjusts the Balance of Endogenous Th1/Th2 Cytokines and Induces the Tolerance of the Cardiac Allografts, H. Furukawa, K. Oshima, T. Tung, H. Russell, G. Cui, H. Laks, L. Sen, Surgery/Cardiothoracic Surgery, UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA; 2Medicine/Cardiology, UCLA Medical Center/UCLA School of Medicine, Los Angeles, CA


1Department of Cardiovascular Surgery, Kyoto University, Kyoto, Kyoto, Japan; 2Department of Biomaterials, Kyoto University, Kyoto, Japan

(173) Inhibition of NF-κB by IκB Super Repressor Gene Transfer Ameliorates Ischemia-Reperfusion Injury after Experimental Lung Transplantation, T. Ishiyama, S. Dhamarajan, M. Hayama, G.A. Patterson

1Surgery, Washington University School of Medicine, Saint Louis, MO


1Internal Medicine - Transplantation, Erasmus Medical Center Rotterdam, Rotterdam, ZH, Netherlands; 2Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, ZH, Netherlands; 3Thoracic Surgery, Erasmus Medical Center Rotterdam, Rotterdam, ZH, Netherlands; 4Cytokine Biology Unit - CLAI, Utrecht University, Utrecht, Utrecht, Netherlands

(175) The Role of P38 in Obliterative Airway Disease in Rats, A.S. Farivar, S.M. Woolley, M.S. Mulligan.

1Cardiothoracic Surgery, University of Washington Medical Center, Seattle, WA

(177) MHC-I Expression on Donor Allogeneic Embryonic Stem Cells Transplanted for Myocardial Repair Correlates with Indices of Differentiation, T. Kofidis, J.L. de Bruin, R.-J. Swijnenburg, D.R. Lebl, D.T. Cooke, M. Tanaka, R.C. Robbins, Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA

(178) Stimulation of Paracrine Pathways Enhances Embryonic Stem Cell Engraftment and Differentiation in the Injured Heart, J.L. de Bruin, T. Kofidis, T. Yamane, M. Tanaka, I.L. Weissman, R.C. Robbins, Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA; Department of Immunology, Stanford University Medical School, Stanford, CA

(179) Cytokine Gene Expression Profile in Myocardial Infarction and the Cardioprotective Effect of Des-Aspartate-Angiotensin-I (DAA-I), R.A. Jalil, H.Kh. Haider, S. Jiang, L. Ye, N.M. Idris, P.Z. Ding, K.M. Sim, E.K.W. Sim, Cardiothoracic Surgery, National University of Singapore, Singapore; National University Medical Institutes, National University of Singapore, Singapore; National Heart Centre, Singapore General Hospital, Singapore; Department of Pharmacology, National University of Singapore, Singapore

(180) In Vitro Functional Assessment of Human Skeletal Myoblast after Transduction with Adenoviral Bicistronic Vector Carrying Human VEGF\(_{165}\) and ANG-1, L. Ye, H.Kh. Haider, R. Ge, P.K. Law, N.M. Idris, R.A. Jalil, S. Aziz, E.K.W. Sim, Cardiothoracic Surgery, National University of Singapore, Singapore; National University Medical Institutes, National University of Singapore, Singapore; Department of Biological Sciences, National University of Singapore, Singapore; Cell Transplants Inc., Singapore, Singapore; Washington Adventist Hospital, Washington, DC

Mechanical and Circulatory Support

(181) First Clinical Experience with the Incor LVAD, C. Schmid, T. Tjan, C. Etz, C. Schmidt, F. Janssen, M. Rothenburger, H.H. Scheld, Thoracic and Cardiovascular Surgery, University Hospital Muenster, Muenster, NRW, Germany; Anesthesiology and Operative Intensive Care, University Hospital Muenster, Muenster, NRW, Germany

(182) Recent Trends in Biventricular Mechanical Circulatory Support, D.J. Farrar, R.L. Kormos, S.H. Reichenbach, J.D. Hill, Research and Development, Thoratec Corporation, Pleasanton, CA; Surgery, University of Pittsburgh, Pittsburgh, PA; Surgery, University of California, San Francisco, San Francisco, CA

(183) Improved Heart Transplant Survival in Patients Bridged with Ventricular Assist Device, M.C.Y. Chan, S. Moffatt, E.S. Shao, B. Cantin, M. Pelletier, P. Oyer, R.C. Robbins, S.A. Hunt, Cardiovascular Medicine, Stanford University, Stanford, CA; Cardiothoracic Surgery, Stanford University, Stanford, CA

(184) Short and Long Term LVAD Use Decreases Pulmonary Vascular Resistance, D.B. Dyke, E. Batts, A. Wu, T. Koelling, S. Wright, F.D. Pagani, Division of Cardiology, University of Michigan Health System, Ann Arbor, MI; Department of Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI; Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI

(185) Body Mass Index and Outcomes after Left Ventricular Assist Device Placement, J. Butler, R.L. Howser, P.M. Portner, R.N. Pierson III, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN; World Heart Inc., Oakland, CA; Department of Cardiothoracic Surgery, Stanford University, Stanford, CA; Division of Cardio Surgery, University of Maryland Medical Center, Baltimore, MD

Incidence and Clinical Management of Life-Threatening Left Ventricular Assist Device (LVAD) Failure, E.J. Birks, C.T. Bowles, M. Hipkin, J. Hardy, N.R. Banner, M.H. Yacoub, A. Khaghani, Transplant Unit, Royal Brompton and Harefield Hospital, Harefield, Middlesex, United Kingdom

Changes in Collagen Fractions of the Myocardium Induced by Mechanical Unloading of the Left Ventricle, J. Mueller, H. Liang, G. Wallukat, Y. Weng, R. Hetzer, Cardiac Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

Left Ventricular Recovery Following Support with Left Ventricular Assist Device, M.M. Colvin-Adams, S. Park, J. Thompson, A. Boyle, S. Ormaza, K. Liao, L.W. Miller, Cardiology, University of Minnesota, Minneapolis, MN; Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN

Total Artificial Heart CardioWest in Small Patients, P. Leprince, A. Pavie, Ph. Leger, N. Bonnet, E. Vaissier, J.P. Levasseur, V. Bors, I. Gandjbakhch, CT Surgery, Pitie Salpetriere Hospital, Paris, France

6:00 PM – 7:00 PM
Nursing and Social Sciences Scientific Council Meeting (Grand Ballroom B)
Pathology and Basic Science Scientific Council Meeting (Plaza A)
Pediatric Scientific Council Meeting (Union Square 21)
Pulmonary Hypertension Scientific Council Meeting (Plaza B)

6:30 PM-7:30 PM
Poster Display Session 1 Tear-Down (Franciscan/Yosemite)

7:00 PM-8:00 PM
Corporate Council Reception (President’s Suite)

6:30 PM-9:00 PM
SATELLITE SYMPOSIUM 9 (Imperial)
Challenges and Solutions for Improving Outcomes in Lung Transplant Supported by an educational grant from Chiron
Moderators: Hermann Reichenspurner, MD and Duane Davis, MD

6:30 PM Dinner Reception
7:15 PM Welcoming Remarks
7:20 PM A Historical Odyssey of Lung Transplantation: Challenges Overcome and Challenges To Come, Hermann Reichenspurner, MD, University Hospital Eppendorf, Hamburg, Germany
7:40 PM Surgical Issues in Lung Transplantation, Duane Davis, MD, Duke University Medical Center, Durham, NC
8:00 PM Current Issues in Lung Transplantation: Immunological Basis of Rejection, Adrianna Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA
8:20 PM Emerging Strategies in Lung Transplantation, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN
8:35 PM Panel Discussion

FRIDAY, APRIL 23, 2004
7:00 AM-8:00 AM  
Transplant Registry Meeting (Imperial)

7:00 AM-8:00 AM  
Morning Coffee (Grand Ballroom A)

7:00 AM-10:00 AM  
Poster Display Session 2 Set-Up (Franciscan/Yosemite)

7:00 AM-4:30 PM  
Exhibits Open (Grand Ballroom A)

7:00 AM-5:30 PM  
Speaker Ready Room (Green Room)

7:00 AM-6:30 PM  
Registration Desk Open (Yosemite)

7:55 AM-10:00 AM  
PLENARY SESSION: Late Breaking Clinical Trials in Heart Transplantation  
(Grand Ballroom B)  
Moderators: Sharon Hunt, MD and Robert C. Bourge, MD

7:55 AM Welcome and Introductions

8:00 AM (191)  
A Randomized, Prospective, Multi-Center Comparison of Tacrolimus, Mycophenolate Mofetil (MMF) and Steroids vs. Cyclosporine (Modified USP), MMF and Steroids vs Tacrolimus, Sirolimus and Steroids in De Novo Cardiac Transplant Recipients - 6 Month Report,  
J.A. Kobashigawa,1, 3 L. Miller,2 S. Russell,2 G. Ewald,2 M. Zucker,2 L. Goldberg,2 H. Eisen,2 D. Tolzman,2 W.E. Fitzsimmons,  
1University of California at Los Angeles, Los Angeles, CA; 2University of Minnesota, Minneapolis, MN; 3Duke University, Durham, NC; 4Washington University, St. Louis, MO; 5Beth Israel Hospital, Newark, NJ; 6University of Pennsylvania, Philadelphia, PA; 7Temple University, Philadelphia, PA; 8Fujisawa Healthcare, Inc., Deerfield, IL

8:15 AM (192)  
Molecular Testing and Prediction of Clinical Outcome in Heart Transplantation: A Prospective Multicenter Trial,  
M.R. Mehra, J. Kobashigawa, S. Hunt, H.J. Eisen, R. Starling, F.L.,1,  
1Cardiovascular Diseases, Ochsner Clinic, New Orleans, LA; 2UCLA, Los Angeles, CA; 3UCLA, Los Angeles, CA; 4University of Minnesota, Minneapolis, MN; 5Duke University, Durham, NC; 6Washington University, St. Louis, MO; 7Temple University, Philadelphia, PA; 8Fujisawa Healthcare, Inc., Deerfield, IL

8:30 AM (193)  
Sirolimus from the Time of Heart Transplantation - Persistent Protection from Graft Vasculopathy at 2 Years,  
A. Keogh, D. Muller, S. Faddy, P. Ruygrok, M. Richardson, A. Galbraith, St Vincent's Hospital, Sydney, Australia; Green Lane Hospital, Auckland, New Zealand; The Alfred Hospital, Melbourne, Australia; Prince Charles Hospital, Brisbane, Australia

8:45 AM (194)  
The Effect of Etanercept on Cardiac Transplants,  
G. Torre-Amione,1, 2 J.B. Young,3 B. Radovancevic,4 M. Koerner,2 V. Thohan,2 R. Bogev,2  
1Department of Medicine, Cardiology Section, Baylor College of Medicine, Houston, TX; 2The Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX; 3Kaufman Center for Heart Failure, The Cleveland Clinic Foundation, Cleveland, OH; 4Texas Heart Institute, St. Luke's Episcopal Hospital, Houston, TX; 5Transplant Section, Texas Transplant Institute, San Antonio, TX

9:00 AM (195)  
A 12-Month, Multicenter, Randomized, Adaptive Design, Open-Label Study To Evaluate the Benefit of C2 Hour Monitoring of Neoral on Safety and Efficacy Outcomes in De Novo Cardiac Transplant Recipients Receiving Basiliximab Induction,  
M. Cantarovich, H. Ross, J. Arizon,
9:15 AM (196) Randomised Controlled Trial of C0 Versus C2 Guided Therapeutic Drug Monitoring of Cyclosporin-A in Stable Heart-Transplant Patients, F. Ozalp, M.B. Will, A.J. McLennan, R.S. Gardner, W. Bolrand, T.A. McDonagh, A.J. Murday, Scottish Cardiopulmonary Transplant Unit, Glasgow Royal Infirmary, North Glasgow University Hospitals NHS Trust, Glasgow, United Kingdom; Department of Biochemistry, Gartnaval General Hospital, North Glasgow University Hospitals NHS Trust, Glasgow, United Kingdom

9:30 AM ISHLT Lifetime Achievement Award Recipient Invited Lecture: From Transplantation to Regeneration and Back, Sir Magdi Yacoub, MD, Magdi Yacoub Institute, Heart Science Center, Harefield, Middlesex, United Kingdom

10:00 AM-10:30 AM Coffee Break (Grand Ballroom A)

10:30 AM-NOON CONCURRENT SESSION 13 Mechanical Circulatory Support 2: Issues of Extended Use of MCS: Preparing for the New Era of Destination Therapy (Grand Ballroom B)
Moderators: Clifford H. Van Meter, Jr., MD and Aly El-Banayosy, MD

10:30 AM (197) Outpatients on Mechanical Circulatory Support: Experience with over 80 Patients; T.N.H. Drews, M. Jurmann, D. Kemper, M. Pasic, Y. Weng, R. Hetzer, German Heart Institute Berlin, Augustenburger Platz 1, Berlin, Germany

10:45 AM (198) An Automatic Speed Adaptation System for Implantable Rotary Blood Pumps and Its Clinical Evaluation, H. Schima, M. Vollkron, B. Benkowski, G. Morello, M. Quitian, M. Hiesmayr, E. Wolner, G. Wieselthaler, Department of Cardiothoracic Surgery and LBI, University of Vienna, Austria; "Department of Biomed. Eng., University of Vienna, Austria; "Department of Physical Medicine, University of Vienna, Austria; "Department of Cardiovasc Anaesthesia, University of Vienna, Austria; "Micromed Technology Inc, Houston, TX

11:00 AM (199) Right Ventricular Stroke Work Index (RVSWI) Predicts Duration of Inotropic Support after Left Ventricular Assist Device Implantation, S. Schenk, P.M. McCarthy, J. Feng, K.J. Hoercher, R.C. Starling, J.B. Young, L. Zhou, J.L. Navia, E.H. Blackstone, K. Fukamachi, Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH


11:30 AM (201) Withdrawn

11:45 AM (202) Predictors of Survival with a Totally Implantable Left Ventricular Assist System (LVAS): The European Lionheart Clinical Utility Baseline Study (CUBS), W.E. Pae, J.P. Boehmer, R. Koerfer, A. El-Banayosy, R. Hetzer, M. Vigano, A. Pavie, for the CUBS Study Group, Cardiothoracic Surgery and Cardiology, Penn State Milton S. Hershey Medical Center, Hershey, PA; Cardiothoracic Surgery and Cardiology, Penn State Milton S. Hershey Medical Center, Hershey, PA; Cardiothoracic Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany; Cardiothoracic Surgery, Bad Oeynhausen Heart Center, Bad Oeynhausen, Germany

10:30 AM-NOON CONCURRENT SESSIONS 14 Post Transplant Complications 1: A Potpourri (Imperial)
Moderators: Kate Gould, MB BS and Thomas Dengler, MD

10:45 AM (204) Two Year Pre-Emptive Approach of Post Transplant Lymphoproliferative Disease after Lung Transplantation, E.A.M. Verschuuren, A. de Haan, M. Erasmus, T.H. The, W. van der Bij, Pulmonology, University Hospital Groningen, Groningen, Netherlands; Medical Biology, University Hospital Groningen, Groningen, Netherlands; Clinical Immunology, University Hospital Groningen, Groningen, Netherlands

11:00 AM (205) Role of Voriconazole Prophylaxis for the Prevention of Invasive Aspergillosis (IA) at Six Months in Lung Transplant Recipients, S. Husain, D.B. Zaldonis, E.J. Kwak, K.R. McCurry, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA; Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

11:15 AM (206) Caspofungin (CSF) for Invasive Aspergillosis after Thoracic Organ Transplantation: First Experience in 10 Patients, J. Groetzner, P. Landwehr, K. Kaczmarek, M. Mueller, I. Adamidis, M. Weis, P. Ueberfuhr, P. Lamm, S. Daebritz, B. Meiser, B. Reichart, Department of Cardiovascular Surgery, Ludwig Maximilians University Hospital Grosshadern, Munich, Germany

11:30 AM (207) The Role of Hypogonadism on Bone Loss after Cardiac Transplantation: Is a Testosterone Replacement Therapy Necessary?, H.-U. Stempfel, J. Stief, P. Oberfuhr, K. Theisen, H.-Y. Sohn, Cardiology, Medical Poliklinik-Innenstadt, LMU, Munich, Germany; Cardiac Surgery, Klinikum Grosshadern, LMU, Munich, Germany

11:45 AM (208) Therapy To Prevent Osteoporosis May Be Discontinued One Year after Heart Transplantation in Patients with Normal Bone Density, V. Addesso, A. Cohen, D.J. McMahon, S. Maybaum, D. Mancini, P.B. Namerow, Medicine, Columbia University, New York, NY

10:30 AM-NOON CONCURRENT SESSION 15
Evolution of Immunosuppressive Strategies (Plaza)

10:30 AM (209) Results of a Tolerance-Enhancing Protocol in Human Lung Transplantation, K.R. McCurry, A. Zeevi, D.B. Zaldonis, A. Bertani, K. Spichy, K. McDade, A. Jacono, S.A. Yousem, T.E. Starzl, Department of Surgery, University of Pittsburgh, Pittsburgh, PA; Department of Pathology, University of Pittsburgh, Pittsburgh, PA; Division of Pulmonary, University of Pittsburgh, Pittsburgh, PA

10:45 AM (210) Final Results of the Study of Safety and Tolerability of Simulect® (Basiliximab) Versus OKT3 in Heart Transplantation, J.L. Rodríguez Lambert, M.G. Crespo Leiro, J. Segovia, L. Almenar, E. Roig, M.A. Gómez Sánchez, E. Lage, N. Manito, L.A. Pulipon, Cardiology, Heart Transplantation, H. Central de Asturias, Oviedo, Spain; Cardiology. Heart Transplantation, H. Juan Canalejo, La Coruña, Spain; Cardiology. Heart Transplantation, H. Clínica Puerta de Hierro, Madrid, Spain; Cardiology. Heart Transplantation, H. La Fe, Valencia, Spain; Cardiology. Heart Transplantation, H. Clínic i Provincial, Barcelona, Spain; Cardiology. Heart Transplantation, H. Virgen del Rocio, Sevilla, Spain; Cardiology. Heart Transplantation, H. de Bellvitge, L'Hospitalet del Llobregat, Barcelona, Spain

11:00 AM (211) Comparison of Basiliximab and Antithymocyte Globulin as Induction Agents after Lung Transplantation, R.R. Hachem, G.A. Patterson, E.P. Trulock, Pulmonary Division, Washington University School of Medicine, St. Louis, MO; Thoracic Surgery, Washington University School of Medicine, St. Louis, MO

11:15 AM (212) Comparison of Sirolimus Versus Azathioprine in a Tacrolimus Based Immunosuppressive Regimen in Lung Transplantation, S.M. Bhorade, V. Ahya, R. Kotloff, M. Baz, V. Valentine, S. Arcasoy, R. Love, R. Young, W.T. Vigneswaran, E.R. Garrity, Medicine, Loyola University Medical Center, Maywood, IL; Medicine, University of Pennsylvania Medical Center, Philadelphia, PA; Medicine, University of Florida, Gainesville, FL; Medicine, Ochsner Transplant Center, New Orleans, LA; Medicine, Columbia University, New York, NY; Thoracic/ Cardiovascular Surgery, University of Wisconsin, Madison, WI; Medicine, University of Alabama, Birmingham, AL

11:30 AM (213) Conversion to Sirolimus Lessens Renal Dysfunction in Heart Transplant (HTx)
Patients, J. Hunt, M. Lerman, T. Dewey, M. Magee, M. Mack, Transplant Center, Medical City Dallas Hospital, Dallas, TX

11:45 AM (214) Cyclosporin C2 Levels Determine Rejection Rates after Lung Transplantation; A.R. Glanville, C.L. Aboyoun, J. Morton, M. Plitt, M.A. Malouf, The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

NOON–12:15 PM
ANNUAL BUSINESS MEETING (Members only) (Grand Ballroom B)

NOON – 1:30 PM
ISHLT Editorial Board Meeting (Union Square 23/24)

12:30 PM–2:00 PM
LUNCHEON SYMPOSIUM: Immunosuppression in the Young and Old: More Similar Than Different?
(Imperial)
Supported by an educational grant from Fujisawa
Moderators: Bruno M. Meiser, MD and Linda J. Addonizio, MD

12:30 PM Long Term Outcomes with Calcineurin Inhibitor Immunotherapy in Adult Heart Transplantation, Jon Kobashigawa, MD, University of California at Los Angeles, Los Angeles, CA
12:50 PM Long Term Outcomes with Calcineurin Inhibitors in Pediatric Heart Transplantation, Steven A. Webber, MD, Children's Hospital of Pittsburgh, Pittsburgh, PA
1:10 PM Modified Immunosuppression in the Elderly Lung Transplant Recipient, Andreas Zuckerman, MD, University of Vienna, Vienna, Austria

1:30 pm Panel Discussion

2:00 PM–3:30 PM
CONCURRENT SESSION 16
Clinical Heart Transplantation 2: Miscellaneous
(Grand Ballroom B)
Moderators: Jayan Parameshwar, MD and Myung Park, MD

2:00 PM (215) Preferential Depletion of Myeloid Type Peripheral Blood Dendritic Cells during Acute Rejection of Human Heart Allografts, P. Athanassopoulos, L.M.B. Vaessen, A.H.M.M. Balk, A.P.W.M. Maat, A.J.J.C. Bogers, W. Weimar, Cardiothoracic Surgery; Internal Medicine; Cardiology, Erasmus MC, Rotterdam, Netherlands

2:15 PM (216) Prophylactic Suture Annuloplasty of the Tricuspid Valve During Orthotopic Heart Transplantation (OHT) – Intermeďiate Results of a Randomized Clinical Trial, V. Jeevanandam, P. Mather, H. Russell, S. Furokawa, J. Raman, Cardiac & Thoracic Surgery, University of Chicago Medical Center, Chicago, IL; Cardiac & Thoracic Surgery, Temple University, Philadelphia, PA

2:30 PM (217) Simvastatin Decreases Myocardial Tumor Necrosis Factor- Content in Heart Transplant Recipients, C.K. Wallace, S.J. Stetson, S.A. Kucuk, K.A. Becker, J.A. Farmer, S.C. McRee, M.M. Koerner, G.P. Noon, G. Torre-Amione, The Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX; The M.E. DeBakey Department of Surgery, Division of Transplantation and Assist Devices, The Methodist Hospital, Houston, TX; Medicine (Section of Cardiology), Baylor College of Medicine, Houston, TX; The Gene and Judy Campbell Lab for Cardiac Transplantation, The Methodist Hospital, Houston, TX; The Winters Center for Heart Failure Research, The Methodist Hospital, Houston, TX; Baylor College of Medicine, Houston, TX

2:45 PM (218) 10-Year Results of the Pravastatin Randomized Trial in Heart Transplant Recipients, J.A. Kobashigawa, J.D. Moriguchi, G. Cogert, A. Hage, M.A. Hamilton, M.E. Vassilakis, A. Marquez, L. Yeatman, J. Patel, H. Laks, Division of Cardiology, University of California at Los Angeles, Los Angeles, CA

3:00 PM (219) Negative Association between Blood Transfusions and Acute Cardiac Allograft Rejection, F.G. Fernandez, A. Jaramillo, G. Ewald, J. Rogers, M.K. Pasque, T. Mohanakumar, N.
Moazami,1 1Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO; 2Cardiology, Washington University School of Medicine, St. Louis, MO

3:15 PM (220) The Success of the Urgent Heart Offering Schemes in the UK, F.M. Seeney,1 J.H. Dark,2 R.L. Potter,1 J.C. Hussey,1 C.J. Rudge,1 UK Transplant, Bristol, United Kingdom; 2Cardiopulmonary Transplantation, Freeman Hospital, Newcastle, United Kingdom

2:00 PM-3:30 PM
CONCURRENT SESSION 17
Lung/Heart-Lung Transplantation 3: Modifying Outcomes in Lung and Heart-Lung Transplantation (Imperial)
Moderators: John Dark, MD and Lianne G. Singer, MD

2:00 PM (221) Highly Efficient Reduction of Waiting List Mortality in Lung Transplantation, M. Strueber,1 A.R. Simon,1 G. Warnecke,1 B. Gohrbandt,1 S. Fischer,1 J. Niedermeyer,2 A. Havenich,1 1Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, Hannover, Hannover, Germany; 2Department of Thoracic Medicine, Hannover Medical School, Hannover, Hannover, Germany

2:15 PM (222) Impact of Pulmonary Artery Pressure on Survival Following Lung Transplantation for Idiopathic Pulmonary Fibrosis, T.M. Whelan,2 R.F. Kelly,1 M.I. Hertz,2 L.B. Edwards,3 P.S. Dahlberg,1 Cardiovascular and Thoracic Surgery, University of Minnesota, Minneapolis, MN; 2Pulmonary Medicine, University of Minnesota, Minneapolis, MN; 3Research, ISHLT, Addison, TX

2:30 PM (223) Procalcitonin and Modified SOFA Score: The Best Predictors of Mortality after Heart and Lung Transplantation, N. Qedra,1 F.D. Wagner,1 J.J. Jonitz,1 K. Wegscheider,2 S. Buz,1 M. Loebe,2 R. Hetzer,3 Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Berlin, Germany; 2Department of Biometrics and Statistics, Department of Biometrics and Statistics, Hamburg, Hamburg, Germany; 3Michael E. DeBakey Department of Surgery, Division of Transplantation and Assist Devices, Baylor College of Medicine, Houston, TX

2:45 PM (224) Primary Graft Failure Is Associated with Increased Long-Term Mortality Following Lung Transplantation Independent of Development of BOS, J.D. Christie,1,3 V.N. Ahya,1 A. Pochetting,1 C. Gaughan,1 R.M. Kotloff,1 1Pulmonary and Critical Care Medicine; 2Thoracic Surgery; 3Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA

3:00 PM (225) Effect of Renal Replacement Therapy on Pulmonary Mechanics in Lung Transplantation, V.G. Valentine,1 L. Seoane,1 D.M. Fuchs,1 M.T. Knowler,1 G.S. Dhillon,1 D.E. Taylor,1 1Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA

3:15 PM (226) Outcome of Heart-Lung and Bilateral-Sequential Single Lung Transplantation for Cystic Fibrosis: A UK National Study, J.S. Ganesh,1 C.A. Rogers,1 R.S. Bonser,1 N.R. Banner,1 On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

2:00 PM-3:30 PM
CONCURRENT SESSION 18
Clinical Heart Failure 2: Advanced Heart Failure Management, Prognostication and Heart Transplant Outcome (Plaza)
Moderators: William T. Abraham, MD and Adrian B. VanBakel, MD, PhD

2:00 PM (227) Development and Validation of a Model To Predict Perioperative Mortality Following Heart Transplantation in the UK, J.S. Ganesh,1 C.A. Rogers,1 R.S. Bonser,1 N.R. Banner,1 On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, Clinical Effectiveness Unit, The Royal College of Surgeons of England, London, United Kingdom

2:15 PM (228) Renal Dysfunction Is More Likely in Recipients Bridged to Heart Transplantation with Inotropes Than with Left Ventricular Assist Devices: An Analysis of Pre-Transplant Characteristics in the Modern Era, S.G. Drakos,1 E.M. Gilbert,1 S.A. Moore,1 J.C. Stringham,1 E.H. Hammond,1 J.W. Long,1 T.C. Fuller,1 T.W. Kent,1 D.A. Bull,1 S.S. Schmitz,1 M.E. Hagan,1 B.A. Campbell,1 J.W. Folsom,1 L.A. Stamos,1 B.D. Horne,1 D.G. Renlund,1 Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine and Veterans
2:30 PM (229) **Impact of Body Mass Index on Survival Following Heart Transplantation.** J. Jimenez, L. Edwards, J. Jara, B. Bednard, S. Pham, S. Mallon, Medicine, University of Miami, Jackson Memorial Med. Ctr., Miami, FL; Surgery, University of Miami, Jackson Memorial Med. Ctr., Miami, FL; Research, United Network Organ Sharing, Richmond, VA


3:00 PM (231) **Nesiritide Serial Outpatient Infusions over 12 Weeks Show Trends towards Improved Left Ventricular Systolic Function Compared to “Standard” Therapy.** M.T. Saltzberg, A.J. Neumann, D.P. Horton, Midwest Heart Foundation, Downers Grove, IL; Scios, Inc, Sunnyvale, CA

3:15 PM (232) **Waiting List Survival and Cardiac Transplant Outcome of Patients Supported on Left Ventricular Assist Device vs. Inotropic Support: Comparison of Two Eras.** A. Zuckermann, A. Bodjajian, D. Dunkler, G. Wieselthaler, A. Mühbauer, W. Röthy, R. Pacher, M. Hüßmann, E. Wolner, M. Grimm, Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria; Department of Cardiology, University of Vienna, Vienna, Vienna, Austria

3:30 PM-4:00 PM
Coffee Break (Grand Ballroom A)

4:00 PM-5:30 PM
CONCURRENT SESSION 19
Aristotle's Corner
(Grand Ballroom B)
Moderators: John Wallwork, FRCP and Mandeep R. Mehra, MD

4:05 PM (233) **Clinton Redux: It’s the Malignancy, Stupid!** P.J. Hauptman, Division of Cardiology, Saint Louis University School of Medicine, St. Louis, MO

4:23 PM (234) **Xenotransplantation: A New Darwinian Advantage?** Z.I. Khalpey, J.L. Platt, Transplant Biology and the Depts of Surgery, Immunology & Pediatrics, Mayo Clinic, Rochester, MN

4:41 PM (235) **The Lazarus Syndrome and the Cult of the Superman** A.R. Glanville, The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

4:54 PM (236) **Transplant Rejection: Vertebrate Animals’ Programmed Maintenance of Internal Dynamic Molecular Architecture** O.E. Pajaro, Cardiothoracic Surgery, Mayo Clinic, Jacksonville, FL

5:12 PM (237) **Why Left Ventricular Assist Devices Are Not yet a Product That Has Matured to the Tornado Phase of the Market: Or Why Aren’t We Using More LVAD’s?** R.L. Kormos, Cardiothoracic Transplant Surgery, University of Pittsburgh, Pittsburgh, PA

4:00 PM-5:30 PM
CONCURRENT SESSION 20
Pathology: New Developments in Heart Transplant Pathology
(Imperial)
Moderators: Susan Stewart, FRCPath and Michael C. Fishbein, MD

4:00 PM (238) **C4d Staining of Cardiac Allografts Correlates with Alloantibody** R.N. Smith, N. Brousaides, S. Saidman, A.B. Collins, Pathology, Massachusetts General Hospital, Boston, MA

4:15 PM (239) **Detection of Vimentin Specific Autoimmune CD8+T Cells in Cardiac Transplant Patients** L.D. Barber, A. Whitelegg, J.A. Madrigal, N.R. Banner, M.L. Rose, Royal Free Hospital, Anthony Nolan Research Institute, London, United Kingdom; Transplant Medicine, Harefield Hospital, Harefield, Middlesex, United Kingdom; National Heart and Lung Institute, Imperial College, Harefield, Middlesex, United Kingdom
4:30 PM (240) C-Reactive Protein and Development of a Prothrombogenic Microvasculature in Heart Transplant Recipients, C.A. Labarrere, H.L. DiCarlo, M.A. Ortiz, C. Terry, D.E. Pitts, D.A. Hormuth, Methodist Research Institute, Clarian Health Transplant Center, Clarian Health Partners, Inc., Indianapolis, IN

4:45 PM (241) Acute Cellular Rejection after Human Heart Transplantation Is Associated with ICOS+ Graft-Infiltrating T Lymphocytes and Increased Endothelial Expression of Inducible Costimulator Ligand (ICOSL), R. Klingenberg, F. Autschbach, C. Gleissner, A. Koch, Ph.A. Schnabel, G. Richter, H.A. Katus, T.J. Dengler, Cardiology, University Hospital Heidelberg, Heidelberg, Germany; Pathology, University Hospital Heidelberg, Heidelberg, Germany; Cardiothoracic Surgery, University Hospital Heidelberg, Heidelberg, Germany; Pediatrics, University Hospital Halle, Halle, Germany

5:00 PM (242) Recipient Origin Cardiomyocytes in Endomyocardial Biopsies of Human Transplanted Hearts, A. Angelini, C. Castellani, M. Della Barbera, M. Valente, A. Gambino, A.L. Cafferio, G. Gerosa, G. Thiene, Institute of Pathological Anatomy, University of Padua, Padua, Italy; Department of Cardiovascular Surgery, University of Padua, Padua, Italy; Department of Cardiology, University of Padua, Padua, Italy

5:15 PM (243) The Effect of Immunosuppression on Bone Marrow-Derived Recipient Cells in Murine Cardiac Allografts, N. Rezai, A. Kerjner, S. Corbel, F.M.V. Rossi, B.M. McManus, T.J. Podor, Pathology and Laboratory Medicine, The iCAPTURE Centre, St. Paul's Hospital-University of British Columbia, Vancouver, B.C., Canada; Medical Genetics, Biomedical Research Centre/UBC, Vancouver, B.C., Canada

4:00 PM-5:30 PM CONCURRENT SESSION 21 Basic Science and Immunobiology 2: Chronic Rejection: Basic Mechanisms (Plaza) Moderators: Bruce R. Rosengard, MD and George Tellides, MD

4:00 PM (244) Inhibition of the Receptor Kinase Activity of VEGF and PDGF Protects Against the Development of Cardiac Allograft Arteriosclerosis, A.I. Nykänen, J.M. Tikkanen, P.K. Koskinen, K.B. Lemström, Cardiopulmonary Research Group of the Transplantation Laboratory, Helsinki University Central Hospital, Helsinki, Finland


4:30 PM (246) Targeting STAT-1 and AP-1 Transcription Factors by Decoy-Oligodeoxynucleotides Prevents Graft Vasculopathy in a Chronic Rat Cardiac Transplantation Model, T.H.W. Stadlbauer, S. Fiedel, H. Fingerhuth, A.H. Wagner, M. Hecker, H. Hölscheimer, Pathology and Laboratory Medicine, The iCAPTURE Centre, St. Paul's Hospital-University of British Columbia, Vancouver, B.C., Canada; Department of Cardiovascular Physiology, University of Giessen, Giessen, Germany; Department of Cardiovascular Physiology, University of Goettingen, Goettingen, Germany

4:45 PM (247) P53 Plays a Significant Role in the Pathogenesis of Allograft Vasculopathy, M. Thanikachalam, S. Li, A. Simmonds, M. Cheung, R. Vazquez-Padron, C.A. Liotta, A. Gambotto, A. Aitouche, S.M. Pham, Surgery, University of Miami, Miami, FL; Surgery, University of Pittsburgh, Pittsburgh, PA

5:00 PM (248) Combined Treatment with Epsilon Protein Kinase C Activator and Delta Protein Kinase C Inhibitor Ameliorates Ischemia Reperfusion Injury and Graft Coronary Artery Disease in Murine Cardiac Allografts, M. Tanaka, R.D. Terry, T. Koyanagi, K. Inagaki, T. Kofidis, M. Chochy-Rosen, R.C. Robbins, Department of Cardiothoracic Surgery, Department of Molecular Pharmacology, Stanford University, Stanford, CA

5:15 PM (249) The Profibrotic Cytokine Transforming Growth Factor Beta (TGF β) Is Elevated Early in the Development of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant Recipients (LTR), T.J. McWilliams, L. Zheng, B.E. Orsida, B.J. Levvey, E.H. Walters, H.M. Whitford, G.I. Snell, T.J. Williams, Allergy, Clinical Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia; Allergy, Clinical Immunology and Respiratory Medicine, Monash University, Melbourne, VIC, Australia
5:30 PM-6:30 PM
Moderated Poster Session 2/Wine and Cheese Reception (Yosemite)

Pediatric Menagerie
Moderators: Walter Uber, PharmD

(250) Cytomegalovirus (CMV) Prophylaxis and Infection in Pediatric Heart Transplant Recipients, K.R. Kanter,1 D.C. Naftel,2 E. Pahl,3 C.E. Canter,4 S.A. Webber,5 R.N. Vincent,1 J.K. Kirklin,2 W.R. Morrow,6 Pediatric Heart Transplant Study Group, 1Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, GA; 2Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL; 3Pediatric Cardiology, Northwestern School of Medicine, Chicago, IL; 4Pediatric Cardiology, Washington University, St. Louis, MO; 5Pediatric Cardiology, Childrens Hospital of Pittsburgh, Pittsburgh, PA; 6Pediatric Cardiology, Arkansas Children's Hospital, Little Rock, AR

(251) Basiliximab in Critically Ill Children Undergoing Heart Transplantation: Initial Data, K.A. Ford,1 C.M. Cale,2 P.G. Rees,3 M.J. Elliott,2 M. Burch,3 1Pharmacy Department, Great Ormond Street Hospital for Children, London, United Kingdom; 2Immunology Department, Great Ormond Street Hospital for Children, London, United Kingdom; 3Cardiology Department, Great Ormond Street Hospital for Children, London, United Kingdom

(252) Association of Growth Hormone Therapy with the Development of Bronchiolitis Obliterans Syndrome in Pediatric Lung Transplant Recipients, S.C. Sweet,1 M.T. de la Morena,1 P.M. Schuler,1 C.B. Huddleston,2 E.N. Mendeloff,2 1Department of Pediatrics, Washington University, St. Louis, MO; 2Department of Cardiothoracic Surgery, Washington University, St. Louis, MO

(253) Renal Insufficiency Is Associated with Early Mortality in Pediatric Lung Re-Transplantation, M.T. de la Morena,1 S.C. Sweet,1 K. Schechtman,3 P.M. Schuler,1 E.N. Mendeloff,2 C.B. Huddleston,2 1Pediatrics, Washington University School of Medicine, St. Louis, MO; 2Cardio-Thoracic Surgery, Washington University School of Medicine, St. Louis, MO; 3Biostatistics, Washington University School of Medicine, St. Louis, MO

(254) Pediatric Lung Transplant: Do Primary Pulmonary Hypertension Patients Have Worse Outcome?, S. Koulouri,1 M.S. Woo,1 M.V. Horn,1 E. Perez,1 V.A. Stames,1 J.R. Szmuszkovicz,1 1Cardiothoracic Transplant Program, Childrens Hospital Los Angeles, Los Angeles, CA

(255) Impact of Sirolimus on Lipid Profiles in Pediatric Thoracic Organ Recipients, A. Byno,1 Y. Law,1 G. Boyle,1 S. Miller,1 P. Fitzgerald,1 S. Gandhi,1 R. Sindhi,1 S. Webber,1 1Cardiology and Transplantation, Children's Hospital, Pittsburgh, PA

New Tools in Advanced Heart Failure Assessment and Management
Moderators: Edoardo G. Gronda, MD


(257) Neurohumoral and Immune Markers as Predictors of Acute Deterioration in Patients with End Stage Heart Failure Requiring Ventricular Assist Device or Heart Transplantation, E.V. Potapov,1 F.D. Wagner,1 F. Hennig,1 H.D. Volk,2 S. Ignatenko,1 H.B. Lehmkuhl,1 R. Hetzer,1 1Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany; 2Immunology, Charité-Universität University Berlin, Berlin, Germany

(258) The Munich Score - A Clinical Index To Predict Survival in Patients with Chronic Heart Failure in the Era of New Medical Therapies, H.-U. Stempfle,1 A. Alt,1 J. Stief,1 K. Theisen,1 U.
(259) The Effects of Levosimendan in Refractory Congestive Heart Failure Needing IV Inotropic Drugs: A Logistic Regression Analysis of the BELIEVE Study Comparing Responders Versus Non Responders, E.A. Bocchi, F. Villas-Boas, on Behalf of the BELIEVE Investigators, 1Heart Failure Clinics, Heart Institute (InCor), University of São Paulo Medical School, São Paulo, SP, Brazil; 2Heart Failure Working Group, Brazilian Society of Cardiology, Rio de Janeiro, RJ, Brazil

(260) Decrease of Waiting List Mortality in Cardiac Transplantation Though Transplant Numbers Are Dropping. The Impact of Optimal Bridging, A. Mühlbauer, A. Zuckermann, A. Bohdjalian, G. Wieselthaler, E. Wolner, M. Grimm, Department of Cardio-Thoracic Surgery, University of Vienna, Vienna, Vienna, Austria

(261) Role of Left Ventricular Assist Device for Patients in Acute Myocardial Infarction Complicated by Cardiogenic Shock, S.J. Park, M. Colvin-Adams, S. Ormaza, K.K. Liao, R. Segurola, A. Boyle, L.W. Miller, Joint Cardiac Program, California Pacific Medical Center, San Francisco, CA; Medicine, University of Minnesota, Minneapolis, MN; Surgery, University of Minnesota, Minneapolis, MN


(263) Multi-Frequency Forced Oscillation Technique [FOT] for Assessment of Lung Allograft Function: A Pilot Study, D.J. Ross, M.D. Goldman, R.M. Strieter, J.A. Belperio, A. Ardehali, Medicine, UCLA, Los Angeles, CA; Medicine, King Drew/UCLA, Los Angeles, CA; Surgery, UCLA, Los Angeles, CA

(264) Differential Gene Expression Profiling in Lung Transplant Recipients with Chronic Rejection, B.S. Lu, A.D. Yu, G.C. Cao, E.R. Garrity, W.T. Vigneswaran, S.M. Bhorade, Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL; Preventive Medicine and Epidemiology, Loyola University Medical Center, Maywood, IL; Thoracic and Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL


(266) A Cost-Effectiveness and Cost-Utility Study of Lung Transplantation, H.M. Vasiliadis, J.P. Collet, J. Penrod, M. Abrahamowicz, P. Ferraro, C. Poirier, Department of Epidemiology and Biostatistics, McGill University, Montreal, QC, Canada; Centre for the Analysis of Cost-Effective Care, Montreal General Hospital, Montreal, QC, Canada; Division of Clinical Epidemiology, Montreal General Hospital, Montreal, QC, Canada; Heart-Lung and Lung Transplant Program, Hopital Notre Dame, Montreal, QC, Canada

(267) MRSA Infection Is the Most Important Risk Factor for the Development of Bronchial Anastomotic Complications after Lung Transplantation, M.A. Malouf, L. Singleton, M. Plit, A.R. Glanville, The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia

Basic Science and Immunobiology
Moderator: Michael S. Mulligan, MD
(268) Immunisation with Vimentin Causes Rejection of Syngeneic Cardiac Grafts, S. Nair,1 A. McCormack,1 A. Holder,1 A. de Sousa,1 M. Burke,2 E. Lidington,1 M. Rose,1 1National Heart and Lung Institute, Imperial College, Harefield, Middlesex, United Kingdom; 2Pathology Department, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom

(269) Host Cells Contribute to Myocardium Early, Rather Than Late, after Allogeneic and Syngeneic Murine Heart Transplantation, L.B. Balsam,1 M. Tanaka,1 A.J. Wagers,2 I.L. Weissman,2 R.C. Robbins,1 1Cardiothoracic Surgery, Stanford University, Stanford, CA; 2Pathology, Stanford University, Stanford, CA

(270) Acceptance of Third-Party Cardiac Allografts in Neonatally-Tolerized Mice Is Transferable by Regulatory CD4+ T Cells, B. Hofmann,1 L. Mai,1 K. Tao,1 L.J. West,1 1Paediatric Transplant Service, Hospital for Sick Children, Toronto, ON, Canada. This work was supported by the Canadian Institutes for Health Research, Heart and Stroke Foundation of Ontario and Physicians' Services Inc. Foundation.

(271) Alterations in Gene Expression of Toll-Like Receptors in Human Lung Transplantation, C.F. Andrade,1 H. Kaneda,1 S. Der,1 M. Tsang,1 C.C. Santos,1 S. Keshavjee,1 M. Liu,1 1Department of Surgery - Thoracic Surgery Research Laboratory, Toronto General Hospital, University Health Network, Toronto, ON, Canada; 2Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada

(272) Biochanin-A Attenuates Acute Cardiac Allograft Rejection without Affecting the Reproductive System – In Vivo and In Vitro Studies, S. Schrepfer,1 T. Deuse,1 F. Koch-Nolte,2 H.J. Schäfer,2 H. Reichenspurner,1 1Cardiovascular Surgery, University Hamburg, Hamburg, Germany; 2Immunology, University Hamburg, Hamburg, Germany; 3Pathology, University Hamburg, Hamburg, Germany

(273) PAI-1 and Allograft Vasculopathy: Insight from a Murine Model of Transplantation, R.L. Benza,1 G.S. Mohanty,1 C.S. Coffey,2 P.G. Anderson,3 K. Lyle,1 J.F. George,4 1Medicine, University of Alabama at Birmingham, Birmingham, AL; 2Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 3Pathology, University of Alabama at Birmingham, Birmingham, AL; 4Surgery, University of Alabama at Birmingham, Birmingham, AL

5:30 PM-6:30 PM
General Poster Session 2 (Franciscan Ballroom)

Nursing/Social Sciences/Health Care

(274) Quality of Life after Heart Transplantation in Japanese Patients, K. Shitakura,3 S. Nunoda,1 G. Yamanaka,1 Y. Kubo,1 M. Shinagawa,1 K. Ohtsuka,1 S. Ohkawa,1 1Department of Medicine, Tokyo Women's Medical University, Daini Hospital, Tokyo, Japan

(275) A Randomized Evaluation of a Telehealth Intervention To Improve Well-Being, Mood States, and Social Intimacy in Wait-Listed Lung Transplant Patients, J.R. Rodrigue,1 M.A. Baz,2 M.R. Widows,1 S.L. Ehlers,1 1Clinical and Health Psychology, University of Florida, Gainesville, FL; 2Medicine, University of Florida, Gainesville, FL

(276) Development of the VAD-QoL: A VAD Specific Quality of Life Questionnaire, C.N. Hallas,1 J. Wray,1 C. Bowles,1 N.R. Banner,1 1Transplant Unit, Harefield Hospital, Harefield, Middlesex, United Kingdom; 2Artificial Heart Programme Co-ordinator, Harefield Hospital, Harefield, Middlesex, United Kingdom

(277) Two-Year Follow-Up of Psychological State in Patients Referred for Heart Transplant, L.S. Evangelista,1 K. Dracup,2 C. Westlake,3 V. Erickson,1 M.A. Hamilton,4 G.C. Fonarow,4 1School of Nursing, University of California, Los Angeles, Los Angeles, CA; 2School of Nursing, University of California, San
(278) Psychosocial Determinants and Consequences of Subclinical Non-Compliance in Lung Transplant Recipients, A. Cassano-Bailey, A. Szabo, P. Wightman, L. Tan, H. Unruh, 
1Manitoba Lung Transplant Program, University of Manitoba, Winnipeg, MB, Canada

(279) Health-Related Quality of Life in Adolescents after Heart Transplantation, K. Uzark, L. Griffin, P. Murphy, S. Hallowell, M. Kostyk, J. Dupuis, K. Jones, Cardiology, Cincinnati Children's Hospital, Cincinnati, OH; Cardiac Transplant, Loma Linda University Medical Ctr, Loma Linda, CA; Cardiology, St. Louis Children's Hospital, St. Louis, MO; Pediatric Cardiology, Cleveland Clinic Foundation, Cleveland, OH; Heart Transplant, Children's Memorial Hospital, Chicago, IL

(280) The Relationship between Self Perception and Adherence in Adolescents and Young Adults, J. Wray, S. Waters, T. Sensky, R. Radley-Smith, 
1Paediatrics, Royal Brompton and Harefield NHS Trust, Harefield, Middlesex, United Kingdom; 2Faculty of Medicine, Imperial College, London, United Kingdom

(281) Pediatric Heart Transplantation: Quality of Life (QOL) Outcomes in Adolescents, S.J. Anthony, S.M. Pollock-Barziv, R. Niedra, A.I. Dipchand, L.J. West, 
1Division of Cardiology, Hospital for Sick Children, Toronto, ON, Canada; 2Department of Social Work, Hospital for Sick Children, Toronto, ON, Canada; 3Pediatric Academic Multi-Organ Transplant Program, Hospital for Sick Children, Toronto, ON, Canada

(282) Psychosocial Variables and Quality of Life after Lung Transplantation, Ch. Kugler, U. Tegtbur, M. Strueber, J. Niedermeyer, A. Haverich, Thoracic Surgery, Medical School Hannover, Hannover, Niedersachsen, Germany; 2Sportsmedicine, Medical School Hannover, Hannover, Niedersachsen, Germany; 3Pulmology, Medical School Hannover, Hannover, Niedersachsen, Germany

Immunosuppression - Animal

1Division of Cardiac Surgery, University of Maryland, Baltimore, MD; 2Departments of Pediatrics and Medicine, Vanderbilt University, Nashville, TN

(284) Combination Regimens of FK778 with Tacrolimus and Mycophenolate Mofetil in Experimental Cardiac Transplantation, T. Deuse, S. Schrepfer, H. Reichenspurner, Cardiovascular Surgery, University Hamburg, Hamburg, Germany

Immunosuppression: Clinical

1Kaufman Center for Heart Failure, Cleveland Clinic Foundation, Cleveland, OH

(286) Risk Factors for Acute Rejection and Vasculopathy among 634 Patients Treated with Everolimus or Azathioprine, R.C. Starling, J. Kobashigawa, H. Eisen, J. Jaffe, Y. Li, 
1Cleveland Clinic Foundation, Cleveland, OH; 2UCLA, LA, CA; 3Temple University, Philadelphia, PA; 4Novartis Pharmaceuticals, E.Hanover, NJ; 5Novartis Pharmaceuticals, E.Hanover, NJ

1Clinical
(288) Caveats of Cyclosporine Dosing Based on C2 Monitoring, J. Thekkudan, J.E. Fildes, R. Sivaprakasam, N. Khasati, S. Datta, R. Martyszczuck, A.A. Maachal, B. Keevil, C.T. Leonard, N. Yonan, The Transplant Centre, South Manchester University Hospitals Trust, Wythenshawe, Manchester, United Kingdom; Department of Biochemistry, South Manchester University Hospitals Trust, Wythenshawe, Manchester, United Kingdom

(289) Efficacy of Thymoglobulin® for the Treatment of BOS after Lung Transplantation and Predictors of a Therapeutic Response, R.R. Hachem, G.A. Patterson, E.P. Trulock, Pulmonary; Thoracic Surgery, Washington University School of Medicine, St Louis, MO

(290) Initial Benefit of Mycophenolate Mofetil (MMF) in Heart Transplant Recipients with Renal Impairment Is Maintained at Two-Year Follow Up, M.J. Matuszewski, T.J. Locke, D.N. Hopkinson, P.C. Braidley, Heart and Lung Transplant Unit, Northern General Hospital, Sheffield, South Yorkshire, United Kingdom

(291) Renal Function Is Preserved Following Heart Transplantation Using IL-2 Receptor Blockade, G. Wheatley, C.W. Yancy, M.A. Wait, D.M. Meyer, M.E. Jessen, M.C. Paul, P. Kaiser, R.A. Bhojani, M. Drazner, W.S. Ring, J.M. DiMaio, Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX; Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX

(292) Impact of Sirolimus on Gonadal Function in Heart Transplant Recipients, I. Adamidis, I. Kaczmarek, B. Meiser, P. Landwehr, M. Mueller, J. Groetzner, P. Ueberfuhr, B. Reichart, Cardiac Surgery, Ludwig-Maximilians-University, Grosshadern University Hospital, Munich, Bavaria, Germany

(293) Optimal Time Point To Predict Cyclosporine, Tacrolimus and Mycophenoic Acid Area-Under-the-Curve (AUC)0-12 hr in Long-Term Heart/Heart-Lung Transplant Patients, M. Cantarovich, N. Giannetti, R. Cecere, G. Fontaine, J.-G. Besner, Medicine; Cardiovascular and Thoracic Surgery; Nursing, Transplant Program, McGill University Health Center, Montreal, QC, Canada; Faculte de Pharmacie, Universite de Montreal, Montreal, QC, Canada

(294) Sirolimus(SRL) in Heart Transplantation: Preliminary Results of a Multicenter Registry in Spain, M.G. Crespo, N. Manito, G. Rábago, J.F. Delgado, J.M. Arizón, E. Lage, J. Palomo, Cardiología, H.Juan Canalejo; H.Bellvitge; C.U.Navarra; H.Doce Octubre; H.Reina Sofia; H.Virgen Rocío; H.Gregorio Marañón

(295) Therapeutic Drug Monotoring of Everolimus (RAD) May Be Beneficial in Stable Lung Transplant Recipients, U. Pirron, H. Mayer, J. Kovari, H. Schmidli, Business Unit Transplantation, Novartis Pharma AG, Basel, Switzerland

Clinical Lung/Heart-Lung Transplantation

(296) Cytolytic Induction Therapy Is a Risk Factor for Bronchiolitis Obliterans Syndrome after Lung Transplantation, A.R. Glanville, V.G. Valentine, C.L. Aboyoun, M.A. Malouf, The Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; Lung Transplantation, Ochsner Clinic Foundation, New Orleans, LA


(298) Unilateral Acute and Chronic Rejection after Living-Donor Lobar Lung Transplantation, H. [missing author name]
(299) Comparison and Validation of Three Quality of Life Instruments for the Functional Assessment of Pulmonary Arterial Hypertension, R. Chua, A. O’Loughlin, A.M. Keogh, K. Brown, C. Corrigan, Heart Lung Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia


(301) Sustained Long Term Improvement after Transition from I.V. Epoprostenol to S.C. Treprostinil Therapy in Patients with Pulmonary Arterial Hypertension, J.-L. Vachiery, S. Huez, K. Retailleau, R. Naeije, Cardiology, ULB Erasme, Brussels, Belgium

(302) Experimental Pulmonary Hypertension Markedly Induces Pulmonary Artery Transient Receptor Potential Protein Expression, P.E. Wolkowicz, H.E. Grenett, M.A. Garces, R. Benza, S. Kim-Park, Medicine/ Cardiology, University of Alabama at Birmingham, Birmingham, AL; Medicine/Human Gene Therapy, University of Alabama at Birmingham, Birmingham, AL

(303) Silent Symptomatic Gastro-Oesophageal Reflux (GOR) in Cystic Fibrosis (CF) Pre Post Lung Transplantation- Are They a Problem?, B. Button, S. Roberts, G. Snell, B. Levvey, T. Williams, T. Kotsimbos, J. Wilson, Allergy, Immunology & Respiratory Medicine, The Alfred, Melbourne, Australia; Gastroenterology, The Alfred, Melbourne, Australia

(304) Skin Diseases after Lung Transplantation, Ch. Eich, R. Speich, E.W. Russ, W. Weder, A. Boehler, Lung Transplant Program, University Hospital, Zurich, Switzerland


(306) Impact of Secondary Pulmonary Hypertension of Lung Transplantation Outcome, T. Fitton, T. Kosowski, C.J. Barreiro, V. Chan, B.T. Bethea, M. Borja, J. Orens, J.V. Conte, Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD

(307) Withdrawn

Mechanical and Circulatory Support

(308) Low-Dose Prophylactic Intravenous Immunoglobulin Does Not Prevent HLA Allosensitization in LVAD Recipients, S.G. Drako, J.W. Long, J.C. Stringham, T.C. Fuller, B.A. Campbell, S.S. Schmitz, K.E. Nelson, S.A. Moore, E.M. Gilbert, D.G. Renlund, Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine and Veterans Affairs Medical Center, Salt Lake City, UT

(309) Impact of Diabetes on Outcomes after Left Ventricular Assist Device Placement, J. Butler, R.L. Howser, P.M. Portner, R.N. Pierson III, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN; World Heart Inc, Oakland, CA; Department of Cardiothoracic Surgery, Stanford University, Stanford, CA; Division of Cardiac Surgery, University of Maryland Medical Center, Baltimore, MD
(310) Left Ventricular Assist System: Clinical Freedom from Device Replacement, T. Mussivand, D.A. Hasle, K.S. Holmes, Cardiovascular Devices Division, University of Ottawa Heart Institute, Ottawa, ON, Canada

(311) Preclinical Animal Trial and Initial Clinical Experience with the Ventrassist-LVAS, D.S. Esmore, F.L. Rosenfeldt, G.A. Edwards, J.C. Negri, R.F. Salamonson, D.M. Kaye, M.R. Buckland, P.J. Ayre, N.L. James, J.D. Begg, J.C. Woodard, Cardiothoracic Surgery, Alfred Hospital, Melbourne, VIC, Australia; Veterinary Science, University of Melbourne, Melbourne, VIC, Australia; Ventracor Pty Ltd., Sydney, NSW, Australia


(314) Effect of Mechanical Circulatory Support on Outcomes after Heart Transplantation in the Modern Era, S.G. Drakos, J.W. Long, J.C. Stringham, E.M. Gilbert, S.A. Moore, B.D. Horne, B.A. Campbell, K.E. Nelson, D.G. Renlund, Utah Transplantation Affiliated Hospitals (UTAH) Cardiac Transplant Program, LDS Hospital, University of Utah School of Medicine and Veterans Affairs Medical Center, Salt Lake City, UT

(315) The Thoratec IVAD: A New Implantable Ventricular Assist Device, M.S. Slaughter, S.S.L. Tsui, A. El-Banayosy, R.L. Kormos, T.B. Iconogle, J.D. Hill, Surgery, Cardiothoracic Division, Advocate Christ Medical Center, Oak Lawn, IL; Surgery, Papworth Hospital, Cambridge, United Kingdom; Surgery, Heart Center NRW, Bad Oeynhausen, Germany; Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; Surgery, Sacred Heart Medical Center, Spokane, WA; Surgery, California Pacific Medical Center, San Francisco, CA


(318) Reduced Infection with Use of Left Ventricular Assist Device (LVAD) as an Alternative to Transplantation, L.W. Miller, S.J. Park, J.W. Long, D.E. Renlund, A.J. Boyle, M.M. Colvin-Adams, Cardiology, University of Minnesota, Minneapolis, MN; Surgery, University of Minnesota, Minneapolis, MN; Surgery, LDS Hospital, Salt Lake City, UT

(319) First German Experience with the CardioWest TAH - Report from a Single Center, A. El-Banayosy, L. Arusoglu, M. Morshuis, L. Kizner, P. Samowski, R. Koerfer, Department of Cardiothoracic Surgery, Heart and Diabetescenter NRW, Bad Oeynhausen, Germany

Donor Management, Organ Preservation, Organ Distribution

(320) Lung Transplantation Using Lungs from Donors 50 Years of Age and Older, S. Fischer, P. Struckmeier, R. Tessmann, A.R. Simon, J. Niedermeyer, B. Gohrbandt, G. Warnecke, A. Haverich, Hannover Thoracic Transplant Program, Hannover Medical School, Hannover, NS,
(321) Beneficial Effects of Tumor Necrosis Factor Converting Enzyme Inhibitor on Reimplantation Lung Injury, T. Goto,1 A. Ishizaka,2 M. Kohno,1 M. Sawafuji,1 K. Kobayashi,1 1Department of Surgery, Keio University, Tokyo, Japan; 2Department of Medicine, Keio University, Tokyo, Japan

(322) Long-Term Preservation Using a New Apparatus Combined with Suppression of Proinflammatory Cytokines Improves Donor Heart Function Following Transplantation in a Canine Model, K. Oshima,1 I. Takeyoshi,1 J. Mohara,1 H. Tsutsumi,1 S. Ishikawa,1 K. Matsumoto,2 Y. Morishita,1 1Second Department of Surgery, Gunma University Faculty of Medicine, Maebashi, Gunma, Japan; 2Department of Pathology, Nippon Medical School Second Hospital, Kawasaki, Kanagawa, Japan

(323) Does Donor Catecholamine Administration Affect Early Lung Function Post-Transplantation?, M.E. Mukadam,1 D.K. Harrington,1 I.C. Wilson,1 S.J. Rooney,1 D.P. Pagano,1 R.D. Thompson,1 R.S. Bonser,1 Cardiothoracic Transplantation Unit, University Hospital, Birmingham, West Midlands, United Kingdom

(324) Effect on Cardioplegic Solution with Poly(ADP-Ribose) Synthetase (PARS) Inhibitors on Myocardial Ischemia-Reperfusion Injury in Rat Hearts, K. Yamazaki,1 S. Miwa,1 K. Ueda,1 S. Tanaka,1 S. Toyokuni,1 O. Unimonh,1 K. Takaba,1 T. Ikeda,1 K. Nishimura,1 M. Komeda,1 1Department of Cardiovascular Surgery, Kyoto University, Kyoto, Kyoto, Japan

(325) A Heat Shock Protein 70 Inducer, Geranylgeranylacetone, Suppresses Ischemia-Reperfusion Injury after Lung Transplantation in Rats, T. Sugawara,1 T. Tabata,1 Y. Matsumura,1 Y. Okada,1 Y. Matsuda,1 T. Kondo,1 1Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan

(326) Comparison of Left Ventricular Tissue and Right Atrial Tissue for Activation of Mitogen-Activated Protein Kinases in Canine Heart Transplantation from Non-Heart-Beating Donors. N. Koike,1 I. Takeyoshi,1 S. Ohki,1 M. Tokumine,1 Y. Morishita,1 1Second Department of Surgery, Gunma University Faculty of Medicine, Maebashi, Gunma, Japan

(327) Prevention of Severe Ischemic-Reperfusion Injury Utilizing a Multifaceted Approach during Procurement, Storage, and Reperfusion in Lung Transplantation, A. Stewart,1 S. Arcasoy,1 S. Kawut,1 J. Wilt,1 J. Sonett,1 Division of Lung Transplantation, Columbia Presbyterian Medical Center, New York, NY

(328) Quantifying the Resuscitation of Hearts Procured from Nonheartbeating Donors with Radiolabeled Annexin V, D. Prastein,1 J. Gu,1 A. Wright,1 M. Kwon,1 B. Line,1 B. Griffith,1 R.N. Pierson,1 F. Gage,2 R. Poston,1 Division of Cardiothoracic Surgery, University of Maryland School of Medicine, Baltimore, MD; 2Organ Recovery Systems, Inc., Des Plaines, IL

Post Transplant Complications

(329) Transcutaneous Electrical Nerve Stimulation for Severe Gastroparesis after Lung Transplantation, J.G. Weinkauf,1 R.C. Robbins,2 J. Theodore,1 J.L. Faul,1 1Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA; 2Cardiothoracic Surgery, Stanford University Medical Center, Stanford, CA

(330) The Role of Self-Expandable Metallic Stents (SEMS) in Promoting Healing of Post Lung Transplant Bronchial Dehiscence, M.M. Mughal,1 T.R. Gildea,1 S. Murthy,2 M. DeCamp,2 G. Pettersson,2 A.C. Mehta,1 1Pulmonary & Critical Care, The Cleveland Clinic Foundation, Cleveland, OH; 2Thoracic & Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH

(331) Association of Anti-Donor HLA Class I Antibodies with Early Coronary Transplant
Vasculopathy, G.V. Gonzalez-Stawinski, P.M. McCarthy, J.B. Young, R.C. Starling, M.H. Yamani, K. Hoercher, E. Beyer, P.E. Parrino, D.J. Cook, The Cleveland Clinic Transplant Center, The Cleveland Clinic Foundation, Cleveland, OH

(332) Long-Term Results of Angioplasty Versus Stenting in Cardiac Transplant Recipients with Allograft Vasculopathy, L. Simpson, P.K. Mehta, B.J. Hott, J.D. Vega, W.M. Book, Internal Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA; Surgery, Emory University School of Medicine, Atlanta, GA

(333) Comparison of Inflammatory Activation and Restenosis after Percutaneous Coronary Intervention in Heart Transplant Recipients and Patients with Stable Angina Pectoris, A. Hognestad, K. Endresen, R. Wergeland, J. Mellembakken, T.E. Møllnes, T. Omland, J.K. Kjekshus, P. Aukrust, A.K. Andreassen, Department of Cardiology, Rikshospitalet, Oslo, Norway; Department of Clinical Chemistry, Rikshospitalet, Oslo, Norway; Department of Gynaecology, Rikshospitalet, Oslo, Norway; Department of Immunology, Rikshospitalet, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, Norway

(334) Incidence and Severity of Rejection and Infection in Patients Bridged to Transplantation with Ventricular Assist Devices, P. Kaul, S. Haj-Yahia, E.J. Birks, C.T. Bowles, J. Hardy, M.L. Rose, N.R. Banner, M.H. Yacoub, A. Khagani, Department of Transplantation, Harefield Hospital, Harefield, Middlesex, United Kingdom

(335) Prophylactic Sternal Plating in the Cardiac Transplant Population, J.P. Agarwal, J. Raman, V. Jeevanandum, A.S. Anderson, A.Y. Kim, D.H. Song, Plastic and Reconstructive Surgery, University of Chicago Hospitals, Chicago, IL; Cardiothoracic Surgery, University of Chicago Hospitals, Chicago, IL; Cardiology, University of Chicago, Chicago, IL

(336) Posttransplant Lymphoproliferative Disorder (PTLD) May Not Be Associated with Development of Bronchiolitis Obliterans, R.G. Nador, A. Yiannopoulos, J. Theodore, N.R. Henig, Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA

(337) TGF1 Polymorphisms and Transplant Coronary Artery Disease, S.G. Miriuka, P. Tzakas, B. Wong, D. Ramzy, D.H. Delgado, D.E.C. Cole, H.J. Ross, Division of Heart Transplant, Toronto General Hospital - UHN, Toronto, ON, Canada; Departments of Laboratory Medicine and Pathobiology, Medicine and Paediatrics (Genetics), University of Toronto, Toronto, ON, Canada

Heart Transplantation

(338) Impair in Endothelial-Dependent Forearm Vasodilation in Heart Transplantation, A. Cuppoletti, F. Pérez Villa, M. Sitges, M. Llancaqueo, M. Azqueta, C. Pare, J. Orús, M. Roqué, I. Vallecros, J. Magriñà, E. Roig, Cardiovascular Institute, Hospital Clinic. IDIBAPS. University of Barcelona, Barcelona, Spain

(339) Eras of Immunosuppression Change Risk Factors for Long-Term Survival after Cardiac Transplantation, A. Zuckermann, A. Bodhjalian, D. Dunkler, A. Mühlbauer, S. Rödler, J. Anchersmit, E. Wolner, M. Grimm, Department of Cardiothoracic Surgery, University of Vienna, Vienna, Vienna, Austria

(340) The Impact of Cytogam on Cardiac Transplant Recipients with Moderate Hypogammaglobulinemia, M.H. Yamani, R.C. Starling, R. Avery, S. Mawhorter, A. McNeil, N.B. Ratliff, D. Cook, D. Pelegrín, P. Colosimo, K. Kiefer, R. Hobbs, D. Taylor, P. McCarthy, J.B. Young, Cardiovascular Medicine; Infectious Disease; Anatomic Pathology; Allogen Laboratory; CardioThoracic Surgery, Cleveland Clinic Foundation, Cleveland, OH

(341) Donor-Transmitted Coronary Atherosclerosis and Cardiac Allograft Microvasculopathy, O.
(342) Peripheral Vascular Disease Adversely Affects Survival for Cardiac Transplant Recipients, S. Xydas, C. Mutrie, J.S. Chang, J.K. Yang, D. Vigilance, N.C. Dang, D.M. Mancini, Y. Naka, M.C. Oz, J.C. Lantis, Departments of Surgery and Medicine, Columbia University, NY, NY

(343) Inhaled Nitric Oxide as Rescue Therapy for Right Ventricular Insufficiency after Orthotopic Heart Transplantation, S. Datta, A. Machaal, J. Thekkudan, R. Sivaprakasan, A.K. Deiraniya, N. Yonan, Transplant Unit, Wythenshawe Hospital, Manchester, Lanchershire, United Kingdom

(344) Primary Graft Failure (PGF) in Cardiac Transplantation (OHT) over an 8 Year Period: The Relationship between Donor and Recipient Factors, P. Anagnostopoulos, C. Savopoulou, L. Shears, J. Ristich, A. Patel, R. Kormos, Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA


Basic Science and Immunobiology

(346) Tissue Implantation with Autologous Myoblast Sheet Improved Cardiac Performance in the Impaired Myocardium, Y. Sawa, I. Memon, Y. Miyamoto, S. Taketani, S. Miyagawa, H. Kondoh, T. Shimizu, T. Okano, H. Matsuda, Department of Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawata-chou Shinjyu-ku, Tokyo, Japan

(347) STAT-1 and AP-1 Decoy-Oligodeoxynucleotide Therapy Delays Acute Rejection and Prolongs Cardiac Allograft Survival, T.H.W. Stadlbauer, H. Fingerhuth, A.H. Wagner, M. Hecker, H. Hoelschermann, Department of Cardiology, University Hospital Giessen, Giessen, Germany; Department of Cardiovascular Physiology, University of Goettingen, Goettingen, Germany

(348) Chemokinereceptor 7 (CCR7) Plays an Important Role in the Development of Transplant Arteriosclerosis, S.M. Ensminger, S. Helm, B.M. Spriewald, M. Manoharan, L. Ohl, T. Fischlein, M. Weyand, R. Forster, Department of Cardiovascular Medicine III, Friedrich-Alexander University, Erlangen-Nuremberg, Erlangen, Bavaria, Germany; Institute of Clinical Immunology, Hannover Medical School, Hannover, Lower Saxony, Germany

(349) Melatonin and Acute Cardiac Allograft Rejection, F.J. Jung, L. Yang, L. Haerter, I. Inci, D. Schneider, D. Lardinois, M. Keel, W. Weder, S. Korom, Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland; Department of Trauma Surgery, University Hospital Zurich, Zurich, Switzerland

(350) Inhibition of Obliterative Airway Disease Development in Murine Tracheal Allografts by Matrix Metalloproteinase-9 Deficiency, F.G. Fernandez, L.G. Campbell, R.M. Senior, S. Itohara, E.P. Trulock, G.A. Patterson, T. Mohanakumar, A. Jaramillo, Surgery, Washington University School of Medicine, St. Louis, MO; Medicine, Washington University School of Medicine, St. Louis, MO; Riken Brain Science Institute, Wako, Saitama, Japan

(351) Vascular Endothelial Growth Factor Gene Polymorphism Are Associated with Allograft Coronary Artery Disease after Clinical Heart Transplantation, S. Datta, J. Fildes, J. Thekkudan, R. Sivaprakashan, N. Yonan, I.V. Hutchinson, Transplant Unit, Wythenshawe Hospital, Manchester, Lankershire, United Kingdom; Department of Immunology, University of Manchester, Manchester, Lankershire, United Kingdom
(352) Embryonic Stem Cell Transplantation Elicits a Primarily Th-1 Host T-Cell Response, T. Kofidis,1 J.L. de Bruin,1 M. Zwierchoniewska,1 R.-J. Swijnenburg,1 D.T. Cooke,1 D.R. Lebl,1 M. Tanaka,1 E. Fedoseyeva,1 R.C. Robbins,1 1Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA

(353) Myocardial Restoration with Embryonic Stem Cell Bioartificial Tissue Transplantation, T. Kofidis,1 J.L. de Bruin,1 G. Hoyt,1 T. Yamane,2 R.-J. Swijnenburg,1 D.R. Lebl,1 M. Tanaka,1 I.L. Weissman,2 R.C. Robbins,1 1Cardiothoracic Surgery/Falk Research Center, Stanford University Medical School, Stanford, CA; 2Department of Immunology, Stanford University Medical School, Stanford, CA

(354) Overexpression of Human BCL-2 Attenuates Graft Coronary Artery Disease by Modulating Local Th1 Immune Response but Not Host Immune Response in Murine Cardiac Allografts, M. Tanaka,1 R.D. Terry,1 S. Nakae,2 D.T. Cooke,1 T. Kofidis,1 R.C. Robbins,1 1Department of Cardiothoracic Surgery; 2Department of Pathology, Stanford University, Stanford, CA

(355) Both after Heart and Bone Marrow Transplantation the Heart Harvest Bone Marrow Derived Cardiomyocytes, R.A. De Weger,1 I. Verbrugge,1 L.F. Verdonck,2 N. De Jonge,2 M. Van Oosterhout,1 D. Van Wichen,1 Y. De Souza,1 F.G. Gmelig Meyling,1 1Pathology, UMC-U, Utrecht, Utrecht, Netherlands; 2Heart and Lung Institute, UMC-U, Utrecht, Utrecht, Netherlands; 3Hematology, UMC-U, Utrecht, Utrecht, Netherlands; 4Immunology, UMC-U, Utrecht, Utrecht, Netherlands

6:00 PM – 7:00 PM
Infectious Disease Council Meeting (Imperial)
Heart Failure and Transplant Medicine Scientific Council Meeting (Grand Ballroom B)
Pulmonary Transplantation Scientific Council Meeting (Plaza)
Cell Transplantation/Tissue Engineering Scientific Council Meeting (Union Square 21)

6:30 PM-MIDNIGHT
Poster Teardown (Franciscan/Yosemite)

4:30 PM-8:30 AM
Exhibit Hall Teardown (Grand Ballroom A)

7:00 PM-8:00 PM
BUS DEPARTURE TO EXPLORATORIUM

7:30 PM-10:00 PM
PRESIDENT’S GALA RECEPTION (Exploratorium Museum)

9:30 PM
BUS RETURN FROM EXPLORATORIUM

SATURDAY APRIL 24, 2004

7:00 AM-8:00 AM
MCSD Database Meeting (Imperial)

7:00 AM-8:00 AM
Morning Coffee (Yosemite)

7:00 AM-10:30 AM
Registration Desk Open (Yosemite)

7:00 AM– 4:30 PM
7:00 AM-5:30 PM
Speaker Ready Room (Green Room)

7:55 AM-10:00 AM
PLENARY SESSION
(Grand Ballroom B)
Moderators: Mark L. Barr, MD and Stephan Schueler, MD

7:55 AM Welcome and Introductions
8:00 AM Caves Award Winner Presentation
8:15 AM Research Grant Awards Presentations

Featured Abstract
8:30 AM (356) Outcome of Listing for Cardiac Transplantation (Tx) for Failed Fontan: A Follow-Up Multi-Institutional Study, D. Bernstein, D. Naftel, C. Chin, L. Addonizio, P. Gamberg, D. Hsu, E. Blume, C. Canter, R. Morrow, J. Kirklin, Pediatric Heart Tx Study Group, Pediatrics, Stanford University, Stanford, CA; Pediatrics, Columbia University, New York, NY; Cardiology, Harvard University, Boston, MA; Pediatrics, University of Arkansas, Little Rock, AK; Cardiovascular Surgery, University of Alabama, Birmingham, AL; Pediatrics, Washington University, St. Louis, MO

8:45 AM Invited Lecture: Thoracic Transplantation for Congenital Heart Disease in Children and Adults, Tom Spray, MD, The Children's Hospital of Philadelphia, Philadelphia, PA

Featured Abstract
9:15 AM (357) The Presence of Non-HLA IgM Antibody Adversely Effects Graft Survival Following Both Heart and Lung Transplantation, R.E. Stanford, J.D. Smith, A.J. Danskine, N. Banner, M.L. Rose, National Heart and Lung Institute, Imperial College, Harefield, United Kingdom; Tissue Typing Laboratory, Harefield and Royal Brompton NHS Trust, Harefield, United Kingdom; Department of Transplantation, Harefield and Royal Brompton NHS Trust, Harefield, United Kingdom

9:30 AM Invited Lecture: Implications of Circulating Antibodies After Thoracic Transplantation, Ronald H. Kerman, MD, University of Texas Medical School, Houston, Houston, TX

10:00 AM-10:30 AM
Coffee Break (Yosemite)

10:30 AM-NOON
CONCURRENT SESSION 22
Post Transplant Complications 2: Cardiac Vasculopathy
(Grand Ballroom B)
Moderators: Branislav Radovancevic, MD and Robert L. Scott, MD

10:30 AM (358) Common Chemokine Receptor Single Nucleotide Polymorphisms Are Associated with Transplant Vasculopathy in Heart Transplant Recipients, S.G. Miruaka, D.H. Delgado, B. Wong, V. Rao, D.E.C. Cole, R.A. Hegele, H.J. Ross, Division of Heart Transplant, Toronto General Hospital - UHN, Toronto, ON, Canada; Departments of Laboratory Medicine and Pathobiology, Medicine and Paediatrics (Genetics), University of Toronto, Toronto, ON, Canada; Blackburn Cardiovascular Genetics Laboratory, Robarts Research Institute, London, ON, Canada


11:00 AM (360) Cardiac MR Identifies Transplantarteriopathy by a Reduced Endomyocardial
Perfusion, O.M. Muehling,1 P. Panse,4 M. Jerosch-Herold,3 R.F. Wilson,2 N. Wilke,4 L.W. Miller,2
1 Department of Medicine, University of Munich, Munich, Germany; 2 Department of Medicine, University of
Minnesota, Minneapolis, MN; 3 Department of Radiology, University of Minnesota, Minneapolis, MN;
4 Department of Radiology, University of Florida, Jacksonville, FL

11:15 AM (361) Impaired Coronary Flow Reserve by Contrast-Enhanced Transthoracic
Echocardiography Predicts Cardiac Allograft Vasculopathy, F. Tona,1 A.L.P. Caforio,1 R. Montisci,1
A. Gambino,2 M. Pinto,1 M. G. Leone,1 G. Feltrin,2 C. Sarrais,1 R. Carta,1 A. Portale,1 G. De Simone,1 D.
Calzolari,1 A. Angelini,1 G. Thiene,2 G. Gerosa,1 S. Iliceto,1 Cardiology; Cardiovascular Surgery
1 Pathology, University of Padova, Padova, Italy

11:30 AM (362) Graft Vasculopathy: Comparison of Cyclosporine and Tacrolimus over 15+ Years,
D.A. Baran,1 S. Kaplan,2 S. Lubitz,2 I. Galin,1 S. Alvi,1 R. Correa,1 M. Courtney,1 M. Chan,1 D. Spielvogel,2
S.L. Lansman,1 A.L. Gass,1 Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ;
Cardiovascular Institute, M. Sinai Medical Center, New York, NY

11:45 AM (363) Cytomegalovirus Burden and Progressive Severity of Cardiac Allograft
Vasculopathy, L. Potena,1 C. Magelli,2 W.F. Fearon,1 A.C. Yeung,1 F. Coccolo,2 G. Magnani,2 F.
Grigioni,1 P. Ortolani,1 H.T. Lukart,1 S.A. Hunt,1 E.S. Mocarski,1 J.P. Cooke,1 D.B. Lewis,1 A. Branzi,2 H.A.
Valantine,1 1 Department of Cardiovascular Medicine, Stanford University, Stanford, CA; 2 Institute of
Cardiology, University of Bologna, Bologna, BO, Italy

10:30 AM-NOON
CONCURRENT SESSION 23
Lung/Heart-Lung Transplantation 4: Mechanisms of Early Immune and Inflammatory Injury in
Lung Transplantation
(Imperial)
Moderators: Annette Boehler, MD and Thomas K. Waddell, MD

10:30 AM (364) Upregulation of IL-17 in Acute Rejection after Lung Transplantation, L.J. Dupont,1
B. Vanaudenaerde,1 W. Wuyts,1 D. Van Raemdonck,2 G. Verleden,1 Department of Respiratory
Medicine, UZ Kuleuven, Leuven, Belgium; Department of Thoracic Surgery, UZ Kuleuven, Leuven,
Belgium

10:45 AM (365) Elevated IL-15 in Acute Lung Allograft Rejection, A.D. Yu,1 B.S. Lu,1 W.T.
Vigneswaran,1 E.R. Garrity,1 S.M. Bhorade,1 Pulmonary and Critical Care Medicine, Loyola University
Medical Center, Maywood, IL; Cardiovascular and Thoracic Surgery, Loyola University Medical Center,
Maywood, IL

11:00 AM (366) Impact of Pre-Transplant T Cell Depletion Combined with Tacrolimus Monotherapy
on the Immune Responses in Lung Transplant Recipients, A. Zeevi,1 A. L. Girnita,1 K.J. Spichty,1 D.
Zaldonis,1 K. McDade,1 A.T. Jaccono,1 S.A. Yousem,1 J. Britz,2 R. Kowalski,1 J. Woodcock,1 C.
Bentlejewski,1 K.R. McCurry,1 Pathology, University of Pittsburgh, Pittsburgh, PA; Thoracic Surgery;
Pulmonary and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA

11:15 AM (367) Exhaled Nitric Oxide (eNO) Correlates with IL-17 in Bronchoalveolar Lavage Fluid
(BALF) during Acute Lung Rejection, B.M. Vanaudenaerde,1 W.A. Wuyts,1 L.J. Dupont,1 D.E. Van
Raemdonck,1 G.M. Verleden,1 Lab of Pathology, Lung Transplantation Unit, University Hospital
Gasthuisberg, Leuven, Belgium; Department of Thoracic Surg, Lung Transplantation Unit, University
Hospital Gasthuisberg, Leuven, Belgium

11:30 AM (368) Pulmonary Capillaritis in Lung Transplant Recipients: Response to Therapy and
Effect on Long-Term Allograft Function, T.L. Astor,1 D. Weill,1 M.R. Zamora,1 Division of Pulmonary
and Critical Care Medicine, University of Colorado Health Sciences Center, Denver, CO

11:45 AM (369) P-Glycoprotein and Outcome Following Lung Transplantation, J.E. Fildes,1 J.
Thekkudan,1 R. Gunatadugudu,1 A. Owen,2 D. Singh,2 N. Yonan,2 C.T. Leonard,3 The Transplant Centre,
Manchester; Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool,
United Kingdom; North West Lung Research Centre, South Manchester University Hospital Trust,
Wythenshawe, Manchester, United Kingdom

10:30 AM-NOON
10:30 AM (370) HLA Sensitization but Not Tolerance to Incompatible Donor ABO Antigens Follows Tissue Allograft Placement in Infant Norwood Patients, N.E. Lobach, L. Hornberger, J.F. Smallhorn, A.I. Dipchand, N. denHollander, G. VanArsdell, S.M. Pollock-BarZiv, L.J. West, Paediatrics, Hospital for Sick Children, Toronto, ON, Canada; Regional Histocompatibility Lab, Toronto General Hospital, Toronto, ON, Canada

10:45 AM (371) Discovery and Validation of Molecular Pathways and Diagnostic Testing for Cardiac Rejection in Children: A Multi-Center Study, S. Webber, D. Bernstein, S. Mital, L. Addonizio, C. Bentley, A. Byno, G. Boyle, J. Phillips, J. Wohlgehmuth, A. Zeevi, Pediatrics, Children's Hospital, Pittsburgh, PA; Pediatrics, Stanford University, Palo Alto, CA; Pediatrics, Columbia University, New York, NY; XDx, Inc., South San Francisco, CA

11:00 AM (372) Panel-Reactive Antibody Cross-Reactivity and Outcomes in the Pediatric Heart Transplant Study Group, W.T. Mahle, D.C. Naftel, P. Rusconi, R.E. Edens, R.E. Shaddy, Pediatric Heart Transplant Study Group, Emory Univ; University of Alabama, Birmingham; University Miami; University Iowa; University Utah

11:15 AM (373) Sirolimus Immunosuppression in Paediatric Heart Transplant Patients: A Single Centre Experience, N.E. Lobach, S.M. Pollock-BarZiv, L.J. West, A.I. Dipchand, Paediatrics, Hospital for Sick Children, Toronto, ON, Canada


11:45 AM (375) Prospective Follow-Up of Panel Reactive Antibodies in Children 5-Years Following Implantation of Cryopreserved Allografts, D.K. Hooper, J.A. Hawkins, T.C. Fuller, T. Profaizer, R.E. Shaddy, Pediatrics, University of Utah, Salt Lake City, UT; Surgery, University of Utah, Salt Lake City, UT; Pathology, University of Utah, Salt Lake City, UT

NOON–2:00 PM
ISHLT Board of Directors Meeting (Executive Boardman)

12:15 PM-1:45 PM
LUNCHEON SYMPOSIUM
Cytomegalovirus in Heart and Lung Transplantation: Issues and Challenges
(Grand Ballroom B)
Supported by an educational grant from Roche
Moderators: Martin Zamora, MD, and Jim J. Egan, MD

12:15 PM Chairmans' Introduction, Martin Zamora, MD, University of Colorado, Denver, CO and Jim J. Egan, MD, Mater Misericordiae Hospital, Dublin, Ireland

12:20 PM Overview of Risks Associated with CMV Infection in Thoracic Transplantation, Raymund R. Razonable, MD, Mayo Clinic and Foundation Rochester, MN

12:45 PM Prevention and Treatment Challenges for CMV in Thoracic Transplantation, Martin Zamora, MD, University of Colorado, Denver, CO

1:10 PM Can the Impact of CMV on Endothelial Function be Prevented in Heart Transplantation?, Karl Lemstrom, MD, PhD, Helsinki University, Helsinki Finland

1:35 PM Questions and Answer Session

2:00 PM-3:30 PM
CONCURRENT SESSION 25
Clinical Heart Transplantation 3: Risk Factors and Outcomes
(Grand Ballroom B)
2:00 PM (376)  Late Outcomes after Heart Transplantation in Adults with Congenital Heart Disease: A Multi-Institutional Analysis, B.S. Clemson, J.K. Kirklin, C.E. Canter, D.C. Naftel, J.B. Young, J.A. Hill, R.J. Rodeheffer, B. Radovancevic, S. Faulkner, The Cardiac Transplant Research Database, 1University of Alabama at Birmingham, Birmingham, AL

2:15 PM (377)  Ten Year Follow-Up of the Functional and Morphological Adaptation of Undersized Donor Hearts Following Cardiac Transplantation, P.J. Mather, S. Furukawa, P.J. Mather, S. Furukawa, Y. Jeevanandam, 1Internal Medicine, Division of Cardiology, Temple University School of Medicine, Philadelphia, PA; 2Cardiothoracic Surgery, Temple University School of Medicine, Philadelphia, PA; 3Cardiothoracic Surgery, University of Chicago, Chicago, IL

2:30 PM (378)  Outcomes of Cardiac Transplantation with Donors 50 Years of Age and Greater, S.R. Meyer, M.J. Bentley, J.C. Mullen, D.L. Modry, A. Koshal, I.M. Rebeyka, D.B. Ross, S. Wang, Surgery, Division of Cardiac Surgery, University of Alberta, Edmonton, AB, Canada


3:00 PM (380)  Independent Predictors of Develop of Renal Dysfunction after Heart Transplantation in Patients with Previously Normal Renal Function, I.P. Garrido, M.G. Crespo-Leiro, M.J. Paniagua, J. Muniz, A. Castro-Beiras, Heart Transplantation Unit, Hospital Juan Canalejo, A Coruna, A Coruña, Spain; Instituto de Ciencias de la Salud, Universidad de A Coruña, A Coruña, Spain

3:15 PM (381)  Decreased Survival in Heart Transplant Patients Requiring Chronic Dialysis: A Canadian Experience, M. Cantarovich, F. Ivis, K. Badovinac, Medicine, Transplant Program, McGill University Health Center, Montreal, QC, Canada; Canadian Organ Replacement Register, Canadian Institute for Health Information, Toronto, ON, Canada

2:00 PM-3:30 PM CONCURRENT SESSION 26

2:00 PM (382)  Hemorrhagic Shock and Resuscitation in Organ Donors: L-Arginine Improves Impaired Lung Transplant Function, G. Preissler, H.U. Ebersberger, I.V. Huff, M.E. Eichhorn, K. Messmer, K.W. Jauch, F. Loeye, Department of Surgery, University Hospital Grosshadern, Munich, Germany; Institute for Surgical Research, University Hospital Grosshadern, Munich, Germany

2:15 PM (383)  Nebulized N-Acetyl Cysteine Protects the Pulmonary Graft from the Non-Heart-Beating Donor inside the Cadaver, F. Rega, W. Wuyts, B. Vanaudenaerde, N. Jannis, A. Neyrinck, T. Lerut, G. Verleden, D. Van Raemdonck, Center for Experimental Surgery and Anaesthesiology, KU Leuven, Leuven, Belgium; Laboratory of Pneumology, KU Leuven, Leuven, Belgium; Department of Thoracic Surgery, University Hospital Gasthuisberg, Leuven, Belgium

2:30 PM (384)  Improved Viability and Reduced Apoptosis in Subzero 21 Hours Preservation of Transplanted Rat Hearts Using Antifreeze Proteins, G. Amir, B. Rubinsky, L. Horovitz, B.S. Yousif, J. Leor, A.K. Smolinsky, J. Lavee, Heart Transplantation Unit, Department of Cardiac Surgery, Sheba Medical Center, Tel Hashomer, Israel; Department of Bioengineering and Department of Mechanical Engineering, University of California, Berkeley, CA; The Neufeld Cardiac Research Institute, Tel Aviv University, Tel Aviv, Israel

2:45 PM (385)  S-Nitroso-Human Serum Albumin Improves Organ Preservation in Orthotopic Heart Transplantation in the Pig, R. Gottardi, I. Szerafin, S. Semroth, S. Hallstrom, H. Gasser, R. Seitelberger, E. Wolner, B.K. Podesser, Ludwig Boltzmann Institute for Cardiosurgical Research, University Vienna, Austria; Department for Cardiothoracic Surgery, University Vienna, Austria
3:00 PM (386) Impact of 24 Hour Continuous Hypothermic Perfusion on Heart Preservation by Assessment of DNA Damage and Repair, T.P. Fitton, C.J. Barreiro, B.T. Bethea, C. Wei, R. Lin, L. Amado, F. Gage, J. Hare, W.A. Baumgartner, J.V. Conte, Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD


2:00 PM-3:30 PM CONCURRENT SESSION 27 Basic Science and Immunobiology 3: Pathobiology of Heart Failure (Plaza)

Moderators: Robert C. Robbins, MD and David S. Feldman, MD

2:00 PM (388) Antagonists of Stretch-Activated Ion Channels Restore Contractile Function in Hamster Dilated Cardiomyopathy, A.C. Nicolosi, C.S. Kwok, Z.J. Bosnjak, Cardiothoracic Surgery, Medical College of Wisconsin, Milwaukee, WI

2:15 PM (389) The Role of Nitric Oxide in Cardiomyogenesis Using Embryonic Stem Cells, L.L. Shears, S. Kanno, R.L. Kormos, K.R. McCurry, T.R. Billiar, Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

2:30 PM (390) Increased Gene Expression of Inflammatory Cytokines and Endotoxin Receptors in Peripheral Blood Mononuclear Cells of Patients with Chronic Heart Failure, T.J. Dengler, M. Schoels, R. Klingenberg, C.A. Gleissner, T. Giese, Cardiology, University of Heidelberg, Heidelberg, Germany; Immunology, University of Heidelberg, Heidelberg, Germany

2:45 PM (391) TNF Inhibition at the Time of Myocardial Infarction Attenuates the Subsequent Development of Heart Failure, M.F. Berry, T.J. Pirolli, L.T. Bish, M.A. Moise, J.W. Burdick, K.J. Morine, V. Jayasankar, T.J. Gardner, H.L. Sweeney, Y.J. Woo, Department of Surgery, Division of Cardiothoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, PA; Department of Physiology, University of Pennsylvania School of Medicine, Philadelphia, PA

3:00 PM (392) Bcl-xL Gene Transfer Reduced Apoptosis and Preserved Cardiac Function after Rat Ischemia/Reperfusion Injury, M. Morikawa, Y. Ito, J. Huang, K. Takahashi, T. Uzuka, K. Ikeda, Y. Honma, H. Hamada, T. Abe, Thoracic & Cardiovascular Surgery, Sapporo Medical University, Sapporo, Hokkaido, Japan; Molecular Medicine, Sapporo Medical University, Sapporo, Hokkaido, Japan

3:15 PM (393) Peripheral Blood Dendritic Cell Phenotype Indicates Immune Predisposition towards Th-1 Responses in Human End-Stage Heart Failure, P. Athanassopoulos, L.M. Vaessen, A. Balk, A. Balk, A. Balk, W. Weimar, Cardiothoracic Surgery; Internal Medicine; Cardiology, Erasmus MC, Rotterdam, Netherlands

3:30 PM-4:00 PM Coffee Break (Yosemite)

4:30 PM – 8:30 PM Exhibit Hall Tear down (Yosemite)

4:00 PM-5:45 PM CLOSING PLENARY SESSION (Grand Ballroom B)

Moderators: Alec Patterson, MD and Shaf Keshavjee, MD

Late Breaking Clinical Trials in Lung Transplantation

4:00 PM (394) A Randomized Trial of Early Administration of Inhaled Cyclosporine in Lung
Transplant Recipients, A.T. Iacono, B.A. Johnson, T.E. Corcoran, D.A. Smith, W.F. Griguer, J.H. Dauber, K.R. McCurry, A. Zeevi, G.J. Burckart, J.G. Youssef, J.L. Vensak, G.C. Smaldone, J.J. Fung, B.P. Griffith, Pulmonary, Allergy, Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA; Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA; Transplant Pathology, University of Pittsburgh, Pittsburgh, PA; Department of Pharmacy, University of Southern California, Los Angeles, CA; Pulmonary/Critical Care Medicine, SUNY Stony Brook, Stony Brook, NY; Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA; Cardiac Surgery, University of Maryland, Baltimore, MD


Controversy in Lung Transplantation: Altering the Lung Transplant Allocation System: The Proposed UNOS Change
4:30 PM Advantages of the Proposed System, Thomas M. Egan, MD, University of North Carolina, Chapel Hill, NC
4:45 PM Does the Proposed Change Disadvantage Certain Patient Diagnostic Sub-Groups?, Robert P. Frantz, MD, Mayo Clinic, Rochester, MN
5:00 PM The Eurotransplant Solution to Address High Urgency Patients, Walter Klepetko, MD, University of Vienna, Vienna, Austria
5:15 PM Panel Discussion

5:30 PM ADJOURN
EXHIBIT HOURS

Grand Ballroom A
Thursday  April 22, 2004  7:00am – 4:30pm
Friday    April 23, 2004  7:00am – 4:30pm

Yosemite
Wednesday April 21, 2004  10:00am – 6:30pm
Thursday   April 22, 2004  7:00am – 6:30pm
Friday     April 23, 2004  7:00am – 6:30pm
Saturday   April 24, 2004  7:00am – 4:30pm
<table>
<thead>
<tr>
<th>EXHIBITING COMPANIES</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abiomed, Inc.</td>
<td>217</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals US, Inc.</td>
<td>213</td>
</tr>
<tr>
<td>Argon Medical Devices, Inc.</td>
<td>315</td>
</tr>
<tr>
<td>Arrow International</td>
<td>408</td>
</tr>
<tr>
<td>ATC Technologies, Inc.</td>
<td>311</td>
</tr>
<tr>
<td>CardioDynamics</td>
<td>419</td>
</tr>
<tr>
<td>Caremark Inc.</td>
<td>415</td>
</tr>
<tr>
<td>Chase Medical</td>
<td>412</td>
</tr>
<tr>
<td>CHF Solutions, Inc.</td>
<td>312</td>
</tr>
<tr>
<td>CTI Clinical Trial &amp; Consulting Services</td>
<td>102</td>
</tr>
<tr>
<td>Elsevier</td>
<td>603</td>
</tr>
<tr>
<td>Fujisawa Healthcare, Inc.</td>
<td>201</td>
</tr>
<tr>
<td>Genzyme Transplant</td>
<td>310</td>
</tr>
<tr>
<td>ISHLT Registry</td>
<td>601</td>
</tr>
<tr>
<td>Medical Insight Research</td>
<td>316</td>
</tr>
<tr>
<td>MedImmune, Inc.</td>
<td>314</td>
</tr>
<tr>
<td>MicroMed Technology, Inc.</td>
<td>114</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals Corporation</td>
<td>701</td>
</tr>
<tr>
<td>PharmaCare (formerly CVS ProCare Pharmacy)</td>
<td>417</td>
</tr>
<tr>
<td>Roche Pharmaceuticals</td>
<td>301</td>
</tr>
<tr>
<td>Saunders/Mosby Medical Books</td>
<td>313</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>309</td>
</tr>
<tr>
<td>Therakos, a Johnson &amp; Johnson Company</td>
<td>308</td>
</tr>
<tr>
<td>Thoratec Corporation</td>
<td>209</td>
</tr>
<tr>
<td>United Network for Organ Sharing (UNOS)</td>
<td>604</td>
</tr>
<tr>
<td>Ventracor Limited</td>
<td>413</td>
</tr>
<tr>
<td>ViraCor Laboratories</td>
<td>416</td>
</tr>
<tr>
<td>Vitrolife</td>
<td>409</td>
</tr>
<tr>
<td>World Heart Corporation</td>
<td>108</td>
</tr>
<tr>
<td>XDx</td>
<td>501</td>
</tr>
</tbody>
</table>
ABIOMED is a leading developer, manufacturer and marketer of devices designed to assist or replace the pumping function of the failing heart. Products include the BVS® 5000 Bi-ventricular Support System; the most widely used advanced cardiac assist system, and the new AB5000™ Circulatory Support System offering the latest cost-effective solution for cardiac assist. The AB5000 system offers uni-ventricular or bi-ventricular support, patient ambulation and transport, all in the most flexible, simple and effective technology available today. The Company's first generation AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an Investigational Device Exemption from the United States Food and Drug Administration.

Actelion Pharmaceuticals US, Inc. (located in South San Francisco, CA) is the U.S. affiliate of Actelion Ltd., a bio-pharmaceutical company headquartered in Switzerland. Actelion is the global leader in creative science related to the endothelium—the single layer of cells lining every blood vessel. Actelion's clinical research and drug discovery focuses on: cardiology, pulmonology, rheumatology, oncology, malaria, and Alzheimer's disease. Its flagship drug, Tracleer® (bosentan) tablets, is approved for pulmonary arterial hypertension and is the first in a new class of drugs known as endothelin receptor antagonists (ERA). Actelion is also currently developing Veletri® (tezosentan), an intravenous ERA. Actelion is quoted on the Swiss Stock Exchange (SWX Main Market: ATLN).

Argon Medical Devices, Inc. manufactures disposable Vascular Access devices for Cardiology, Radiology and Critical Care markets. Founded in 1972, Argon has focused on designing and delivering quality vascular devices to customers with exceptional service.

In 1991 Argon introduced the Jawz® Endomyocardial Biopsy Forcep. The Jawz® Forcep has earned the respect of the transplant community as the premier Heart biopsy device.

Argon also supplies Hydrophilic and Stainless Steel Guide Wires, Standard and Specialty Introducers as well as a myriad of accessories for Vascular Access. Argon Services the market with dedicated domestic sales professionals and several International distributor partnerships.
The world wide technology leader in Cardiac Assist has new technology for Intra-Aortic Balloon pumps and catheters, destination therapy LVAD’s, and centrifugal LVAD pumps. Come see our new fiber-optic WAVE™ catheter. The LionHeart™ LVAD, in the clinical trials, is designed for destination therapy of heart failure patients. Learn more about our results with four patients currently living over two years with the Arrow LionHeart™. Our new Arrow CorAide™ centrifugal LVAD has begun clinical trials. The Arrow CorAide™ development, in partnership with the Cleveland Clinic, features only one moving part in a magnetically suspended centrifugal pump design.

**ATC TECHNOLOGIES, INC.  Booth # 311**
80 Cummings Park
Woburn, MA 01801
Company contact: Paul Kierce
Phone:1-781-939-0725
Fax: 1-781-939-0726
Email ATCTEK@aol.com

Sparrowhawk disposable endomyocardial biopsy forceps are designed and manufactured to provide the precision "cutting action" that is expected and required during the biopsy procedure. The Sparrowhawk biopsy forceps are available in a variety of sizes and lengths, and incorporate formable shafts to meet the specific needs of physicians.

**CAREMARK INC.  Booth # 415**
2211 Sanders Road
Northbrook, IL 60062
Phone: 800-237-2767
Fax: 800-323-2445
Web site: www.carmark.com

Caremark has been a national leader in specialty pharmacy for over 25 years. We provide biotech medications and services to participants with chronic or genetic conditions. With Caremark Specialty Pharmacy Services, every individual is assigned a pharmacist-led CareTeam, which reviews dosing and medication schedules, troubleshoots injection-related issues, discusses side effect management, and reinforces physician instructions to ensure that the individual’s prescribed medication is administered appropriately. Caremark also handles all insurance benefits investigations. To learn more about how Caremark Specialty Pharmacy Services can help you and your patients, please call 1-800-237-2767, fax 1-800-323-2445, or visit our Web site at www.carmark.com

**CARDIODYNAMICS  Booth #419**
6175 Nancy Ridge Drive
San Diego, CA 92121
Phone:1-800-778-4825
Fax:1-858-535-9622
Web Site: www.cdic.com

BioZ ICG (Impedance Cardiography) provides noninvasive hemodynamic parameters, including cardiac output, systemic vascular resistance, and fluid status, through four dual sensors on the patient’s neck and chest. BioZ ICG has been used in over 2.5 million patient applications in a variety of clinical settings because it aids clinicians in the assessment, diagnosis, and treatment of patients including perioperative, critical care, sub-acute, and emergency. Products include the stand-alone BioZ ICG Monitor, BioZ ICG Module for GE Patient Monitors.
CHASE MEDICAL  Booth #412  
1876 Firman Drive  
Richardson, TX  75081  
Contact: Cynthia Bock  
Tel: 972-783-0644  
Fax: 972-235-3446  
Email: cbock@chasemedical.com

Chase Medical provides innovative products and programs for the treatment of CHF. Products include TR²ISVR Surgical Ventricular Restoration System featuring the Mannequin Endoventricular Shaper and SIMON 3D Cardiac Analysis System. TR²ISVR enables the surgeon to efficiently and reproducibly restore dilated ventricles to a more normal size, shape and orientation resulting in significantly improved EF, and less risk of post-operative MR. SIMON provides a comprehensive analysis of LV function with more than 50 parameters presented in tabular and 3D format. SIMON provides tools to assess tissue viability and structure of the ventricle, monitor disease state, and help in surgical planning.

CHF SOLUTIONS, INC.  Booth #312  
7601 Northland Dr.  
Brooklyn Park, MN  55428  
Phone: 866-709-4030  
Fax: 763-463-4663  
Web site: www.chfsolutions.com

The System 100 uses a technique called "Ultrafiltration" to simply, safely and precisely remove excess fluid from fluid-overloaded patients. Up to four liters of excess fluid can be removed in up to an eight hour period using the System 100.

CTI CLINICAL TRIAL AND CONSULTING SERVICES  Booth # 102  
6460 Harrison Avenue  
Cincinnati, OH  45247  
Contact: Genie Dubuk  
Phone: 513-598-9290  
Fax: 513-598-3426  
Email: info@ctifacts.com  
Website: www.CTIFacts.com

CTI Clinical Trial and Consulting Services provides innovative clinical trial services and consulting solutions for the pharmaceutical industry in the specific areas of transplantation, infectious disease and end stage organ disease, including dialysis and liver function.

ELSEVIER  Booth #603  
Health Sciences Division  
170 S. Independence Mall West  
Suite 300E  
Philadelphia, PA  19106  
Phone: 215-238-7800  
Fax: 215-238-6462  
www.elsevierhealth.com

ELSEVIER, a premier worldwide health science publishing company featuring the SAUNDERS, MOSBY, CHURCHILL LIVINGTONSTONE, BUTTERWORTH HEINEMANN, and HANLEY-BELFUS imprints, is proud to publish THE JOURNAL OF HEART AND LUNG TRANSPLANTATION, the Official Publication of the International Society for Heart and Lung Transplantation. Visit us at booth # 603 and browse through our complete selection of publications in TRANSPLANTATION, SURGERY, AND CARDIOVASCULAR
FUJISAWA HEALTHCARE, INC. Booth #201
3 Parkway North
Deerfield, IL 60015
Phone: 847-317-8800
Fax: 847-317-5953
Web site: www.fujisawaHealthcare.com

Fujisawa Healthcare, Inc. manufactures and markets proprietary pharmaceutical products in specialty therapeutic areas where there is an unmet medical need. Fujisawa’s global mission to explore the frontiers of human health underscores the company’s commitment to the field of immunology, where aggressive research and development initiatives have helped to put Fujisawa at the forefront of transplantation.

Genzyme Transplant Booth #310
500 Kendall Street
Contact: Kevin Campbell
Cambridge, MA 02142
Phone: 617.768.6298
Fax: 617.768.6419

Genzyme is proud to announce that SangStat is now a wholly owned subsidiary, to be recognized in the future as Genzyme Transplant. The Genzyme Transplant group will continue building on its foundation in transplantation to discover, develop and market high value therapeutic products in the transplantation, immunology and hematology/oncology areas. The flagship product of Genzyme Transplant is Thymoglobulin® (Anti-thymocyte [Rabbit]. Thymoglobulin is a polyclonal antibody directed against several epitopes on T-cells, B-cells as well as adhesion molecules on monocytes and macrophages. Additional products marketed by Genzyme Transplant include Gengraf® (Co-Promotion with Abbott)

ISHLT/REGISTRY Booth # 601
1100 Boulders Pkwy, Suite 500
Richmond, VA 23225
Contact: Burkely Keck
Phone: 804-330-8500
Fax: 804-327-1449

The ISHLT Transplant/Mechanical Circulatory Assist Device Database collects worldwide transplant and assist device data. Data are utilized for scientific study to increase the body of knowledge regarding thoracic transplantation and cardiac device management. This year’s exhibit will feature online availability of center-specific analysis for review by ISHLT members who represent the center submitting the data. In addition, ISHLT members can view preliminary screens for the device database and receive information on how to provide data to the transplant and device database.

MEDICAL INSIGHT RESEARCH Booth #316
Remco op den Kelder
25 Burlington Mall Road, 6th Floor
Burlington, MA 07803
Phone: 781-273-5480
Fax: 781-273-5484

Medical Insight Research is an economic research and strategy consulting firm specializing in the healthcare, pharmaceutical, and biotechnology industry.

MEDIMMUNE, INC. Booth # 314
35 W. Watkins Mill Road
MedImmune, Inc. is a biotechnology company focused on developing and marketing products that address medical needs in areas such as infectious disease, transplantation medicine, autoimmune disorders and cancer. CytoGam® (cytomegalovirus immune globulin intravenous (Human) (CMV-IVIG) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas and heart. In transplants of these organs other than kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir.

MICROMED TECHNOLOGY, INC.  Booth # 114
8965 Interchange Dr.
Houston, TX 77054
Contact: Betty S. Russell, Ex. Vice President
Phone: 713-838-9210
Fax: 713-838-9214
Email: brussell@micromedtech.com
Web site: www.micromedtech.com

MicroMed will present the DEBakey VAD®, the most widely used implantable axial-flow VAD. Developed in collaboration with NASA, Drs. Michael DeBakey and George Noon, the C-cell battery size pump is highly durable and designed to provide full left ventricular support. This miniaturized pump is lightweight, is virtually silent and provides flows in excess of 10L/M for use in broad BSA ranges. The system is in multi-center clinical trials in the US for use as both bridge to transplantation and for destination therapy. The DeBakey VAD Child, the first implantable VAD for pediatric use, will also be displayed. The DeBakey VAD is CE approved.

NOVARTIS PHARMACEUTICALS CORPORATION  Booth # 701
One Health Plaza
East Hanover, NJ  07936
Phone: 888-NOW-NOVA
Web site: www.Novartis-Transplantation

This year, Novartis, the makers of Neoral® (cyclosporine, USP [Modified]), Sandimmune® (cyclosporine, USP), and Simulect® (basiliximab), marks its 20th year as the leading contributor to the advancement of transplantation. Our focus is to develop meaningful therapeutic advances that improve the quality of life of transplant recipients and enhance the long-term success of transplantation. In partnership with the transplant community, 30 leading research instructions, and with over 300 scientists and clinicians dedicated to transplant research, we maintain the broadest pipeline in the field with three compounds in clinical trials, and more than a dozen projects in preclinical development.

PharmaCare (formerly CVS ProCare Pharmacy)  Booth # 417
600 Penn Center Boulevard
Pittsburgh, PA  15235
Contact: Jennifer Maxwell
Phone: 1-800-238-7828
Web:  www.cvsprocare.com

PharmaCare (formerly CVS ProCare Pharmacy) is designed to meet the specialized needs of individuals living with organ transplants and other challenging health conditions. PharmaCare provides a full range of quality pharmaceutical care, from dispensing the latest FDA–approved medications, to over-the-counter medications. When you choose PharmaCare as your pharmacy, you can be confident in knowing that your patient’s pharmacy care is in the hands of the most advanced pharmacy experts in the country. To learn more about the many specialized services provided by PharmaCare or to enroll your patients,
please call us today toll free at 1-800-238-7828.  www.cvsprocare.com

ROCHE Booth # 301
PBC Congresses
Bldg 74/40.409
4070 Basel, Switzerland
Contact: Nils Meyer, International Congress Manager
Phone: 41-61-688-71-26
Fax: 41-61-688-14-09
Email: nils.meyer@Roche.com
Web Site: www.roche.com

Roche is proud to be a sponsor of the 24th Annual Meeting of the International Society for Heart & Lung Transplantation in San Francisco. We invite you to visit our exhibit where our specialists will discuss any questions you may have related to our pharmaceutical products and services. We are also interested in hearing about any issues of interest to you related to the health care industry in general. We look forward to meeting you on the exhibit floor.

SAUNDERS/MOSBY MEDICAL BOOKS
Booth # 313
284 Shearwater
Foster City, CA 94404
Contact: Taum Dell’Armo
Phone: 800-955-0345

Medical Books offered at publisher’s discount prices.

SCANLAN INTERNATIONAL, INC.  Booth #309
One Scanlan Plaza
St. Paul, MN  55107
Phone: 651-298-0997
Fax: 651-298-0018
Email: info@scanlangroup.com
Web site: www.scanlangroup.com

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Offering a wide array of Titanium Needle Holders, forceps and clamps and stainless steel instrumentation, including Micro surgical instrumentation, Scanlan SUPER CUT™ and ULTRA SHARP® scissor collection, Scanlan DIAMOND DUST™ instrumentation, Heifetz™ temporary occlusion clips. Scanlan offers a wide variety of custom modifications to accommodate surgeons’ specific needs. Single-use products include SCANLAN® Surg-I-Loop® PLUS, single use aorta/vein punch, A/C LOCATOR® and RADIOMARK® graft markers, Vascu-Statt® single-use bulldog clamps, as well as SURG-I-PAW® jaw covers and SOFT-GRIP™ fabric clamp covers.

THERAKOS, A JOHNSON & JOHNSON COMPANY  Booth # 308
437 Creamery Way
Exton, PA 19341
Phone: 610-280-1014
Fax: 610-280-1087
Web site: www.therakos.com

THERAKOS, a Johnson & Johnson Company, is a worldwide leader in extracorporeal disease management through the establishment of extracorporeal photoimmune therapy as a standard medical practice. Our UVAR ® XTS ™ System and UVADEX ® Methoxsalen Sterile Solution are approved for the palliative treatment of skin manifestations in Cutaneous T-Cell Lymphoma.
THORATEC CORPORATION  Booth # 209
6035 Stoneridge Drive
Pleasanton, CA 94588
Phone 925-847-8600
Fax 925-847-8574

Thoratec® Corporation, a world leader in circulatory support, provides a broad range of complementary cardiac assist product offerings for the treatment of congestive heart failure. As a single, trusted source, only Thoratec offers both implantable and paracorporeal ventricular assist devices. Our HeartMate® LVAS and Thoratec VAD Systems are ideally suited for short to long term, left, right or biventricular support in patients of almost any size.

UNITED NETWORK FOR ORGAN SHARING (UNOS)  Booth #604
700 N. 4th Street
Richmond, VA  23219
Phone: 804-782-4890
Web site: www.unos.org

UNOS is a 501 (c) 3 non-profit, scientific, educational and charitable organization that oversees the national Organ Procurement and Transplantation Network. Responsibilities include: facilitating organ donation through research, education and advocacy; managing the U.S. transplant waiting list matching donors to recipients; and maintaining a database that monitors U.S. transplant recipients. Through private, charitable funding, UNOS also works to increase organ availability and continuously improve the outcomes and quality of life of transplant candidates and recipients.

VENTRACOR LIMITED  Booth # 413
126 Greville Street,
Chatswood, NSW 2067 AUSTRALIA
Contact:  Dr John Woodard
Phone:  61 2 9406 3100
Fax:    61 2 9406 3101
Email:   john.woodard@ventracor.com

Ventracor Limited’s VentrAssist™ left ventricular assist system (LVAS)
The VentrAssist™ is a third generation LVAS with a unique design which features only one moving part, a hydrodynamically suspended impeller.
The VentrAssist™ LVAS provides left heart support and is designed as a permanent alternative to a heart transplant. The titanium alloy pump is implanted below the diaphragm and is connected to the circulatory system using standard fabric tubes known as vascular grafts. The device itself measures 2.5 inches (60 mm) in diameter and weighs just 10oz (298 grams). This allows it to be used in both children and adults.

VIRACOR LABORATORIES  Booth # 416
1210 NE Windsor Dr.
Lee’s Summit, MO  64086
Phone: 800-305-5198
Fax: 816-347-0143
Website: www.viracor.com

A diagnostic and research laboratory supporting the transplant community. Providing rapid turn-around, quantitative real-time PCR assays for the detection of Adenovirus, BK Virus, EBV, CMV, HHV-6, HHV-7, HHV-8, HSV1 & HSV2, ImmuKnow™, JCV, SV-40, VZV, Parvo B19 and other pathogens.

VITROLIFE  Booth # 409
3601 South Inca Street,
Englewood, 80110, CO, USA
Contact: P.J. Stewart
Product Description: Vitrolife develops specialized media and devices for preparation and cultivation of cells, tissues and organs. The products of Vitrolife Transplantation Systems are clinically proven solutions supporting thoracic and cardio-vascular surgery. Vitrolife's Perfadex(R) is optimized for preservation of lungs for transplantation.

WORLDHEART CORPORATION  Booth #108
1 Laser Street
Ottawa, Ontario K2E 7V1 Canada
Contact: Jennifer Poulsen
Phone: 613-226-4278
Fax: 613-723-8522
Web site: www.worldheart.com

WorldHeart Corporation, a global medical device company based in Ottawa, Ontario and Oakland, California, is currently focused on the development and commercialization of pulsatile ventricular assist devices. Its Novacor LVAS (left ventricular assist system) is well established in the marketplace and its next-generation technology, HeartSaverVAD™, is a fully implantable assist device intended for long-term support of patients with heart failure.

XDx  Booth # 501
750 Gateway Blvd., Suite H
South San Francisco, CA 94080
Gavin Williams
Phone: 650-624-0120
Fax: 650-624-0125
Email: gwilliams@xdxinc.com

XDx is a molecular diagnostics company located in South San Francisco, CA. XDx is finalizing development of AlloMap molecular expression testing, a multi-gene expression test for monitoring acute rejection and immune status in cardiac transplant patients. Using a simple blood sample, AlloMap molecular expression testing aims to translate an individual's immune response into clinically actionable information and improve cardiac transplantation patient management. AlloMap molecular expression testing will be offered by the XDx Reference Laboratory, scheduled to open in late 2004. Multi-center clinical validation studies are currently ongoing.
FUTURE ISHLT MEETINGS

APRIL 6 - 9, 2005
ISHLT 25TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
Philadelphia, PA

December 8-11, 2004
3RD INTERNATIONAL CONGRESS ON IMMUNOSUPPRESSION/ISHLT 6TH FALL EDUCATION MEETING
San Diego, California, USA

APRIL 5 – 8, 2006
ISHLT 26TH ANNUAL MEETING AND SCIENTIFIC SESSIONS
Madrid, Spain